

TP248.195
QUEEN
TP
248.195
.C2 1 22
Q4
1992

IC



Région du Québec

**QUÉBEC BIOTECHNOLOGY COMPANIES
DIRECTORY (1992)**



Industrie, Sciences et
Technologie Canada

Industry, Science and
Technology Canada

Canada

**QUÉBEC BIOTECHNOLOGY COMPANIES
DIRECTORY (1992)**

INDUSTRY, SCIENCE AND
TECHNOLOGY CANADA
LIBRARY

JAN 25 1993
BwDA
BIBLIOTHÈQUE
INDUSTRIE, SCIENCES ET
TECHNOLOGIE CANADA

BIOTECHNOLOGY IS CHALLENGING THE WORLD

"Within just a few years biotechnology has replaced conventional technologies in a wide variety of sectors, decreasing production costs and increasing both quantity and quality of products."

COMPANIES DESCRIPTION.

This Directory is an update of "Québec Biotechnology Company Directory - 1990 ". The information provided here is objective; there are no comparative or evaluative analyses of the companies or their products. The information comes from a variety of sources such as newspapers, magazines and journals, annual reports, investment reports, and direct communications with officers of companies through the use of a questionnaire.

ISTC's directory covers biotechnology companies and other major companies that have in-house biotechnology research groups or agreements with biotechnology companies. Companies for which there is little available information have been omitted, as have companies with limited biotechnology activities.

The information contained in this Directory involves Companies in Biotechnology in Québec. On March 1st 1992, ISTC updated over 105 companies and more than 230 contacts associated with these companies. These biotechnology firms have been selected on the basis of:

- having technology they are interested in sharing/selling in order to advance their business prospects,
- looking for joint venture partners with whom further R&D or product development efforts might take place,
- being active in sectors where Québec has specific interest and/or expertise.

The Companies related to the Biotechnology Industry have been divided into eight sectors of activity, as described below.

<u>SECTORS OF ACTIVITY</u>	<u>ALIAS</u>
- AGRICULTURE (Plants, Horticulture, Biofertilizers...).	A
- ENVIRONMENT (Biomass, Waste Treatment, Bioleaching...).	E
- FISHERIES (Aquaculture, Fish Farming, Marine Biomass...)	F
- HEALTH CARE (Animal & Human, Diagnostics & Therapeutics).	H
- NUTRITION (Food Processing, Fermentation...)	N
- PULP & PAPER, FORESTRY (Reafforestation, biomass processing...)	P
- SUPPLIERS (Mfg Products & Equipments related to Biotechnology).	S
- VENTURE CAPITAL	V

FIELDS DESCRIPTION:

This directory will provide you the detailed information mentioned below for the biotechnology companies in the province of Québec.

Company Name and Address:

Gives main address (City, Province, Zip Code), telephone and fax numbers.

Employees:

Gives number of employees, and when known, number of PhDs on staff.

Contacts:

President, and list management involved in relevant marketing and R&D areas.

History:

Contains information on founders, founding date, name changes, previous subsidiaries or investments, previous agreements, and former investors.

Facilities:

Includes facilities involved in biotechnology in square meter.

Subsidiaries / Divisions:

Includes subsidiaries of biotechnology and nonbiotechnology companies.

Investors:

Includes investors in the biotechnology company profiled.

Business Strategy:

Reflects new or changed directions of the company.

Agreements:

Consists of a brief summary of the research and contents of the agreement.

Research & Development:

Briefly describes research interests and technologies worked on by the company or its subsidiaries. Research done through agreements with other companies is also included.

Products on the Market:

Includes all products of biotechnology companies.

Products in Development:

Generic trade names, uses of the product, and development stages.

Agreements Being Sought:

Indicates categories of strategic alliances desired.

All this information, for each company, will be presented to you in alphabetical order, classified by sectors of activity. A general index on the following pages will guide you in your search for information. This Directory is also available in French.

**QUEBEC BIOTECHNOLOGY COMPANIES
(SECTORS OF ACTIVITIES)
(1992)**

	Agriculture	Environment	Fisheries	Health Care	Nutrition	Pulp & Paper Forestry	Suppliers	Venture Capital
	A	E	F	H	N	P	S	V
ADS Groupe Conseil Inc.		E						
Agro-Recherches Inc.	A							
Agropur, Coopérative Alimentaire					N			
AKAM Entreprise Inc.		E						
Aliments Délisle Ltée					N			
Altamira Capital Corp.								V
Aquabiotech Inc.			F					
Aquaresearch Ltd.		E						
Aquaterre Inc.	A							
B.V.Sorbex Inc.		E						
BCM Biotech Inc.		E						
Bio-Expert Inc.							S	
Bio-Méga Inc.				H				
Bio-Research Laboratories Ltd.				H				
BioAska Inc.						P		
Biocapital								V
Biochem Pharma Inc.				H				
Biogénie Inc.		E						
Biolix Inc.		E						
Biomatrix Medical Canada Inc.				H				
Biomax Inc.		E						
Bioram Inc.							S	
Biorex Inc.			F					
Bioscan Continental Inc. (BCI)				H				
Biosignal Inc.				H				
Biovet Inc.				H				
Botanical Phytotech Inc.	A							
Boviteq Inc.	A							
Burroughs Wellcome Inc.				H				
C.R.E.A. Lab Inc.		E						
Canadian Liquid Air Ltd.							S	
Canadian Medical Research Associates Inc.				H				
Cascades Inc.						P		
Centre de recherche en sylvichimie						P		
CGF Pharmatech Inc.				H				

QUEBEC BIOTECHNOLOGY COMPANIES
(SECTORS OF ACTIVITIES)
(1992)

	Agriculture	Environment	Fisheries	Health Care	Nutrition	Pulp & Paper Forestry	Suppliers	Venture Capital
	A	E	F	H	N	P	S	V
Diagnogene Inc.		E						
Domtar Research Centre						P		
Ealing Scientific Ltd.								
EnviroConseil Inc.		E					S	
Envirodev Inc.		E						
Enviromine Inc.		E						
Envirotem Inc.		E						
Fraises de l'Île d'Orléans Inc.	A							
Fromage Saputo (Les) Ltée					N			
Gendron Lefebvre		E						
Groupe Bio-Contrôle							S	
Haemacure Biotech Inc.				H				
Ibex Technologies Inc.				H				
Immunocorp Sciences Inc.				H				
ITR Laboratories Inc.				H				
Jean-Marie Bélanger Inc.						P		
John Meunier Inc.		E						
Kami Mark Inc.				H				
Lactel Group					N			
Lallemand Inc.					N			
Lipopharm Inc.				H				
Lyo-San Inc.					N			
Medicorp Sciences Inc.				H				
Merck Frosst Canada Inc.				H				
Monenco Inc.		E						
MPB Technologies Inc.							S	
Multiplants in Vitro	A							

QUEBEC BIOTECHNOLOGY COMPANIES
(SECTORS OF ACTIVITIES)
(1992)

	Agriculture	Environment	Fisheries	Health Care	Nutrition	Pulp & Paper Forestry	Suppliers	Venture Capital
	A	E	F	H	N	P	S	V
Noranda Technology Centre		E						
Novacap Investments Inc.								V
Omega Laboratories Ltd.				H				
Pampev Inc.						P		
PAPRICAN						P		
Pfizer Canada Inc.				H				
Pharmacia Biotech Canada							S	
Phoenix International Life Sciences Inc.				H				
Polychol Inc.				H				
Polyferm Inc.		E						
Premier Enterprises CDN Ltd.		E						
Promotions Technologies R&D Inc.								V
Quantum Biotechnologies Inc.				H				
Quélab Laboratories Inc.				H				
Richelieu Biotechnologies Inc.				H				
Robinson Electronic Systems Inc.							S	
Rosell Institute Inc.					N			
Rougier Bio-Tech Ltd.				H				
Sandoz Canada Inc.				H				
Sanexen Environmental Services Inc.		E						
Sarstedt Canada Inc.							S	
Schering Canada Inc.				H				
Serrener Consultations Inc.		E						
Serres Coopératives de Guyenne (Les)	A							
Services Bio-Contrôle		E						
Simport Plastics Ltd.							S	
SNC-Lavalin Inc.		E						
Société de Capital Technologique Inc.								V
Sodexen Inc.		E						
Steica Group			F					
Stephens Analytical Inc.							S	
Synermed Inc.				H				

**QUEBEC BIOTECHNOLOGY COMPANIES
(SECTORS OF ACTIVITIES)
(1992)**

	Agriculture	Environment	Fisheries	Health Care	Nutrition	Pulp & Paper Forestry	Suppliers	Venture Capital
	A	E	F	H	N	P	S	V
Tecksol Inc.							S	
Teknika Group		E						
Temeco Enterprises Inc.						P		
Temfibre Inc.						P		
Thermaculture Inc.	A							
Valoraction Inc.		E						
Vins Andr�s du Qu�bec (Les) Lt�e					N			
W.H.Perron & Co. Ltd.	A							
Waterloo Environmental Inc.		E						
Xymotech Biosystems Inc.							S	
Zenon Environment Inc.		E						

**QUEBEC BIOTECHNOLOGY COMPANIES
DIRECTORY (1992)**

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
E	ADS GROUPE CONSEIL Inc.	2155 Guy Suite 1200	Montréal, Québec H3H 2L9	(514)932-4454	(514)932-1518	René Fontaine C. Lavoie	Director, R&D Director
A	AGRO-RECHERCHES Inc.	1030 Rémi-Lachance	L'Assomption, Québec J0K 1G0	(514)589-9620	(514)589-9621	Michel Caron	President
N	AGROPUR COOPERATIVE ALIMENTAIRE	510 Principale P. O. Box 6000	Granby, Québec J2G 7G2	(514)375-1991	(514)375-2099	Jacques Cartier Yvan Grégoire Pierre La Haye Robert Poirier	President Director, R&D Dir, Technical Services General Director,
E	AKAM ENTREPRISE Inc.	545 Road 249	Windsor, Québec J1S 2L7	(819)845-5993	(819)845-4998	André Mathieu	President
N	ALIMENTS DELISLE Ltée	100 de Lauzon	Boucherville, Québec J4B 1E6	(514)655-7331	(514)655-2201	Robert Aubin Robert Bluteau	President Dir, Technical Services
V	ALTAMIRA CAPITAL CORP.	475 Dumont Ave. Suite 300	Dorval, Québec H9S 5W2	(514)631-2682	(514)631-1257	Robert Mee	Vice President
F	AQUABIOTECH Inc.	6 Du Parc P.O. Box 447	Grande-Rivière, Québec G0C 1V0	(418)385-2251	(418)385-3343	Hélène Drouin	President
E	AQUARESEARCH Ltd.	27 Highway 143 South P.O. Box 208	North Hatley, Québec J0B 2C0	(819)842-2890	(819)842-2902	M.-C. Cantin Karl F. Ehrlich	President VP, Scientific Director
A	AQUATERRE Inc.	209 Road 132	St-Fabien, Québec G0L 2Z0	(418)869-3197	(418)869-2215	Yves Lavoie	Operation, R&D Manager
E	B. V. SORBEX Inc.	3480 University McGill University	Montréal, Québec H3A 2A7	(514)398-4276	(514)398-6678	B. Volesky	President
E	BCM BIOTECH Inc.	P. O. Box 7277	Charlesbourg, Québec G1G 5E5	(418)628-1337	(418)623-8793	Michel Pagé	President
S	BIO-EXPERT Inc.	3075 Hamel Blvd. Suite 227	Québec, Québec G1P 4C6	(418)877-5711	(418)877-5713	Jean-François Bourassa Alain Marchand	General Manager President
H	BIO-MEGA Inc.	2100 Cunard	Laval, Québec H7S 2G5	(514)682-4640	(514)682-8434	Paul Anderson James Chafouleas Pierre Dallaire	Associate Director, Associate Director, Controller, Treasurer

QUEBEC BIOTECHNOLOGY COMPANIES
DIRECTORY (1992)

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
						Jacques Gauthier	President
						Yvan Guindon	VP, R&D
						Jorge Jaramillo	Director, Pharmacology
						Suman Rakhit	Director, Chemistry
						Jacques Roux	Dir., Human Resources
H	BIO-RESEARCH LABORATORIES Ltd.	87 Senneville Road	Senneville, Québec H9X 3R3	(514)630-8200	(514)457-3883	Michael F. Ankcom	President and CEO
						Winn Brink	Dir., Client Services
						Brian Broxup	Director, Scientific
						Yves Deschamps	Director, Clinical Labs
						Joan Lefebvre	Purchasing Manager
						George Lulham	Director, Toxicology
						Jim Noveroske	VP, Toxicology
						Barry Osborne	VP, Marketing
						Paul Sidney	Dir., Regulatory Affairs
						Pierre Tellier	VP, Pathology
P	BIOASKA Inc.	1030 Rémi-Lachance	L'Assomption, Québec J0K 1G0	(514)589-9620	(514)589-9621	Yvon Brousseau	President
						Michel Caron	VP, R & D
V	BIOCAPITAL	1550 Metcalfe Suite 1100	Montréal, Québec H3A 1X6	(514)847-5750	(514)285-4597	Gérald André	VP, Scientific Affairs
						Normand Balthazard	President
						Bernard Coupal	Director General
H	BIOCHEM PHARMA Inc.	2550 Daniel Johnson Blvd. Suite 600	Laval, Québec H7T 2L1	(514)681-1744	(514)681-4207	Francesco Bellini	President and CEO
						Gervais Dionne	VP, R&D

**QUEBEC BIOTECHNOLOGY COMPANIES
DIRECTORY (1992)**

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
						Guy Ely	Medical Director
						John Gillard	Dir., Therapeutic Res.
						Philippe Lacaille	Exec VP, and CEO
						François Legault	VP, Finance & Treasurer
						Jim McDonald	VP, Public Affairs
						Silvio Nuzzo	VP, Diagnostic Division
						Roger Perrault	President, IAF Biovac
						Lawrence Wilson	VP, Legal Affairs
E	BIOGENIE Inc.	350 Franquet Suite 10	Ste-Foy, Québec G1P 4P3	(418)653-4422	(418)653-3583	Benoit Cyr	President
						Jean-Luc Sansregret	Vice President
E	BIOLIX Inc.	2755 Dalton Suite 110	Ste-Foy, Québec G1P 3T1	(418)657-2666	(418)657-5600	Richard Painchaud	President
H	BIOMATRIX MEDICAL CANADA Inc.	275 Labrosse	Pointe-Claire, Québec H9R 1A3	(514)697-8851	(514)697-3670	Endre A. Balazs	President, CEO
						John Fielder	Advisor of the Board
						Danielle Simoneau-Grenon	Dir., Human Resources
						Donald E. Woodhouse	VP, Manufacturing
E	BIOMAX Inc.	764 St. Joseph East Suite 124	Québec, Québec G1K 3C4	(418)529-2585	(418)648-8951	Carl Genois	President
						André Lavoie	Vice President
S	BIORAM Inc.	2633 Le Corbusier Blvd.	Laval, Québec H7S 2E8	(514)973-8228	(514)973-1966	Yvon Brousseau	VP, Bus. Development
						Michel English	VP, Finance & Operation
						Pierre Michaud	President
						Claude Portier	VP, Engineering
F	BIOREX Inc.	969 route de l'Eglise Suite 250	Ste-Foy, Québec G1V 3V4	(418)654-1316	(418)654-9217	Marc Gagnon	President

**QUEBEC BIOTECHNOLOGY COMPANIES
DIRECTORY (1992)**

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
H	BIOSCAN CONTINENTAL Inc. (BCI)	350 Industriel Blvd. Suite 201	St-Eustache, Québec J7R 5V3	(514)974-0151	(514)491-3069	Gita Banik Upendra K. Banik S. Cowan	President VP, CEO, Dir. R&D Admin. Secretary
H	BIOSIGNAL Inc.	316 Carré St-Louis	Montréal, Québec H2X 1A5	(514)844-0118	(514)843-7372	Michael Denis Guy Lambert	Scientific Director President
H	BIOVET Inc.	1550 Metcalfe Suite 1100	Montréal, Québec H3A 1X6	(514)847-5751	(514)285-4597	Camil Moore	Vice President
A	BOTANICAL PHYTOTECH Inc.	6695 Thimens Blvd.	St-Laurent, Québec H4S 1W2	(514)333-5595	(514)333-5582	Lazar Jevremovic Richard Nelson	Vice President President
A	BOVITEQ Inc.	1425 Grand Rang St-François P. O. Box 577	St-Hyacinthe, Québec J2S 7A9	(514)774-7949	(514)774-1740	Daniel Bousquet	Director, R&D
H	BURROUGHS WELLCOME Inc.	16751 Trans-Canada Highway	Kirkland, Québec H9H 4J4	(514)694-8220	(514)694-8201	Kristina Adomonis	Dir., Business Dev.
E	C.R.E.A. LAB Inc.	360 St-Roch North	Rock Forest, Québec J1N 2T3	(819)864-6877	(819)864-7954	Arnold Ross	President
S	CANADIAN LIQUID AIR Ltd.	1155 Sherbrooke West	Montréal, Québec H3A 1H8	(514)499-2604	(514)499-8136	Yves Bourhis	Director, R&D
H	Canadian Medical Research Associates Inc	550 Sherbrooke West Suite 1205	Montréal, Québec H3A 1B9	(514)842-3759	(514)842-7871	Oleg Romar	Chairman of the Board
P	CASCADES Inc.	471 Marie-Victorin	Kingsey Falls, Québec J0A 1B0	(819)363-2747	(819)363-2921	Claude Audet Martin P. Pelletier	Coordinator, Environment Director, R&D
P	CENTRE DE RECHERCHE EN SYLVICHIMIE	11 Main P. O. Box 38	Gatineau, Québec J8P 6J1	(819)643-9099	(819)643-1295	Yvon Gauthier	President
H	CGF PHARMATECH Inc.	3516 Griffith	St-Laurent, Québec H4T 1A7	(514)343-0344	(514)343-0340	Jean-Paul Chausseau Louise E. Gaboriault	President VP, Corporate Affairs
E	DIAGNOGENE Inc.	P. O. Box 8519	Ste-Foy, Québec G1V 4N5	(418)653-3847		Jean-Marc Juteau Marc Sirois	President VP, R & D
P	DOMTAR RESEARCH CENTRE	22025 Trans-Canada Road West	Senneville, Québec H3R 1L6	(514)457-6810	(514)457-4527	P. Desjardins Robert Eamer	President Vice President, R & D

**QUEBEC BIOTECHNOLOGY COMPANIES
DIRECTORY (1992)**

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
S	EALING SCIENTIFIC Ltd.	6010 Vanden Abeele	St-Laurent, Québec H4S 1R9	(514)335-0792	(514)335-3482	Elie Massuda	Director, R&D
E	ENVIROCONSEIL Inc.	3420 St-Joseph Blvd. East	Montréal, Québec H1X 1W6	(514)255-6375	(514)252-0071	Jacques Beaulieu	Director
						André Bisaillon	President
						Jean Chartrand	Director
						Pierre Forest	Director
						Jude Simundic	Director,
						Michel Thessereault	Dir., Public Relations
E	ENVIRODEV Inc.	360 St-Roch North	Rock Forest, Québec J1N 2T3	(819)864-6877	(819)864-7954	Lawrence W. Perry	President
E	ENVIROMINE Inc.	1352 Delaunay	Ancienne-Lorette, Québec G2E 3V4	(418)877-3997	(418)628-4766	Roger Guay	Vice President
						André Paquet	President
E	ENVIROTEM Inc.	P. O. Box 3000 Témiscaming	Témiscamingue, Québec J0Z 3R0	(819)627-4317	(819)627-1458	Jacques Rocray	President
A	FRAISES DE L'ILE D'ORLEANS Inc.	2035 Royal Ave.	Saint-Laurent, Québec G0A 3Z0	(418)828-1109	(418)828-1109	Louis Gauthier	President
N	FROMAGES SAPUTO Liée	1195 Johnson	St-Hyacinthe, Québec J2S 7Y6	(514)773-1004	(514)773-2042	Jacques R. Rolland	Director, R&D
E	GENDRON LEFEBVRE	1 Place Laval Suite 200	Laval, Québec H7N 1A1	(514)384-1260	(514)629-8737	Roger Desbois	Director, Urban Eng.
						Marc-André Gendron	President
						Denis Guindon	Manufacturing Director
						Chantale Morasse	Director, R&D
S	GROUPE BIO-CONTROLE	2600 Dalton	Ste-Foy, Québec G1P 3S4	(418)653-3101	(418)653-3096	Pierre Racine	Director
H	HAEMACURE BIOTECH Inc.	245 Hymus Blvd.	Pointe-Claire, Québec H9R 1G6	(514)630-8839	(514)630-8845	Teresa Brodniewicz	VP, R&D
						Marc M. Paquin	President
						Andrée Veronneau	Director Marketing
H	IBEX TECHNOLOGIES Inc.	5645 Chemin St-François	St-Laurent, Québec H4S 1W6	(514)956-8430	(514)956-7485	Robert Heft	President

**QUEBEC BIOTECHNOLOGY COMPANIES
DIRECTORY (1992)**

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
						Joe Zimmerman	VP, R&D
H	IMMUNOCORP SCIENCES Inc.	5800 Royalmount Ave.	Montréal, Québec H4P 1K5	(514)733-1900	(514)733-1212	Elliot Block	President, CEO
						Pierre DuRuisseau	VP, General Manager
H	ITR LABORATORIES Inc.	19061 Clark Graham Blvd.	Baie d'Urfé, Québec H9X 3T1	(514)457-7400	(514)457-7303	D. Cuitar	Manager Operation
						J. Eidnes	Manager Accounting
						T. Hirakaws	Vice President
						T. Ladd	Manager Marketing
						A. Locas	Man., Human Resources
						K. Yamanouchi	President
P	JEAN-MARIE BELANGER Inc.	1436 Ducharme Blvd.	LaTuque, Québec G9X 3N8	(819)523-9559	(819)523-3403	J. M. Bélanger	President
						Christian Bélanger	Vice President
E	JOHN MEUNIER Inc.	6290 Perinault	Montréal, Québec H4K 1K5	(514)334-7230	(514)334-5070	Pierre Belisle	Manufacturing Director
						Gilles Filion	Director General
						Hoang Van Hoi	Director, R&D
						Gabriel Meunier	President
H	KAMI MARK Inc.	791 Lajoie	Dorval, Québec H9P 1G7	(514)633-9064	(514)633-9064	Robert Roy	President
N	LACTEL GROUP	180 Bégin Blvd.	Ste-Claire, Québec G0R 2V0	(418)883-3301	(418)883-2346	André Houle	Director, R&D
						André Roy	Director, Marketing
N	LALLEMAND Inc.	1620 Préfontaine	Montréal, Québec H1W 2N8	(514)522-2133	(514)522-2884	Clifford Caron	Vice President
						Jean Chagnon	President
						Nina Chagnon	Sr Scientist
						Richard Degré	Director, R&D

**QUEBEC BIOTECHNOLOGY COMPANIES
DIRECTORY (1992)**

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
						Guy Marleau	VP, Production
H	LIOPHARM Inc.	5929 Trans-Canada Highway Suite 30	St-Laurent, Québec H4T 1A1	(514)747-8942	(514)747-8944	Serge Pitre	VP, General Manager
						Donald Simmons	President
N	LYO-SAN Inc.	500 Aeroparc Blvd. P.O. Box 598	Lachute, Québec J8H 4G4	(514)562-8525	(514)562-1433	Serge Brault	Exec. Vice President
H	MEDICORP SCIENCES Inc.	5800 Royalmount Ave.	Montréal, Québec H4P 1K5	(514)733-3000	(514)733-1212	Elliot T. Block	President
						Pierre Du Ruisseau	VP, R&D
H	MERCK FROSST CANADA Inc.	16711 Trans-Canada Highway	Kirkland, Québec H9H 3L1	(514)695-7920	(514)630-2670	Sandu Goldstein	Director, Research Adm.
						Cecil Pickett	VP, Merck Frosst Labs
						Michael Tamow	President
E	MONENCO Inc.	2045 Stanley P. O. Box 6088, Station "A"	Montréal, Québec H3C 3Z8	(514)499-3300	(514)499-3223	William J. Cosgrove	VP, Corporate Dev.
						Sylvain Léger	Sr Process Engineer
S	MPB TECHNOLOGIES Inc.	1725 N. Service Rd. Trans-Canada Hwy.	Dorval, Québec H9P 1J1	(514)683-1490	(514)683-1727	Morrel Bachynski	President
A	MULTIPLANTS IN VITRO	335, 3rd Rang South	St-Charles-sur-Richelieu, Qc J0H 2G0	(514)584-3794	(514)773-8126	Elizabeth Séguin	President
E	NORANDA TECHNOLOGY CENTRE	240 Hymus Blvd.	Pointe-Claire, Québec H9R 1G5	(514)630-9300	(514)630-9379	Lucy Rosato	Program Manager
V	NOVACAP INVESTMENTS Inc.	1981 McGill College Ave. Suite 515	Montréal, Québec H3A 2X1	(514)282-1383	(514)282-1344	Marc Beauchamp	President
H	OMEGA LABORATORIES Ltd.	11177 Hamon	Montréal, Québec H3M 3E4	(514)335-0310	(514)339-1407	E. R. Vrancken	Director, R&D
P	PAMPEV Inc.	212 Rang St-Lazare	St-Apollinaire, Québec G0S 2E0	(418)881-3114	(418)881-2438	Normand Bélanger	Vice President
P	PAPRICAN	570 St-Jean Blvd.	Pointe-Claire, Québec H9R 3J9	(514)630-4135	(514)630-4134	Lubo Jurasek	Head, Bio. Chemistry
						Joseph Merka	Grants & Contracts
						Jim Rogers	Sr Vice President
						P. E. Wrist	President
H	PFIZER CANADA Inc.	17300 Trans-Canada Highway	Kirkland, Québec H9J 2M5	(514)695-0500	(514)426-7084	Gordon J. Fehr	President

**QUEBEC BIOTECHNOLOGY COMPANIES
DIRECTORY (1992)**

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
S	PHARMACIA BIOTECH CANADA	500 Morgan Blvd.	Baie d'Urfé, Québec H9X 3V1	(514)457-6661	(514)457-4616	Jack Ball Michel Geadah	Director, Canadian Sales President and Dir., R&D
H	PHOENIX INTL LIFE SCIENCES Inc.	2330 Cohen	St-Laurent, Québec H4R 9Z7	(514)333-0033	(514)333-8861	John W. Hooper Judy Zilber	President Vice President, Marketing
H	POLYCHOL Inc.	1550 Metcalfe Suite 1100	Montréal, Québec H3A 1X6	(514)847-5751	(514)285-4597	James McDonald	President
E	POLYFERM Inc.	1044 Woodside Drive	Dollars-Des-Ormeaux, Qc H9B 1P9	(514)340-4525	(514)340-4159	Juliana Ramsay Bruce Ramsay	President Vice President
E	PREMIER ENTERPRISES CDN Ltd.	454 Chemin Témiscouata P. O. Box 2600	Rivière-du-Loup, Québec G5R 4C9	(418)862-6356	(418)862-6685	Bernard Bélanger Alain Bélanger Serge E. Bergeron Marc Méthivier	President Exec. VP VP, Production Director General, R&D
V	PROMOTIONS TECHNOLOGIES R&D Inc.	2755 Dalton Suite 110	Ste-Foy, Québec G1P 3T1	(418)657-2666	(418)657-5600	Richard Painchaud	President
H	QUANTUM BIOTECHNOLOGIES Inc.	6100 Royalmount Ave.	Montréal, Québec H4P 2R2	(514)496-6380	(514)496-6232	Suzanne Lebel Steve Silaty	Director, R&D President
H	QUELAB LABORATORIES Inc.	2331 Dandurand	Montréal, Québec H2G 3C5	(514)277-2558	(514)277-4714	Roger Boulais	CEO
H	RICHELIEU BIOTECHNOLOGIES Inc.	5726 Laurier	St-Hyacinthe, Québec J2S 3V8	(514)774-3505	(514)773-7433	Richard Parsons	President
S	ROBINSON ELECTRONIC SYSTEMS Inc.	5027 Mira Road	Montréal, Québec H3W 2B9	(514)482-2686	(514)482-2686	Anthony Robinson	President
N	ROSELL INSTITUTE Inc.	8480 St-Laurent Blvd.	Montréal, Québec H2P 2M6	(514)381-5631	(514)383-4493	Jean-Louis Bilodeau Edouard Brochu Jean-Paul Julien Francine Mondou	Manufacturing Director President Coordinator, R&D Director, R&D
H	ROUGIER BIO-TECH Ltd.	8480 St-Laurent Blvd.	Montréal, Québec H2P 2M6	(514)381-5631	(514)383-4493	Azadeh Abedian	Sr Scientist

QUEBEC BIOTECHNOLOGY COMPANIES
DIRECTORY (1992)

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
						Guy Angers	Chairman, CEO
						Robert Cyr	Purchasing Manager
						Marcel Dubois	President
						Francine Maynard	VP, Sales and Marketing
						Sushil Mohapatra	Sr Scientist
						Sylvine Savoie	Sr Scientist
						William Shestowsky	Sr Scientist
						Hanna Sikorska	VP, R&D
H	SANDOZ CANADA Inc.	385 Bouchard Blvd.	Dorval, Québec H9R 4P5	(514)631-6775	(514)631-3373	Lyse Beauregard-Zollinger	Project leader, Clinical
						Sylvie Bouchard	Medical Director
						Gerard F. Murphy	Senior Medical Advisor
						Luc Vachon	Co-Dir. Clinical Res.
E	SANEXEN ENVIRONMENTAL SERVICES Inc.	991 Montée Ste-Julie	Varennnes, Québec J3X 1P7	(514)652-4635	(514)652-5857	Robert Dubeau	Dir., Site remediation
						Daniel Latendresse	Dir., Water Treatment
						Jean Paquin	VP, Technology
						Jean-Guy Soulard	President
S	SARSTEDT CANADA Inc.	5655 Bois-Franc	St-Laurent, Québec H4S 1B2	(514)337-6908	(514)337-3640	Alain Côté	President
H	SCHERING CANADA Inc.	3535 Trans-Canada Road	Pointe-Claire, Québec H9R 1B4	(514)426-7300	(514)695-7334	Claude Petitclerc	Medical Research
E	SERRENER CONSULTATIONS Inc.	360 St-Roch North	Rock Forest, Québec J1N 2T3	(819)864-6877	(819)864-7954	Jean Shoiry	President
A	SERRES COOPERATIVES DE GUYENNE	P. O. Box 70, Rang 5	Guyenne, Québec J0Y 1L0	(819)732-0456	(819)732-0493	Fernand Miron	General Director
						Alice Roberge	Director, R&D
E	SERVICES BIO-CONTROLE	2600 Dalton	Ste-Foy, Québec G1P 3S4	(418)653-3101	(418)653-3096	Serge Sévigny	President

**QUEBEC BIOTECHNOLOGY COMPANIES
DIRECTORY (1992)**

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
S	SIMPORT PLASTICS Ltd.	176 du Parc	Beloeil, Québec J3G 4T1	(514)464-1723	(514)464-3394	André Lafond	President
E	SNC-LAVALIN Inc.	2 Place Félix-Martin	Montréal, Québec H2Z 1Z3	(514)866-1000	(514)392-4758	Diana Mourato	Dir., Site remediation
						Bechara Safi	VP, Technical Manager
V	SOCIETE DE CAPITAL TECHNOLOGIQUE Inc.	550 Sherbrooke West Suite 1200	Montréal, Québec H3A 1B9	(514)842-7373	(514)842-7871	Claude McMaster	VP, Technology
						Oleg Romar	Chairman of the Board
E	SODEXEN Inc.	2519 Chomedey Blvd.	Laval, Québec H7T 2R2	(514)333-5766	(514)333-5759	Robert Kalnins	Marketing Director
F	STEICA GROUP	4300 Bourque Blvd. Suite 101	Rock Forest, Québec J1N 2A6	(819)564-4008	(819)564-7638	Luc A. Rainville	Program Director
						Robert Roy	President
S	STEPHENS ANALYTICAL Inc.	2750 Brabant-Marineau	Montréal, Québec H4S 1L1	(514)332-1230	(514)335-6566	Alan Lee	President
H	SYNERMED Inc.	1688, 50th Ave.	Lachine, Québec H8T 2V5	(514)633-1112	(514)633-8039	Guido Bosmans	VP, International Affairs
						Jerry Denney	President
S	TECKSOL Inc.	2505 Dalton	Ste-Foy, Québec G1P 3S5	(418)651-2007	(418)651-8725	Simon Robitaille	President
E	TEKNIKA GROUP	150 Vimy North	Sherbrooke, Québec J1J 3M7	(819)562-3871	(819)563-3663	Alexandra Kantardjieff	Director, R&D
P	TEMECO ENTERPRISES Inc.	P. O. Box 3000	Temiscaming, Québec J0Z 3R0	(819)627-1070	(819)627-1042	Robert Benson	President
						Gerry Grewe	Vice President
P	TEMFIBRE Inc.	P. O. Box 3000	Témiscaming, Québec J0Z 3R0	(819)627-9505	(819)627-1042	Robert A. Benson	VP, General Manager
						Peter Dilling	Manager, Manufacturing
						F. A. Dottori	President, CEO
A	THERMACULTURE Inc.	6695 Thimens Blvd.	St-Laurent, Québec H4S 1W2	(514)333-5595	(514)333-5582	Richard Nelson	President
						Brian Oakes	Vice President
E	VALORACTION Inc.	360 St-Roch North	Rock Forest, Québec J1N 2T3	(819)864-7942	(819)864-7954	Lawrence W. Perry	President
N	VINS ANDRES DU QUEBEC Ltée	3755 Picard	St-Hyacinthe, Québec J2S 1H3	(514)773-7468	(514)773-0789	Nicholas G. Sikorski	VP, General Manager

QUEBEC BIOTECHNOLOGY COMPANIES
DIRECTORY (1992)

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City. Province. Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
A	W. H. PERRON & CO. Ltd.	2914 Labelle Blvd.	Laval, Québec H7P 5R9	(514)332-3619	(514)682-4959	Monique Dumas-Quesnel	Asst Research Director
						Philip Thompson	Vice President
E	WATERLOO ENVIRONMENTAL Inc.	201 Western	Waterloo, Québec J0E 2N0	(514)539-3663	(514)539-2660	Ernest Biéri	President
						Jacques Biéri	Vice President
S	XYMOTEC BIOSYSTEMS Inc.	8180 Devonshire Road Suite 8	Mont-Royal, Québec H4P 2K3	(514)738-1386	(514)738-8499	Charles Salama	General Manager
E	ZENON ENVIRONMENT Inc.	10390 Louis H. Lafontaine	Anjou, Québec H1J 2T3	(514)493-4733	(514)493-4725	Lisette Provencher	

QUEBEC BIOTECHNOLOGY COMPANIES
AGRICULTURE

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
A	AGRO-RECHERCHES Inc.	1030 Rémi-Lachance	L'Assomption, Québec J0K 1G0	(514)589-9620	(514)589-9621	Michel Caron	President
A	AQUATERRE Inc.	209 Road 132	St-Fabien, Québec G0L 2Z0	(418)869-3197	(418)869-2215	Yves Lavoie	Operation, R&D Manager
A	BOTANICAL PHYTOTECH Inc.	6695 Thimens Blvd.	St-Laurent, Québec H4S 1W2	(514)333-5595	(514)333-5582	Lazar Jevremovic	Vice President
						Richard Nelson	President
A	BOVITEQ Inc.	1425 Grand Rang St-François P. O. Box 577	St-Hyacinthe, Québec J2S 7A9	(514)774-7949	(514)774-1740	Daniel Bousquet	Director, R&D
A	FRAISES DE L'ILE D'ORLEANS Inc.	2035 Royal Ave.	Saint-Laurent, Québec G0A 3Z0	(418)828-1109	(418)828-1109	Louis Gauthier	President
A	MULTIPLANTS IN VITRO	335, 3rd Rang South	St-Charles-sur-Richelieu, Qc J0H 2G0	(514)584-3794	(514)773-8126	Elizabeth Séguin	President
A	SERRES COOPERATIVES DE GUYENNE	P. O. Box 70, Rang 5	Guyenne, Québec J0Y 1L0	(819)732-0456	(819)732-0493	Fernand Miron	General Director
						Alice Roberge	Director, R&D
A	THERMACULTURE Inc.	6695 Thimens Blvd.	St-Laurent, Québec H4S 1W2	(514)333-5595	(514)333-5582	Richard Nelson	President
						Brian Oakes	Vice President
A	W. H. PERRON & CO. Ltd.	2914 Labelle Blvd.	Laval, Québec H7P 5R9	(514)332-3619	(514)682-4959	Monique Dumas-Quesnel	Asst Research Director
						Philip Thompson	Vice President

AQUATERRE Inc.
209 Road 132
St-Fabien, Québec G0L 2Z0
Canada

Telephone: (418)869-3197
FAX: (418)869-2215

Founded: 1983
Employees: 10
R&D:
Sales:

Contact: Yves Lavoie (Operation, R&D Manager)

HISTORY:

Founded in 1983 by Yves Lavoie and Jean-Pierre Morissette.
Company was bought by Biorex Inc. in 1987, and became a subsidiary of Biorex.
Since 1989, Aquaterre Inc. is a subsidiary of Purdel, Coop. Agro-alimentaire.

FACILITIES:

10,000 sq. ft. plant.
Composting facilities of 12 ha.

INVESTORS:

PURDEL, Coop. Agro-Alimentaire.

RESEARCH & DEVELOPMENT:

Development of a 100% natural concentrate liquid fish fertilizer.
Pre-commercial operations for composting fish and crab wastes with sphagnum peat moss.
Pilot scale project for an in-vessel composting system.

PRODUCTS ON MARKET:

Processor of high-grade horticultural products.
Biological fertilizer liquid seaweed Biogro.
Specific use of Humix products from peat moss and shrimps compost.
Commercial scale development of a windrow composting system in closely monitored conditions allowing the biodegradation of a balance mix of sphagnum peat moss and shrimp wastes.

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract

Joint VentureX.
Technology TransferX.
Financing

AGRO-RECHERCHES Inc.

1030 Rémi-Lachance
L'Assomption, Québec J0K 1G0
Canada

Telephone: (514)589-9620
FAX: (514)589-9621

Founded: 1990
Employees: 5
R&D:
Sales:

Contact: Michel Caron (President)

HISTORY:

Agro-Recherches Inc., founded in January 1990 and incorporated under the Canada Business Corporation Act, is providing consulting services.

BUSINESS STRATEGY:

Preparation, evaluation and/or follow-up of individual projects.

Research and development subcontracting for new products.

Scientific support for marketing of new products.

Marketing assistance of new products in biotechnology or of other nature but aimed for use in agriculture and horticulture.

RESEARCH & DEVELOPMENT:

Products to be applied in agriculture and/or horticulture.

Agro-Recherches Inc. has established expertise in the areas of plant symbiosis and more specifically with mycorrhizae, as well as with plant growth promoting rhizobacteria (PGPR) and in biological control.

AGREEMENTS BEING SOUGHT:

Distribution.....

Marketing.....

Research Contract....X.

Joint Venture.....

Technology Transfer....X.

Financing.....

Agro-Recherches Inc. takes charge of any trials aimed to the introduction on the Canadian market of foreign products in biotechnology or from other nature for use in agriculture and horticulture.

Agro-Recherches Inc. is also involved with technical and feasibility studies aimed at the establishment of research activities or programs that may associate more than one company.

BOTANICAL PHYTOTECH Inc.

6695 Thimens Blvd.
St-Laurent, Québec H4S 1W2
Canada

Telephone: (514)333-5595
FAX: (514)333-5582

Founded: 1991
Employees:
R&D: 2

Contact: Richard Nelson (President)

Sales:

HISTORY:

Founded in 1991 to carry out collaborative research with FRDC (Food Research and Development Centre, Agriculture Canada) and École Polytechnique de Montréal (Univ. of Montréal).

AGREEMENTS:

CQVB, (Centre québécois de valorisation de la biomasse): collaborative research and funding agreements.

FRDC, (Food Research and Development Centre) collaborative research and funding agreements.

École Polytechnique de Montréal, collaborative research and funding agreements.

RESEARCH & DEVELOPMENT:

Bioreactor processes for production of Anthocyanin.

PRODUCTS IN DEVELOPMENT:

Anthocyanin production methods.

AGREEMENTS BEING SOUGHT:

DistributionX . . .
MarketingX . . .
Research Contract . . .X . . .

Joint VentureX . . .
Technology Transfer . . .X . . .
FinancingX . . .

BOVITEQ Inc.
 1425 Grand Rang St-François
 P. O. Box 577
 St-Hyacinthe, Québec J2S 7A9
 Canada

Telephone: (514)774-7949
FAX: (514)774-1740

Founded: 1986
Employees: 20
R&D:

Contact: Daniel Bousquet (Director, R&D)

Sales:

HISTORY:

BOVITEQ Inc. was founded in 1986 as a department of the Artificial Insemination Centre of Québec.

It was incorporated in April 1991.

FACILITIES:

A main building with offices, meeting room and a laboratory subdivided in different rooms such as cell culture, molecular biology, general preparation and sterilization.

BOVITEQ Inc. has also facilities to keep 250 cows and heifers.

INVESTORS:

Artificial Insemination Centre of Québec.

RESEARCH & DEVELOPMENT:

Embryo freezing.

Superovulation.

Embryo culture.

Embryo division (micromanipulation), and sexing.

PRODUCTS ON MARKET:

Frozen embryos.

Embryo transfer services.

AGREEMENTS BEING SOUGHT:

Distribution
 Marketing
 Research Contract

Joint Venture
 Technology Transfer
 FinancingX..

FRAISES DE L'ILE D'ORLÉANS Inc.

2035 Royal Ave.
 Saint-Laurent, Québec G0A 3Z0
 Canada

Telephone: (418)828-1109**FAX:** (418)828-1109**Founded:** 1979**Employees:** 11**R&D:****Contact:** Louis Gauthier (President)**Sales:** \$ 1 M**HISTORY:**

Founded in November 1979 for the sole purpose of producing and marketing fruits and vegetables.

FACILITIES:

Laboratory space leased from Laval University, Québec.
 20,000 sq. m of cultivated lands for biotechnology research.

AGREEMENTS:

MAPAQ (Ministère de l'agriculture, des pêcheries et de l'alimentation du Québec) : Peas production.

MAPAQ: Agricultural biotechnology.

MAPAQ: Fall strawberries production.

RESEARCH & DEVELOPMENT:

Carrying out R&D on fungus parasites: Trichoderma.

Anti-freeze bacteria.

Predatory spiders.

Bacillus turgensis (B.T.).

PRODUCTS ON MARKET:

Strawberries: 80%

Other fruit and vegetable: 20%

PRODUCTS IN DEVELOPMENT:

Candies with whole freeze-dried strawberries.

Artichoke production.

Peas production.

Control of mushrooms and insects using biotechnology processes.

AGREEMENTS BEING SOUGHT:

Distribution

Marketing

Research Contract

Joint Venture

Technology Transfer

Financing

MULTIPLANTS IN VITRO
 335, 3rd Rang South
 St-Charles-sur-Richelieu, Québec J0H 2G0
 Canada

Telephone: (514)584-3794
FAX: (514)773-8126

Founded: 1989
Employees: 3
R&D:
Sales:

Contact: Elizabeth Séguin (President)

FACILITIES:

Plant tissue culture laboratory with a production capacity of 100,000 plants per year.

BUSINESS STRATEGY:

Multiplication of new plant varieties at minimum cost.

AGREEMENTS:

Agreements with an important commercial laboratory in Europe, and some institutional laboratories in Canada.

PRODUCTS ON MARKET:

In vitro vegetal micropropagation.

Acclimatized plantlets multiplied by tissue culture; mostly new varieties.

AGREEMENTS BEING SOUGHT:

Distribution
 Marketing
 Research Contract

Joint Venture
 Technology Transfer
 Financing

Subcontracts from pharmaceutical or biotech industries working with plants.

SERRES COOPÉRATIVES DE GUYENNE

P. O. Box 70, Rang 5
Guyenne, Québec J0Y 1L0
Canada

Telephone: (819)732-0456

FAX: (819)732-0493

Founded: 1980

Employees: 160

R&D: 1

Contact: Fernand Miron (General Director)
Alice Roberge (Director, R&D)

Sales: \$ 2.5 M

HISTORY:

Operations started in 1980 with 0.6 ha of greenhouse and 3 million tree seedlings.

In 1985, we added 0.6 ha for an 11 million production of tree seedlings.

In 1987, the diversification process started with a first tomato production.

In 1990, a 1.2 ha of glass greenhouse, specialized for tomato production was added with a research department aimed at improving all productions by means of all available technology.

FACILITIES:

2.6 ha of greenhouse.

4.5 ha field spruce and pine culture.

Vitro culture laboratory.

BUSINESS STRATEGY:

Improve in quantity and quality manpower in the region.

Act as a technical model for all forestry and greenhouse operation in the province and eventually worldwide.

AGREEMENTS:

IRBVM (Institut de recherche en biologie végétale de Montréal): collaboration in the development of tomato vitroculture and somatic embryogenesis.

RESEARCH & DEVELOPMENT:

Greenhouse black spruce warping.

Greenhouse tomatoes cultural methods.

Greenhouse tomatoes vitroculture and embryogenesis.

Ornamental vitroculture.

PRODUCTS ON MARKET:

Greenhouse tomatoes: 1.2 M\$

Tree seedlings: 1.3 M\$

PRODUCTS IN DEVELOPMENT:

Food processing: Ketchup de Guyenne.

Ornamental trees.

AGREEMENTS BEING SOUGHT:

Distribution

Marketing

Research Contract

Joint Venture

Technology Transfer . . . X . .

Financing

THERMACULTURE Inc.

6695 Thimens Blvd.
St-Laurent, Québec H4S 1W2
Canada

Telephone: (514)333-5595**FAX:** (514)333-5582**Founded:** 1985**Employees:****R&D:** 5**Contact:** Richard Nelson (President)**Sales:** \$ 185,000**HISTORY:**

Founded by Mr Richard Nelson.

Engaged since 1989 in research and development in the field of energy efficient greenhouse technology.

Started offering consulting services in 1991 in design and operations.

FACILITIES:

1500 sq. ft.: greenhouse development laboratory.

500 sq. ft.: tissue culture laboratory.

AGREEMENTS:

Thermagro Inc.: License for greenhouse technology from Thermaculture R&D program.

Botanical Phytotech Inc.: License for greenhouse technology from Thermaculture R&D program.

Botanical Technologies R&D Partnership: License for greenhouse technology from Thermaculture R&D program.

RESEARCH & DEVELOPMENT:

Controlled environment agriculture.

Plant-tissue culture (new cultures and processes).

Embryogenesis, biomass, miniature roses.

PRODUCTS IN DEVELOPMENT:

Controlled environment agriculture facilities. (Closed cycle energy efficient greenhouse).

Tissue culture automation processes and new cultivars.

Embryogenesis processes.

Biomass production processes.

AGREEMENTS BEING SOUGHT:

DistributionX . . .

MarketingX . . .

Research Contract . . .X . . .

Joint VentureX . . .

Technology Transfer . . .X . . .

FinancingX . . .

W. H. PERRON & CO. Ltd.

2914 Labelle Blvd.
Laval, Québec H7P 5R9
Canada

Telephone: (514)332-3619
FAX: (514)682-4959

Founded: 1928
Employees: 66
R&D: 2 full-time
5 part-time

Contact: Philip Thompson (Vice President)
Monique Dumas-Quesnel (Asst Research Director)

HISTORY:

Founded in 1928, W. H. Perron & Co. Ltd. is a leader in the field of ornamental horticulture.

FACILITIES:

The research & development division is headquartered in Boisbriand, Québec.

Apart from office space, over 900 sq. m. of greenhouse and covered space is used for hybridizing and overwintering plant material.

Roughly 50,000 sq. m. of field are used for testing and evaluating plant material in the ground and in containers.

SUBSIDIARIES / DIVISIONS:

There are four divisions:

Retail: which operates 3 garden centres.

Commercial: specializing in seeds for greenhouse and market growers.

Mail order.

Research & development: which exists in its present structure since 1987.

INVESTORS:

W. H. Perron & Co. Ltd. is a wholly owned subsidiary of Groupe W. H. Perron Inc. whose owners are the management of W. H. Perron & Co. Ltd. as well as the venture capital group FSTQ (Fonds de solidarité des travailleurs du Québec).

AGREEMENTS:

IRBVM (Institut de recherches en biologie végétale de Montréal): Sub-contract for the development of tissue-culture methods of production as well as cytological studies. This agreement is part of a research project funded in part by the National Research Council (NRC). Several agreements exist also for the production of W. H. Perron plant varieties.

RESEARCH & DEVELOPMENT:

Major project is the program of development for IRIS VERSICOLOR.

Complementary to this project is the development of world-first IRIS VERSICOLOR X ensata hybrids.

Several other projects regarding ornamental plant varieties are currently being underway.

PRODUCTS ON MARKET:

Several W. H. Perron varieties are presently on the market.

Best known is SPIRAEA "Goldmound" one of the most popular ornamental shrub varieties in the world.

PRODUCTS IN DEVELOPMENT:

The afore-mentioned IRIS hybrids are closest to market introduction along with biotechnology techniques for rapid production.

AGREEMENTS BEING SOUGHT:

DistributionX..

MarketingX..

Research Contract . . .X..

Joint VentureX..

Technology Transfer . . .X..

FinancingX..

In terms of R&D, the Company seeks agreements with biotechnology companies principally in the field of tissue-culture for rapid production of its hybrids and selections of plant materials. It also seeks agreements with growers and distributors of horticultural products for the propagation, sale, and distribution under license of same.

**QUEBEC BIOTECHNOLOGY COMPANIES
ENVIRONMENT**

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
E	ADS GROUPE CONSEIL Inc.	2155 Guy Suite 1200	Montréal, Québec H3H 2L9	(514)932-4454	(514)932-1518	René Fontaine	Director, R&D
						C. Lavoie	Director
E	AKAM ENTREPRISE Inc.	545 Road 249	Windsor, Québec J1S 2L7	(819)845-5993	(819)845-4998	André Mathieu	President
E	AQUARESEARCH Ltd.	27 Highway 143 South P.O. Box 208	North Hatley, Québec J0B 2C0	(819)842-2890	(819)842-2902	M.-C. Cantin	President
						Karl. F. Ehrlich	VP, Scientific Director
E	B. V. SORBEX Inc.	3480 University McGill University	Montréal, Québec H3A 2A7	(514)398-4276	(514)398-6678	B. Volesky	President
E	BCM BIOTECH Inc.	P. O. Box 7277	Charlesbourg, Québec G1G 5E5	(418)628-1337	(418)623-8793	Michel Pagé	President
E	BIOGENIE Inc.	350 Franquet Suite 10	Ste-Foy, Québec G1P 4P3	(418)653-4422	(418)653-3583	Benoit Cyr	President
						Jean-Luc Sansregret	Vice President
E	BIOLIX Inc.	2755 Dalton Suite 110	Ste-Foy, Québec G1P 3T1	(418)657-2666	(418)657-5600	Richard Painchaud	President
E	BIOMAX Inc.	764 St. Joseph East Suite 124	Québec, Québec G1K 3C4	(418)529-2585	(418)648-8951	Carl Genois	President
						André Lavoie	Vice President
E	C.R.E.A. LAB Inc.	360 St-Roch North	Rock Forest, Québec J1N 2T3	(819)864-6877	(819)864-7954	Arnold Ross	President
E	DIAGNOGENE Inc.	P. O. Box 8519	Ste-Foy, Québec G1V 4N5	(418)653-3847		Jean-Marc Juteau	President
						Marc Sirois	VP, R & D
E	ENVIROCONSEIL Inc.	3420 St-Joseph Blvd. East	Montréal, Québec H1X 1W6	(514)255-6375	(514)252-0071	Jacques Beaulieu	Director
						André Bisailon	President
						Jean Chartrand	Director
						Pierre Forest	Director
						Jude Simundic	Director,
						Michel Thessereault	Dir., Public Relations
E	ENVIRODEV Inc.	360 St-Roch North	Rock Forest, Québec J1N 2T3	(819)864-6877	(819)864-7954	Lawrence W. Perry	President

QUEBEC BIOTECHNOLOGY COMPANIES
ENVIRONMENT

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
E	ENVIROMINE Inc.	1352 Delaunay	Ancienne-Lorette, Québec G2E 3V4	(418)877-3997	(418)628-4766	Roger Guay	Vice President
						André Paquet	President
E	ENVIROTEM Inc.	P. O. Box 3000 Témiscaming	Témiscamingue, Québec J0Z 3R0	(819)627-4317	(819)627-1458	Jacques Rocray	President
E	GENDRON LEFEBVRE	1 Place Laval Suite 200	Laval, Québec H7N 1A1	(514)384-1260	(514)629-8737	Roger Desbois	Director, Urban Eng.
						Marc-André Gendron	President
						Denis Guindon	Manufacturing Director
						Chantale Morasse	Director, R&D
E	JOHN MEUNIER Inc.	6290 Perinault	Montréal, Québec H4K 1K5	(514)334-7230	(514)334-5070	Pierre Belisle	Manufacturing Director
						Gilles Filion	Director General
						Hoang Van Hoi	Director, R&D
						Gabriel Meunier	President
E	MONENCO Inc.	2045 Stanley P. O. Box 6088, Station "A"	Montréal, Québec H3C 3Z8	(514)499-3300	(514)499-3223	William J. Cosgrove	VP, Corporate Dev.
						Sylvain Léger	Sr Process Engineer
E	NORANDA TECHNOLOGY CENTRE	240 Hymus Blvd.	Pointe-Claire, Québec H9R 1G5	(514)630-9300	(514)630-9379	Lucy Rosato	Program Manager
E	POLYFERM Inc.	1044 Woodside Drive	Dollars-Des-Ormeaux, Qc H9B 1P9	(514)340-4525	(514)340-4159	Juliana Ramsay	President
						Bruce Ramsay	Vice President
E	PREMIER ENTERPRISES CDN Ltd.	454 Chemin Témiscouata P. O. Box 2600	Rivière-du-Loup, Québec G5R 4C9	(418)862-6356	(418)862-6685	Bernard Bélanger	President
						Alain Bélanger	Exec. VP
						Serge E. Bergeron	VP, Production
						Marc Métivier	Director General, R&D
E	SANEXEN ENVIRONMENTAL SERVICES Inc.	991 Montée Ste-Julie	Varennnes, Québec J3X 1P7	(514)652-4635	(514)652-5857	Robert Dubeau	Dir., Site remediation
						Daniel Latendresse	Dir., Water Treatment

QUEBEC BIOTECHNOLOGY COMPANIES
ENVIRONMENT

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
						Jean Paquin	VP, Technology
						Jean-Guy Soulard	President
E	<u>SERRENER CONSULTATIONS Inc.</u>	360 St-Roch North	Rock Forest, Québec J1N 2T3	(819)864-6877	(819)864-7954	Jean Shoiry	President
E	<u>SERVICES BIO-CONTROLE</u>	2600 Dalton	Ste-Foy, Québec G1P 3S4	(418)653-3101	(418)653-3096	Serge Sévigny	President
E	<u>SNC-LAVALIN Inc.</u>	2 Place Félix-Martin	Montréal, Québec H2Z 1Z3	(514)866-1000	(514)392-4758	Diana Mourato	Dir., Site remediation
						Bechara Safi	VP, Technical Manager
E	<u>SODEXEN Inc.</u>	2519 Chomedey Blvd.	Laval, Québec H7T 2R2	(514)333-5766	(514)333-5759	Robert Kalnins	Marketing Director
E	<u>TEKNIKA GROUP</u>	150 Vimy North	Sherbrooke, Québec J1J 3M7	(819)562-3871	(819)563-3663	Alexandra Kantardjieff	Director, R&D
E	<u>VALORACTION Inc.</u>	360 St-Roch North	Rock Forest, Québec J1N 2T3	(819)864-7942	(819)864-7954	Lawrence W. Perry	President
E	<u>WATERLOO ENVIRONMENTAL Inc.</u>	201 Western	Waterloo, Québec J0E 2N0	(514)539-3663	(514)539-2660	Ernest Biéri	President
						Jacques Biéri	Vice President
E	<u>ZENON ENVIRONMENT Inc.</u>	10390 Louis H. Lafontaine	Anjou, Québec H1J 2T3	(514)493-4733	(514)493-4725	Lisette Provencher	

ADS GROUPE CONSEIL Inc.

2155 Guy
Suite 1200
Montréal, Québec H3H 2L9
Canada

Telephone: (514)932-4454**FAX:** (514)932-1518**Founded** 1985**Employees:** 45**R&D:****Contact:** René Fontaine (Director, R&D)**Sales:** \$ 1 - 1.5 M

AGREEMENTS:

Institut Armand-Frappier.

RESEARCH & DEVELOPMENT:

Methods of treatment of wastewaters, hydrocarbon-contaminated soils and sludges.

AGREEMENTS BEING SOUGHT:

Distribution

Marketing

Research Contract . . .X. . .

Joint VentureX. . .

Technology Transfer . . .X. . .

Financing

AKAM ENTREPRISE Inc.

545 Road 249
Windsor, Québec J1S 2L7
Canada

Telephone: (819)845-5993**FAX:** (819)845-4998**Founded:** 1990**Employees:****R&D:****Contact:** André Mathieu (President)**Sales:****HISTORY:**

Founded in June 1990, with the specific goal to commercialize Japanese biotechnologies throughout North America (Canada and U.S.A.).

FACILITIES:

Bench scale and industrial size pilot plant for industrial wastewaters treatability studies.
Production shop for biological aerated filter components construction.

BUSINESS STRATEGY:

Development and commercialization of Japanese biotechnologies for environmental control in different industrial sectors (pulp and paper, food, textile, chemical, pharmaceutical, etc...).

AGREEMENTS:

Signed license agreements with a major Japanese company specialized in the field of industrial wastewater treatment.

RESEARCH & DEVELOPMENT:

Industrial wastewater biotreatment.
Toxicity degradation in industrial wastewaters and sludges.
Technologies for industrial wastewater minimization.

PRODUCTS ON MARKET:

ACTICONTACT packed bed reactor for industrial wastewaters treatment.
The system is based on the formation of biological film of porous supporting material.
The biofilm degrades organic and toxic materials present in industrial wastewaters.

PRODUCTS IN DEVELOPMENT:

Screw press for sludge dewatering.
Fibax filtration for industrial process water minimization (pulp and paper with water recycling).

AGREEMENTS BEING SOUGHT:

Distribution.....
Marketing.....
Research Contract...X...

Joint Venture.....X....
Technology Transfer.....
Financing.....

AQUARESEARCH Ltd.

27 Highway 143 South
P.O. Box 208
North Hatley, Québec J0B 2C0
Canada

Telephone: (819)842-2890

FAX: (819)842-2902

Founded: 1984

Employees: 7

R&D:

Contact: Karl F. Ehrlich (VP, Scientific Director)

Sales: \$ 0 - 1 M

HISTORY:

Aquaresearch Ltd. was founded in 1984, as an outgrowth of "Le Centre de recherche environnementale".

Aquaresearch Ltd. specializes in water management based on ecological engineering and the use of the Bacta-Pur™ System developed by Aquaresearch Ltd.

FACILITIES:

Aquaresearch Ltd. currently operates its own office, research, production and representative teaching/training facility of about 700 sq. m. (7000 sq. ft.).

Aquatic restoration studies and prototypes are tested in our five experimental ponds, and 3 ha (7.5 acre) lake.

Aquaresearch Ltd. maintains its own R&D staff and laboratories for bench and pilot scale development as well as for contract biodegradation studies.

"Le Centre de recherche environnementale" operates a commercial fish hatchery, which operates exclusively on water re-use (~98%) technologies.

RESEARCH & DEVELOPMENT:

Optimization of the Bacta-Pur™ System in terms of strain selection and control of physiological condition for the purification of industrial, domestic, aquacultural and agricultural wastes.

Development of bioreactors of a generic type and on a client-specific basis.

Water body restoration.

PRODUCTS ON MARKET:

The Bacta-Pur™ System is based on state-of-the-art biotechnologies, microbial conditioners and growth enhancers, environmental control technologies and experience and knowledge to integrate biotechnology into wastewater treatment, bioremediation and water body restoration.

Aquaresearch Ltd. also markets operational assistance to wastewater treatment including efficiency evaluations, biodegradation studies, and operational manuals based on biological realities of wastewater treatment.

PRODUCTS IN DEVELOPMENT:

Continual improvement in the-state-of-the-art Bacta-Pur™ System.

Biological filters for wastewater and water body restoration.

AGREEMENTS BEING SOUGHT:

DistributionX.

MarketingX.

Research ContractX.

Joint Venture

Technology Transfer

Financing

B. V. SORBEX Inc.

3480 University
 McGill University
 Montréal, Québec H3A 2A7
 Canada

Telephone: (514)398-4276
FAX: (514)398-6678

Founded: 1987
Employees: 3-6
R&D:

Contact: B. Volesky (President)

Sales:

RESEARCH & DEVELOPMENT:

Mechanism of biosorption.

Commercial biosorbent materials for metal removal / recovery.

PRODUCTS ON MARKET:

Services and treatability studies concerning metal-bearing wastewaters.

PRODUCTS IN DEVELOPMENT:

A family of newly developed biosorbents for removal and recovery of heavy metals from industrial solutions and wastewaters.

New biosorbent technology is similar to ion exchange but cheaper and better.

AGREEMENTS BEING SOUGHT:

Distribution
 MarketingX.
 Research Contract . . .X.

Joint VentureX.
 Technology TransferX.
 FinancingX.

BCM BIOTECH Inc.
P. O. Box 7277
Charlesbourg, Québec G1G 5E5
Canada

Telephone: (418)628-1337

FAX: (418)623-8793

Founded: 1988

Employees: 3

R&D:

Contact: Michel Pagé (President)

Sales: \$ 60 000

HISTORY:

Company founded in 1988 by Dr Michel Pagé.
Environment and agro-food business.

FACILITIES:

Laboratory space at Laval University, Faculty of Medicine, Québec.

SUBSIDIARIES/DIVISIONS:

Owned 31 % of MBCM Biotech, Moscow.

BUSINESS STRATEGY:

Development of immunoassay kits for environment, agriculture, veterinary medicine, and human health care.

Consulting services in biotechnology.

Distribution of biotechnology products under license.

AGREEMENTS:

Agreements with two Institutes in Moscow, and with another Canadian biotechnology company.

PRODUCTS IN DEVELOPMENT:

Development of immunoassay kits (ELISA) for the qualitative and quantitative determination of various toxins (saxitoxines), important products in the environment and in the food industry.

Development of immunoassays for domoic acid (marine toxine).

AGREEMENTS BEING SOUGHT:

DistributionX.

Marketing

Research ContractX.

Joint VentureX..

Technology Transfer

FinancingX.

BIOGENIE Inc.
 350 Franquet
 Suite10
 Ste-Foy, Québec G1P 4P3
 Canada

Telephone: (418)653-4422
FAX: (418)653-3583

Founded: 1986
Employees: 20
R&D: 6

Contact: Benoît Cyr (President)

Sales:

FACILITIES:

6000 sq. ft. including engineering and laboratory space (chemical analysis, microbiology, process simulation).
 Soil biotreatment mobile units.

BUSINESS STRATEGY:

Since 1986, Biogénie Inc. has been developing biological processes for treatment of soils, water effluents, and air.

RESEARCH & DEVELOPMENT:

Waste treatment.
 Systems development.
 Thick foam bioreactors for the treatment of heavily-loaded effluents.
 Physical/chemical process for the treatment of contaminated soils.
 Development of a high-rate biotreatment process for soil decontamination.

PRODUCTS ON MARKET:

Soil and groundwater decontamination (organic contaminants, hydrocarbon, pentachlorophenol..)
 Management plan for industrial wastewaters (pulp and paper plants).
 Design of systems for the recovery of wastewater sludges.
 Industrial wastewaters treatability studies (biological treatment).

AGREEMENTS BEING SOUGHT:

Distribution.....	Joint Venture.....X..
Marketing.....	Technology Transfer.....X..
Research Contract....X..	Financing.....

BIOLIX Inc.
 2755 Dalton
 Suite 110
 Ste-Foy, Québec G1P 3T1
 Canada

Telephone: (418)657-2666
FAX: (418)657-5600

Founded: 1988
Employees: 4
R&D:
Sales:

Contact: Richard Painchaud (President)

HISTORY:

Founded in 1988, and is actually developing biotechnology in the mining and environmental field.

BUSINESS STRATEGY:

Biotechnology consultants.

Uses new improved microorganisms along with innovative bioreactors.

AGREEMENTS:

Ressources Sainte-Geneviève.

Centre de recherche minérale du Québec.

RESEARCH & DEVELOPMENT:

Optimization of bioleaching parameters using a novel bioreactor and a new improved bacterial strain.

Biosorption and bioaccumulation.

Bioreactors design and scale-up.

Bioleaching of wastewater treatment and sewage sludges.

AGREEMENTS BEING SOUGHT:

DistributionX..
 Marketing
 Research Contract . . .X..

Joint VentureX..
 Technology Transfer . . .X..
 Financing

BIOMAX Inc.
 764 St. Joseph East
 Suite 124
 Québec, Québec G1K 3C4
 Canada

Telephone: (418)529-2585
FAX: (418)648-8951

Founded: 1986
Employees:
R&D:
Sales:

Contact: Carl Genois (President)
 André Lavoie (Vice President)

HISTORY:

Founded in 1986 as Serrener Inc.
 Company changed name to BIOMAX Inc., in December 1989.

FACILITIES:

28,000 sq. ft. for R&D in yard waste composting (grass and leaves).
 30 sq. m. for laboratory.
 560 sq. m. for R&D, in-vessel composting system for highly putrescible organic wastes.

BUSINESS STRATEGY:

Prior mission was R&D on equipments and systems in waste management.
 Later mission focussed on organic waste management (consulting, R&D, operation, implementation).

RESEARCH & DEVELOPMENT:

Recycling of organic wastes mainly by composting but also by landspreading, chemical stabilisation.

PRODUCTS ON MARKET:

Turnkey systems for:

- Yard waste composting.
- Septage sludge treatment and composting.
- Sewage sludge treatment and composting.

AGREEMENTS BEING SOUGHT:

DistributionX . . .
 MarketingX . . .
 Research Contract . . .X . . .

Joint VentureX . . .
 Technology Transfer . . .X . . .
 FinancingX . . .

C.R.E.A. LAB Inc.
 360 St-Roch North
 Rock Forest, Québec J1N 2T3
 Canada

Telephone: (819)864-6877

FAX: (819)864-7954

Founded: 1990

Employees: 3

R&D:

Contact: Arnold Ross (President)

Sales:

HISTORY:

C.R.E.A. LAB Inc. has been providing environment related research and development for established clients since 1988, working in conjunction with university research centres. The specialized laboratory services include analysis of sewage and septic tank sludge, hazardous and industrial wastes, contaminated soils and sanitary landfill sites.

FACILITIES:

Laboratory for environmental analysis (organic, inorganic and research and development).

INVESTORS:

Serrener Consultation Inc. (100%).

BUSINESS STRATEGY:

Specialized services of environmental analysis, of research and development, and of technical expertise for industry, the municipalities, and the contractors in environment.

PRODUCTS ON MARKET:

Service of inorganic analysis (water, air, soil, waste).

Organic analysis (water, air, soil, waste).

AGREEMENTS BEING SOUGHT:

Distribution.....
 Marketing.....
 Research Contract.....

Joint Venture.....
 Technology Transfer.....
 Financing.....

DIAGNOGENE Inc.

P. O. Box 8519
 Ste-Foy, Québec G1V 4N5
 Canada

Telephone: (418)653-3847 / (514)667-9502

FAX:

Founded: 1991

Employees: 2

R&D:

Contact: Jean-Marc Juteau (President)

Sales:

HISTORY:

DIAGNOGENE Inc. was founded in 1991 to conduct R&D, in the field of environment and health care, using genetic engineering and recombinant DNA technologies.

FACILITIES:

University laboratory facilities (55 sq. m.).

INVESTORS:

Ministère de l'environnement du Québec.

BUSINESS STRATEGY:

R&D and technology transfer for governments and industries.

RESEARCH & DEVELOPMENT:

Detection and identification of pathogenic and water-borne microorganisms by recombinant DNA technologies.

PRODUCTS IN DEVELOPMENT:

Specificity testing of DNA probes for diagnostic.

AGREEMENTS BEING SOUGHT:

DistributionX . . .

Marketing

Research Contract . . .X . . .

Joint Venture

Technology Transfer . . .X . . .

Financing

ENVIROCONSEIL Inc.

3420 St-Joseph Blvd. East
Montréal, Québec H1X 1W6
Canada

Telephone: (514)255-6375

FAX: (514)252-0071

Founded: 1988

Employees: 15

R&D: 1 PhD

Contact: Michel Thessereault (Director, Public Relations)

Sales: \$ 800 000

HISTORY:

Founded in 1988, Enviroconseil Inc. is specialized in environmental studies.
Consulting firm in environment.

SUBSIDIARIES/DIVISIONS:

Division of Laboratoire de Béton Ltd.

GéoConseil Inc.

Sirem, X-Per-X, Bowe & Landry.

AGREEMENTS:

R&D collaborations with McGill Research Centre for study of soils and under water contamination.

RESEARCH & DEVELOPMENT:

Hydrogeology.

Soil contamination.

Biodegradation.

AGREEMENTS BEING SOUGHT:

Distribution

Marketing

Research Contract

Joint Venture

Technology Transfer

Financing

ENVIRODEV Inc.
 360 St-Roch North
 Rock Forest, Québec J1N 2T3
 Canada

Telephone: (819)864-6877
FAX: (819)864-7954

Founded: 1990
Employees: 3
R&D:

Contact: Lawrence W. Perry (President)

Sales:

HISTORY:

November 1991, Envirodev Inc. started 2M\$ research and development project with École Polytechnique de Montréal for microbial degradation process of contaminated soils.

INVESTORS:

Biocapital, Investment Fund in Biotechnology (33%).
 Groupe Serrener Inc. (33%).
 Fafard et Frères (33%).

BUSINESS STRATEGY:

Promoting research and development in environment by participating firms in sectors of full expansion (contaminated soils, and industrial and urban residues).

AGREEMENTS:

North America and Europe exclusive license on using the results of research.

RESEARCH & DEVELOPMENT:

R&D project on manufacturing organic fertilizers from residues.

PRODUCTS IN DEVELOPMENT:

Bioreactor for treatment of contaminated soils.
 Complete treatment procedures for contaminated soils.
 Manufacturing process for organic fertilizers from residues.

AGREEMENTS BEING SOUGHT:

Distribution
 Marketing
 Research Contract

Joint Venture
 Technology Transfer
 Financing

ENVIROMINE Inc.
1352 Delaunay
Ancienne-Lorette, Québec G2E 3V4
Canada

Telephone: (418)877-3997
FAX: (418)628-4766

Founded: 1987
Employees: 2
R&D:
Sales:

Contact: Roger Guay (Vice President)

HISTORY:

Founded in 1987, Enviromine Inc. has been active in the development of mining environment restoration strategies, as well as in the applied research and development fields.

FACILITIES:

The company has access to research laboratories including microbiological facilities, greenhouse and many other experimental tools.

RESEARCH & DEVELOPMENT:

Carrying out research activities in biohydrometallurgy, pre-treatment of refractory gold ores, biodegradation of cyanides in gold mining industry, site restoration and revegetation of mining environments.

Biodegradation of toxic wastes and biotransformation of toxic chemicals.

Control of acid mine drainage by use of biocides.

Control of acid mine water acidity.

PRODUCTS ON MARKET:

Consulting services in restoration on mining environment.

Reprocessing of tailings, fertilization and passive treatment of acid mine drainage.

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract **X** . .

Joint Venture
Technology Transfer
Financing

ENVIROTEM Inc.
P. O. Box 3000
Témiscaming
Témiscamingue, Québec J0Z 3R0
Canada

Telephone: (819)627-4317
FAX: (819)627-1458

Founded: 1990
Employees: 20
R&D:

Contact: Jacques Rocray (President)

Sales:

FACILITIES:

Facility for exploitation of activated sludges.

SUBSIDIARIES/DIVISIONS:

A wholly owned subsidiary of Tembec Inc.

BUSINESS STRATEGY:

Managing and exploiting wastewater treatment system for the industrial complex of Tembec Inc.
Promote and carry out the environmental corporate policy of Tembec Inc.

RESEARCH & DEVELOPMENT:

Carrying out R&D for Tembec Inc.
Develop and commercialize new techniques and/or technologies to minimize the industrial impacts of Tembe Inc. and its divisions on environment.

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract

Joint Venture
Technology Transfer
Financing

GENDRON LEFEBVRE

1 Place Laval
Suite 200
Laval, Québec H7N 1A1
Canada

Telephone: (514)384-1260**FAX:** (514)629-8737**Founded:** 1959**Employees:** 300**R&D:**

Contact: Marc-André Gendron (President)
Roger Desbois (Director, Urban Engineering)

Sales:**BUSINESS STRATEGY:**

Engineering consultants on environmental management.

Automation of methods of analysis.

Feasibility studies and demonstration of new processes optimization and control.

PRODUCTS IN DEVELOPMENT:

Developing methods of biotreatment of industrial and agricultural effluents and potable water, automated analysis, and biosensor probes.

AGREEMENTS BEING SOUGHT:Distribution **X** . .

Marketing

Research Contract

Joint Venture **X** . .Technology Transfer . . . **X** . .

Financing

JOHN MEUNIER Inc.
6290 Perinault Street
Montréal, Québec H4K 1K5
Canada

Telephone: (514)334-7230
FAX: (514)334-5070

Founded: 1948
Employees: 80
R&D:
Sales:

Contact: Gabriel Meunier (President)

RESEARCH & DEVELOPMENT:

Carrying out research and development on filtration through peat moss, compressed air jets, and bio-filters.

Application of biocarbon (biological filter) for pulp and paper treatment of effluents.

PRODUCTS ON MARKET:

Manufactures biological filters for wastewater treatment systems.

AGREEMENTS BEING SOUGHT:

Distribution **X** . . .

Marketing

Research Contract

Joint Venture **X** . . .

Technology Transfer

Financing

MONENCO Inc.

2045 Stanley
P. O. Box 6088, Station "A"
Montréal, Québec H3C 3Z8
Canada

Telephone: (514)499-3300

FAX: (514)499-3223

Founded: 1907

Employees: 1800

R&D: 25, 5 PhDs

Sales: \$ 220 M

Contact: William J. Cosgrove
(VP, Corporate Development)

HISTORY:

Consulting engineering firm specialized in environment, energy and industrial transformation. Services offered to public and private companies, governments, and to international financing organizations operating in Canada and in more than 40 countries.

SUBSIDIARIES/DIVISIONS:

More than 26 subsidiaries worldwide, including 11 subsidiaries throughout Canada.

INVESTORS:

Public company traded on the Montréal Stock Exchange.

RESEARCH & DEVELOPMENT:

Peat extraction and processing. (Biomass conversion).

Hydrocarbons, petrochemical products, BPC and aromatic halogens degradation.

Industrial wastewaters treatment.

Cleaning of contaminated soils.

Pulp and Paper transformation.

Soil remediation.

Laboratory environmental analysis.

AGREEMENTS BEING SOUGHT:

Distribution

Marketing

Research Contract

Joint Venture

Technology Transfer

Financing

NORANDA TECHNOLOGY CENTRE

240 Hymus Blvd.
Pointe-Claire, Québec H9R 1G5
Canada

Telephone: (514)630-9300

FAX: (514)630-9379

Founded: 1963

Employees: 240

R&D: 200

Contact: Lucy Rosato (Program Manager)

Sales: \$ 30 M

HISTORY:

The Noranda Technology Centre was inaugurated in 1963.

Noranda had then decided to explore new sectors of activity in the processing and manufacture of metals.

NTC's research now spans in the fields of forestry, minerals, energy and manufacturing.

FACILITIES:

The Centre covers a total of 166,000 sq. ft.

It houses seven laboratories and four pilot plants.

- Environment and Mining,
- Mineral processing,
- Copper processing,
- Chemical/Metallurgy,
- Energy and product applications,
- Forest technologies.
- Manufacturing technologies.

Human resources and administration make up the eighth department.

INVESTORS:

The Noranda Technology Centre is wholly-owned by Noranda Inc.

BUSINESS STRATEGY:

Technology development in minerals, forestry, energy, and manufacturing.

Economic evaluations.

Technology assessments.

Our mission is to identify, develop and transfer technologies to Noranda operations.

RESEARCH & DEVELOPMENT:

Bioabsorption.

Bioleaching.

Sulphate reduction.

Effluent treatment.

AGREEMENTS BEING SOUGHT:

Distribution.....

Marketing.....

Research Contract.....

Joint Venture.....

Technology Transfer.....

Financing.....

POLYFERM Inc.
1044 Woodside Drive
Dollars-Des-Ormeaux, Québec H9B 1P9
Canada

Telephone: (514)340-4525
FAX: (514)340-4159

Founded: 1991
Employees: 3
R&D: 3

Contact: Juliana Ramsay (President)

Sales:

FACILITIES:

Laboratories located on the premises of École Polytechnique de Montréal.

BUSINESS STRATEGY:

Product development and research contract.

RESEARCH & DEVELOPMENT:

Fermentation technology.

Biodegradation.

Industrial microbiology.

Biopolymers.

PRODUCTS ON MARKET:

Educational kits relating to solid waste management.

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract . . . **x** . . .

Joint Venture
Technology Transfer
Financing

PREMIER ENTERPRISES CDN Ltd.

454 Chemin Témiscouata
P. O. Box 2600
Rivière-du-Loup, Québec G5R 4C9
Canada

Telephone: (418)862-6356
FAX: (418)862-6685

Founded: 1933
Employees: 950
R&D: 33

Contact: Marc Métivier (Director General)
Premier Research Centre

Sales:

HISTORY:

Premier Enterprises CDN Ltd. was founded in 1963, and became the largest North American based company in peat moss business.

Premier Enterprises CDN Ltd. is currently operating peatbog and plants throughout Canada and U.S.A.

FACILITIES:

Québec
Alberta

Manitoba
Minnesota
Saskatchewan

SUBSIDIARIES/DIVISIONS:

Emerald Premier.

Peatrex.

Sogevex.

INVESTORS:

Listed on the Montréal Stock Exchange.

Fonds de solidarité des travailleurs du Québec.

BUSINESS STRATEGY:

Seeking strategic alliances with foreign companies involved in biotechnology, environment and biological controls.

RESEARCH & DEVELOPMENT:

Biopesticide.

Biofiltration engineering.

Biofertilizers.

Waste treatment.

PRODUCTS ON MARKET:

MYCORI MIX®.

PRO-MIX®.

ECOFLO®.

PRODUCTS IN DEVELOPMENT:

P.G.P.R. bacterially inoculated growing medium.

Industrial wastewater treatment systems.

Heavy metal absorption.

Dephosphatation of waste waters.

AGREEMENTS BEING SOUGHT:

DistributionX . . .

Marketing

Research Contract

Joint VentureX . . .

Technology Transfer . . .X . . .

Financing

SANEXEN ENVIRONMENTAL SERVICES Inc.

991 Montée Ste-Julie
Varennnes, Québec J3X 1P7
Canada

Telephone: (514)652-4635

FAX: (514)652-5857

Founded: 1985

Employees: 40

R&D:

Contact: Jean Paquin (VP, Technology)

Sales: \$ 6 M

BUSINESS STRATEGY:

Specialized environmental services based on field work.

AGREEMENTS:

Groupe Sanivan.

RESEARCH & DEVELOPMENT:

Waste treatment company developing systems for biodegradation of toxic wastes including chlorinated compounds, PCB and hydrocarbons in contaminated soils and sludges by selected microorganisms.

Treatment of wastewaters and wastes, decontamination of buildings and equipment.

PRODUCTS ON MARKET:

Biolysis™.

AGREEMENTS BEING SOUGHT:

Distribution

Marketing

Research Contract

Joint Venture

Technology Transfer X . .

Financing

SERRENER CONSULTATIONS Inc.

360 St-Roch North
 Rock Forest, Québec J1N 2T3
 Canada

Telephone: (819)864-6877**FAX:** (819)864-7954**Founded:** 1987**Employees:** 21**R&D:** 3**Sales:** \$ 2 M**Contact:** Jean Shoiry (President)**FACILITIES:**

Offices: - 360 St-Roch North
 Rock Forest (Québec).
 - 47 Duke
 Montréal (Québec).
 - 764 St-Joseph Est, #404
 Québec (Québec).

INVESTORS:

Groupe Serrener Inc. (80%) .
 BioCapital, Investment Fund in Biotechnology (20%).

AGREEMENTS:

Centre québécois de valorisation de la biomasse (CQVB).
 Centre St-Laurent.
 Universities.

BUSINESS STRATEGY:

Solely focused on waste management technologies, promoting integrated concepts for treatment, recovery, reduction and reutilization.

RESEARCH & DEVELOPMENT:

Corporation specializing in waste management and upgrading, with twenty professionals. Participates in the setting-up of solid waste integrated management projects, in which the recovery and recycling of residual matter from residential, commercial and industrial sectors plays an important role.

Serrener Consultations Inc. also is involved in the composting and chemical stabilization of various organic residues, such as septic tank and sewage treatment plant sludge.

PRODUCTS ON MARKET:

Permitting waste sites.
 Characterization studies.
 Site assessment and treatment.
 Recycling for municipal, commercial and industrial sector.
 Landfill and leachate management.
 Sludge dewatering and treatment.
 Composting technologies for organic recovery and re-use.

PRODUCTS IN DEVELOPMENT:

Composting technologies.
 Dewatering of sludges.
 Leachate treatment.

AGREEMENTS BEING SOUGHT:

Distribution
 Marketing
 Research Contract . . . X . . .

Joint Venture X . . .
 Technology Transfer . . . X . . .
 Financing X . . .

SERVICES BIO-CONTROLE

2600 Dalton
Ste-Foy, Québec G1P 3S4
Canada

Telephone: (418)653-3101
FAX: (418)653-3096

Founded: 1984
Employees: 10
R&D: 3

Contact: Serge Sévigny (President)

Sales:

FACILITIES:

Microbiology laboratory: 1000 sq. ft.

SUBSIDIARIES/DIVISIONS:

BioContrôle R&D.

BUSINESS STRATEGY:

Consultation in food microbiology.

Consultation in water treatment.

RESEARCH & DEVELOPMENT:

Probes: antibacterial activity of many industrial disinfectants against microorganisms.

Food microbiology and water microbiology.

PRODUCTS IN DEVELOPMENT:

Pathogenic microorganism identification kits.

AGREEMENTS BEING SOUGHT:

Distribution.....
Marketing.....
Research Contract.....

Joint Venture.....
Technology Transfer.....
Financing.....

SNC-LAVALIN Inc.

2 Place Félix-Martin
Montréal, Québec H2Z 1Z3
Canada

Telephone: (514)866-1000

FAX: (514)392-4758

Founded: 1911

Employees: 6000

R&D:

Contact: Diana Mourato
(Director, Waste Treatment & Site Remediation)

Sales: \$ 300 M

FACILITIES:

Mobile units for biological treatment of wastes.

INVESTORS:

Public company traded on Toronto and Montréal Stock Exchanges.

BUSINESS STRATEGY:

Waste treatment, soil remediation.

RESEARCH & DEVELOPMENT:

Bioreactor scale-up & development for liquid industrial wastes.

Separation devices.

Bioreactor for soil and sludge treatment.

Biofilters.

PRODUCTS IN DEVELOPMENT:

Multiplate bioreactor (liquid industrial wastes).

Bioslurry (hydrocarbon-contaminated soil and sludge).

Biofilter (air treatment).

AGREEMENTS BEING SOUGHT:

Distribution

Marketing

Research Contract . . .X..

Joint VentureX..

Technology Transfer . . .X..

Financing

SODEXEN Inc.
 2519 Chomedey Blvd.
 Laval, Québec H7T 2R2
 Canada

Telephone: (514)333-5766
FAX: (514)333-5759

Founded: 1975
Employees: 30
R&D: 2 PhDs, 5 MSc.
Sales:

Contact: Robert Kalnins (Marketing Director)

HISTORY:

Sodexen Inc. was founded in 1975 by Mr. Gilles J.C. Tremblay.

FACILITIES:

Laboratory: 3000 sq. ft.
 Offices (engineering): 4000 sq. ft.

BUSINESS STRATEGY:

To service industry and government in all aspects of environmental engineering and analysis.

RESEARCH & DEVELOPMENT:

Bioremediation.
 Industrial hygiene.
 Contaminated soil, wastewater treatment.

PRODUCTS IN DEVELOPMENT:

Bioreactors.
 Soil sampler.
 Soil washing with surfactants.
 Zebra mussel control.
 Asbestos fiber detector.
 Volatile organic sampler (stock sampling).

AGREEMENTS BEING SOUGHT:

Distribution
 Marketing
 Research Contract . . .X. . .

Joint VentureX. . .
 Technology Transfer
 Financing

TEKNIKA GROUP
150 Vimy North
Sherbrooke, Québec J1J 3M7
Canada

Telephone: (819)562-3871
FAX: (819)563-3663

Founded: 1928
Employees: 200
R&D: 10
Sales: \$ 6.0 M

Contact: Alexandra Kantardjieff (Director, R&D)

HISTORY:

Our involvement over the past 60 years in the development of a multitude of industries, businesses and municipalities ranks our firm among the most experienced in the design and completion of projects of every scope. Le Groupe Teknika serves all of the province of Québec from its offices in Sherbrooke, Granby and Montréal.

FACILITIES:

Other offices in Granby and Montréal.

SUBSIDIARIES / DIVISIONS:

Teknika R&D Inc., (Sherbrooke).
Les Laboratoires de l'Estrée Inc., (Granby).
Les consultants Lemieux, Royer, Donaldson, Fields et Associés Inc., (Sherbrooke).

INVESTORS:

Owned by 32 shareholders involved in project management and development.

BUSINESS STRATEGY:

Provide the research and development in all branches of engineering.
Operations in the fields of treatment in particular in industrial treatment.

RESEARCH & DEVELOPMENT:

Biological fixed film processes for industrial wastewater treatment and toxic compounds degradation.
Biotechnology engineering for environmental control in different industrial sectors.
Biotechnology engineering applied to sludge management, reutilisation and recovery in different industrial sectors.

PRODUCTS ON MARKET:

Effluent treatment by Acticontac System.

PRODUCTS IN DEVELOPMENT:

Effluent treatment by Acticontac System.

AGREEMENTS BEING SOUGHT:

Distribution.....
Marketing.....
Research Contract...X...

Joint Venture.....X..
Technology Transfer...X..
Financing.....

VALORACTION Inc.
360 St-Roch North
Rock Forest, Québec J1N 2T3
Canada

Telephone: (819)864-7942
FAX: (819)864-7954

Founded: 1988
Employees: 8
R&D: 2
Sales: \$ 1 M

Contact: Lawrence W. Perry (President)

FACILITIES:

DAB, septage dewatering located in Cowansville and Rimouski (Québec).

SUBSIDIARIES/DIVISIONS:

Bio M2.

INVESTORS:

Groupe Serrener Inc. (80%).
Biocapital, Investment Fund in Biotechnology (20%).

BUSINESS STRATEGY:

Develop and license cost effective treatment systems for liquid and solid wastes.

AGREEMENTS:

North American license for DAB Dewatering system.
Eastern Canada agent for Aquatec Inc.

RESEARCH & DEVELOPMENT:

Cost effective treatment systems for:

- Septage and wastewater, industrial and municipal.
- Landfill leachate, mine acid water, septage water.
- Packaged plants with products/services, toxic and non toxic liquids.
- Organic waste composting using windrow, aerated static pile and combination systems for inputs such as sludges, yard, food and animal wastes.
- Chemical stabilization of solid wastes.
- Landfill management drainage, leachate treatment, biogas and liner systems, partial and final closure, recovery and recycling systems.

PRODUCTS ON MARKET:

DAB™ Dewatering systems.
MEDIAFLEX™ filter systems.
AQUATEC™ treatment plants and products.
SITTLER™ compost turner for commercial and farm use.
SIMS 2000 self propelled turner.
Compost platforms design/operating services.
Turborator turbine aerators.

PRODUCTS IN DEVELOPMENT:

In-vessel compost system.

Balance Biological fertilizers from compost.

Organic odour reducer.

AGREEMENTS BEING SOUGHT:

DistributionX . . .

Marketing

Research Contract

Joint Venture

Technology Transfer . . .X . . .

FinancingX . . .

Distribution:

Contracting companies interested to sub-license/distribute DAB dewatering system in USA and Western Canada.

Developing relationships to enter US market with MEDIAFLEX filter system, SITTLER compost turner and composting technologies.

Technology Transfer:

Developing contacts for new technologies for waste treatment; organic and inorganic wastes, air, gas, water, etc.

Financing:

Interested in financial partners for new projects/technologies.

WATERLOO ENVIRONMENTAL Inc.

201 Western
Waterloo, Québec JOE 2N0
Canada

Telephone: (514)539-3663
FAX: (514)539-2660

Founded: 1988
Employees: 8
R&D: 4
Sales:

Contact: Ernest Biéri (President)

HISTORY:

Founded in 1988 as a fully owned subsidiary of Waterloo Evaporators Inc., founded in 1919.

FACILITIES:

30,000 sq. ft., local.
30,000 sq. ft., manufacturing and R&D.
3,000 sq. ft., distribution, Northern Québec.
3,000 sq. ft., distribution U.S.A.

SUBSIDIARIES/DIVISIONS:

Les Équipements R. Douville Inc.
Waterloo U.S.A. Inc.
Environix R&D Inc.

INVESTORS:

Waterloo Evaporators Inc.

BUSINESS STRATEGY:

Specialized in R&D and implementation of liquid waste treatment and recycling.
New techniques in waste management.

RESEARCH & DEVELOPMENT:

Removal and recycling of ink from magazines.
Recycling of organic and inorganic waste.

PRODUCTS ON MARKET:

Biomass combustion burners "Gasifiers".
Liquid cross flow filtration.

PRODUCTS IN DEVELOPMENT:

Ozone generators "Catalytic".
Organic waste recycling plants.

AGREEMENTS BEING SOUGHT:

Distribution.....
Marketing.....X....
Research Contract.....

Joint Venture.....
Technology Transfer.....
Financing.....

ZENON ENVIRONMENT Inc.

10390 Louis H. Lafontaine
Anjou, Québec H1J 2T3
Canada

Telephone: (514)493-4733

FAX: (514)493-4725

Contact: Lisette Provencher

Founded: 1982

Employees: 17

R&D: 5

Sales:

HISTORY:

Founded by la LYONNAISE DES EAUX in December 1982 under the name of SONEXEAU, (Société nouvelle d'exploitation eau et assainissement Inc.).

SONEXEAU had two (2) subsidiaries LAB-TEQ Inc. and CICHEM Ltée.

ZENON ENVIRONMENTAL Inc. bought SONEXEAU in August 1989 and the group has been merged under the names of ZENON ENVIRONMENT Inc. in October 1990.

FACILITIES:

On a total of 1000 sq. m., 60 sq. m. are directly involved in biotechnology and 600 sq. m. in different fields of water air & soil analysis

INVESTORS:

Zenon Environmental Inc. from Burlington, Ontario.

BUSINESS STRATEGY:

Development of water treatment techniques.

Development of membranes treatment uses.

RESEARCH & DEVELOPMENT:

Within a project with Centre Saint-Laurent, we aim at developing the membrane bioreactor uses in the industrial field. The membrane bioreactor is constituted by the association of a biological reactor (aerobic and anaerobic) and membrane filtration modules. The membrane acts as an absolute barrier which keeps the biomass in the reactor, separating the hydraulic detention time from the sludge detention time, allowing to obtain high concentration of biomass.

PRODUCTS ON MARKET:

Principal products are membranes.

The only product related to biotechnology is the membrane bioreactor (ZenoGem™).

PRODUCTS IN DEVELOPMENT:

ZenoGem™: To increase the uses of the ZenoGem by trying different types of membranes inside the ZenoGem to improve this product.

AGREEMENTS BEING SOUGHT:

Distribution.....

Marketing.....

Research Contract.....

Joint Venture.....

Technology Transfer.....

Financing.....

QUEBEC BIOTECHNOLOGY COMPANIES
FISHERIES

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
F	AQUABIOTECH Inc.	6 Du Parc P.O. Box 447	Grande-Rivière, Québec G0C 1V0	(418)385-2251	(418)385-3343	Hélène Drouin	President
F	BIOREX Inc.	969 route de l'Eglise Suite 250	Ste-Foy, Québec G1V 3V4	(418)654-1316	(418)654-9217	Marc Gagnon	President
F	STEICA GROUP	4300 Bourque Blvd. Suite 101	Rock Forest, Québec J1N 2A6	(819)564-4008	(819)564-7638	Luc A. Rainville	Program Director
						Robert Roy	President

AQUABIOTECH Inc.
 6 Du Parc
 P.O. Box 447
 Grande-Rivière, Québec G0C 1V0
 Canada

Telephone: (418)385-2251

FAX: (418)385-3343

Founded: 1989

Employees: 2

R&D:

Contact: Hélène Drouin (President)

Sales:

RESEARCH & DEVELOPMENT:

Biofiltration for closed aquaculture systems (fresh and seawater).
 Scale-up of production facilities, electronic monitoring equipment.

PRODUCTS IN DEVELOPMENT:

Water recirculation aquaculture systems.
 Electronic photoperiod controllers.

AGREEMENTS BEING SOUGHT:

Distribution **X** . . .

Marketing **X** . . .

Research Contract

Joint Venture **X** .

Technology Transfer

Financing

BIOREX Inc.
 969 route de l'Église
 Suite 250
 Ste-Foy, Québec G1V 3V4
 Canada

Telephone: (418)654-1316
FAX: (418)654-9217

Founded: 1978
Employees: 70
R&D: 8
Sales:

Contact: Marc Gagnon (President)

HISTORY:

Founded as Bio-Conseil Inc. in 1978.
 Changed name to BIOREX Inc. in 1987.
 Subsidiary of ACSI-BIOREX Inc. from 1986 to 1990.
 Previous subsidiaries:
 - Aquaterre Inc.
 - Pisciculture des Alléghanys Inc.
 - Criadero de Camarones de Chomes S.A.
 Production facilities abandoned in 1990.

SUBSIDIARIES/DIVISIONS:

Divisions: BIOREX Inc., Gaspé (Québec).
 BIOREX ATLANTIC, Caraquet (N.B.)

BUSINESS STRATEGY:

Consulting on organic farming.
 Consulting on aquaculture and fisheries.

AGREEMENTS:

Le Groupe ACSI Ltée.
 Pisciculture des Alléghanys Inc.
 Aquaterre Inc.
 Criadero de Camarones de Chomes S.A.

RESEARCH & DEVELOPMENT:

Fish farming.
 Marine biotechnology.
 Aquaculture including: salmon sterility and hybridization, shellfish and shrimp culture, seaweed extraction, composting and ensiling.
 Composting and ensiling of marine wrack, manures.
 Mussel breeding.

AGREEMENTS BEING SOUGHT:

Distribution
 Marketing
 Research Contract . . .X..

Joint Venture
 Technology Transfer . . .X.
 Financing

STEICA GROUP
 4300 Bourque Blvd.
 Suite 101
 Rock Forest, Québec J1N 2A6
 Canada

Telephone: (819)564-4008

FAX: (819)564-7638

Founded: 1987

Employees: 12, 1 PhD

R&D:

Contact: Robert Roy (President)

Sales:

FACILITIES:

260 sq. m. of office and laboratory space.

BUSINESS STRATEGY:

Involved in further investments and international agreements.

Negotiations for high-valued exploitation of aquatic biomass (freshwater and marine).

Designing of wastewater treatment using plants.

AGREEMENTS:

Metz Mannheim GmbH: indoor intensive fish farming plan under controlled conditions.

Laval University: new fish feed.

University of Québec (Rimouski): new seafood.

Fisheries & Oceans Canada: unexploited marine biomass.

RESEARCH & DEVELOPMENT:

Intensive fish farming: control on spawning and growth of sockeye, trout, sturgeon and bar.

Fishing, preservation and transformation of two unexploited marine biomass from the Gulf of St.

Laurent (krill and Calanus).

Newfish feed formula, new food for human consumption, value-added.

Designing of wastewater treatment plans with plants adapted to our Northern climate.

PRODUCTS IN DEVELOPMENT:

Tropical fish feed: pilot stage.

Intensive fish farming feed: research stage.

New seafoods: research stage.

AGREEMENTS BEING SOUGHT:

DistributionX . . .

MarketingX . . .

Research Contract . . .X . . .

Joint VentureX . . .

Technology Transfer . . .X . . .

FinancingX . . .

QUEBEC BIOTECHNOLOGY COMPANIES
HEALTH CARE

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
H	BIO-MEGA Inc.	2100 Cunard	Laval, Québec H7S 2G5	(514)682-4640	(514)682-8434	Paul Anderson James Chafouleas Pierre Dallaire Jacques Gauthier Yvan Guindon Jorge Jaramillo Suman Rakhit Jacques Roux	Associate Director, Associate Director, Controller, Treasurer President VP, R&D Director, Pharmacology Director, Chemistry Dir., Human Resources
H	BIO-RESEARCH LABORATORIES Ltd.	87 Senneville Road	Senneville, Québec H9X 3R3	(514)630-8200	(514)457-3883	Michael F. Ankcom Winn Brink Brian Broxup Yves Deschamps Joan Lefebvre George Lulham Jim Noveroske Barry Osborne Paul Sidney Pierre Tellier	President and CEO Dir., Client Services Director, Scientific Director, Clinical Labs Purchasing Manager Director, Toxicology VP, Toxicology VP, Marketing Dir., Regulatory Affairs VP, Pathology
H	BIOCHEM PHARMA Inc.	2550 Daniel Johnson Blvd. Suite 600	Laval, Québec H7T 2L1	(514)681-1744	(514)681-4207	Francesco Bellini Gervais Dionne Guy Ely John Gillard	President and CEO VP, R&D Medical Director Dir., Therapeutic Res.

QUEBEC BIOTECHNOLOGY COMPANIES
HEALTH CARE

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
						Philippe Lacaille	Exec VP, and CEO
						François Legault	VP, Finance & Treasurer
						Jim McDonald	VP, Public Affairs
						Silvio Nuzzo	VP, Diagnostic Division
						Roger Perrault	President, IAF Biovac
						Lawrence Wilson	VP, Legal Affairs
H	BIOMATRIX MEDICAL CANADA Inc.	275 Labrosse	Pointe-Claire, Québec H9R 1A3	(514)697-8851	(514)697-3670	Endre A. Balazs	President, CEO
						John Fielder	Advisor of the Board
						Danielle Simoneau-Grenon	Dir., Human Resources
						Donald E. Woodhouse	VP, Manufacturing
H	BIOSCAN CONTINENTAL Inc. (BCI)	350 Industriel Blvd. Suite 201	St-Eustache, Québec J7R 5V3	(514)974-0151	(514)491-3069	Gita Banik	President
						Upendra K. Banik	VP, CEO, Dir. R&D
						S. Cowan	Admin. Secretary
H	BIOSIGNAL Inc.	316 Carré St-Louis	Montréal, Québec H2X 1A5	(514)844-0118	(514)843-7372	Michael Denis	Scientific Director
						Guy Lambert	President
H	BIOVET Inc.	1550 Metcalfe Suite 1100	Montréal, Québec H3A 1X6	(514)847-5751	(514)285-4597	Camil Moore	Vice President
H	BURROUGHS WELLCOME Inc.	16751 Trans-Canada Highway	Kirkland, Québec H9H 4J4	(514)694-8220	(514)694-8201	Kristina Adomonis	Dir., Business Dev.
H	Canadian Medical Research Associates Inc	550 Sherbrooke West Suite 1205	Montréal, Québec H3A 1B9	(514)842-3759	(514)842-7871	Oleg Romar	Chairman of the Board
H	CGF PHARMATECH Inc.	3516 Griffith	St-Laurent, Québec H4T 1A7	(514)343-0344	(514)343-0340	Jean-Paul Chausseau	President
						Louise E. Gaboriault	VP, Corporate Affairs
H	HAEMACURE BIOTECH Inc.	245 Hymus Blvd.	Pointe-Claire, Québec H9R 1G6	(514)630-8839	(514)630-8845	Teresa Brodniewicz	VP, R&D
						Marc M. Paquin	President

QUEBEC BIOTECHNOLOGY COMPANIES
HEALTH CARE

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
						Andrée Veronineau	Director Marketing
H	<u>IBEX TECHNOLOGIES Inc.</u>	5645 Chemin St-François	St-Laurent, Québec H4S 1W6	(514)956-8430	(514)956-7485	Robert Heft	President
						Joe Zimmerman	VP, R&D
H	<u>IMMUNOCORP SCIENCES Inc.</u>	5800 Royalmount Ave.	Montréal, Québec H4P 1K5	(514)733-1900	(514)733-1212	Elliot Block	President, CEO
						Pierre DuRuisseau	VP, General Manager
H	<u>ITR LABORATORIES Inc.</u>	19061 Clark Graham Blvd.	Baie d'Urfé, Québec H9X 3T1	(514)457-7400	(514)457-7303	D. Cuitar	Manager Operation
						J. Eidnes	Manager Accounting
						T. Hirakaws	Vice President
						T. Ladd	Manager Marketing
						A. Locas	Man., Human Resources
						K. Yamanouchi	President
H	<u>KAMI MARK Inc.</u>	791 Lajoie	Dorval, Québec H9P 1G7	(514)633-9064	(514)633-9064	Robert Roy	President
H	<u>LIOPHARM Inc.</u>	5929 Trans-Canada Highway Suite 30	St-Laurent, Québec H4T 1A1	(514)747-8942	(514)747-8944	Serge Pitre	VP, General Manager
						Donald Simmons	President
H	<u>MEDICORP SCIENCES Inc.</u>	5800 Royalmount Ave.	Montréal, Québec H4P 1K5	(514)733-3000	(514)733-1212	Elliot T. Block	President
						Pierre Du Ruisseau	VP, R&D
H	<u>MERCK FROSST CANADA Inc.</u>	16711 Trans-Canada Highway	Kirkland, Québec H9H 3L1	(514)695-7920	(514)630-2670	Sandu Goldstein	Director, Research Adm.
						Cecil Pickett	VP, Merck Frosst Labs
						Michael Tarnow	President
H	<u>OMEGA LABORATORIES Ltd.</u>	11177 Hamon	Montréal, Québec H3M 3E4	(514)335-0310	(514)339-1407	E. R. Vrancken	Director, R&D
H	<u>PFIZER CANADA Inc.</u>	17300 Trans-Canada Highway	Kirkland, Québec H9J 2M5	(514)695-0500	(514)426-7084	Gordon J. Fehr	President
H	<u>PHOENIX INTL LIFE SCIENCES Inc.</u>	2330 Cohen	St-Laurent, Québec H4R 9Z7	(514)333-0033	(514)333-8861	John W. Hooper	President

QUEBEC BIOTECHNOLOGY COMPANIES
HEALTH CARE

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
						Judy Zilber	Vice President, Marketing
H	POLYCHOL Inc.	1550 Metcalfe Suite 1100	Montréal, Québec H3A 1X6	(514)847-5751	(514)285-4597	James McDonald	President
H	QUANTUM BIOTECHNOLOGIES Inc.	6100 Royalmount Ave.	Montréal, Québec H4P 2R2	(514)496-6380	(514)496-6232	Suzanne Lebel	Director, R&D
						Steve Slilaty	President
H	QUELAB LABORATORIES Inc.	2331 Dandurand	Montréal, Québec H2G 3C5	(514)277-2558	(514)277-4714	Roger Boulais	CEO
H	RICHELIEU BIOTECHNOLOGIES Inc.	5726 Laurier	St-Hyacinthe, Québec J2S 3V8	(514)774-3505	(514)773-7433	Richard Parsons	President
H	ROUGIER BIO-TECH Ltd.	8480 St-Laurent Blvd.	Montréal, Québec H2P 2M6	(514)381-5631	(514)383-4493	Azadeh Abedian	Sr Scientist
						Guy Angers	Chairman, CEO
						Robert Cyr	Purchasing Manager
						Marcel Dubois	President
						Francine Maynard	VP, Sales and Marketing
						Sushil Mohapatra	Sr Scientist
						Sylvine Savoie	Sr Scientist
						William Shestowsky	Sr Scientist
						Hanna Sikorska	VP, R&D
H	SANDOZ CANADA Inc.	385 Bouchard Blvd.	Dorval, Québec H9R 4P5	(514)631-6775	(514)631-3373	Lyse Beauregard-Zollinger	Project leader, Clinical
						Sylvie Bouchard	Medical Director
						Gerard F. Murphy	Senior Medical Advisor
						Luc Vachon	Co-Dir. Clinical Res.
H	SCHERING CANADA Inc.	3535 Trans-Canada Road	Pointe-Claire, Québec H9R 1B4	(514)426-7300	(514)695-7334	Claude Petitclerc	Medical Research
H	SYNERMED Inc.	1688, 50th Ave.	Lachine, Québec H8T 2V5	(514)633-1112	(514)633-8039	Guido Bosmans	VP, International Affairs
						Jerry Denney	President

BIO-MÉGA Inc.
2100 Cunard
Laval, Québec H7S 2G5
Canada

Telephone: (514)682-4640
FAX: (514)682-8434

Founded: 1984
Employees: 112
R&D: 98
Sales:

Contact: Yvan Guindon (VP, R&D)

FACILITIES:

Pharmaceutical research laboratories.

SUBSIDIARIES/DIVISIONS:

Boehringer-Ingelheim (Canada) Ltd.

BUSINESS STRATEGY:

Pharmaceutical research company with emphasis on chemistry, pharmacology, and biochemistry.

RESEARCH & DEVELOPMENT:

Inhibitors of the renin-angiotensin cascade.
Antiviral agents for herpes simplex I and II, and AIDS.

AGREEMENTS BEING SOUGHT:

Distribution.....
Marketing.....
Research Contract.....

Joint Venture.....
Technology Transfer.....
Financing.....

BIO-RESEARCH LABORATORIES Ltd.

87 Senneville Road
 Senneville, Québec H9X 3R3
 Canada

Telephone: (514)630-8200
FAX: (514)457-3883

Founded: 1965
Employees: 483
R&D:

Contact: Winn Brink (Director, Client Services)

Sales: \$ 24 M

HISTORY:

Member: Association of Biotechnology Companies.

Bio-Research is one of the world's leading independent contract research laboratories, serving industry and government in North America, Europe and Japan.

Bio-Research conducts all studies according to Good Laboratory Practice Guidelines.

Facilities have been inspected and approved by:

The United States FDA.

The U.S. Environmental Protection Agency (EPA).

American Association for Accreditation of Laboratory Animal Care (AAALAC).

The Canadian Council on Animal Care (CCAC).

Japanese Ministry of Agriculture, Forestry and Fisheries (MAFF).

Japanese Ministry of Health and Welfare (Pharmaceutical Affairs Bureau).

FACILITIES:

Located on a 32 ha site just outside Montréal, and operates a 170,000 sq. ft. research centre.

The facilities contain 113,000 sq. ft. of AAALAC-approved animal housing, 34,000 sq. ft. of biomedical / analytical laboratory space, and 23,000 sq. ft. of toxicology support services.

INVESTORS:

Caisse de dépôt et placement du Québec.

Mérieux Holdings.

BUSINESS STRATEGY:

The preclinical division specializes in conducting research on investigational drug compounds, particularly in respiratory, cardiovascular, and neurological areas. Its range of techniques includes cardiovascular profiling, intravenous infusion, neurotoxicology, image analysis, electron and fluorescence microscopy, in vivo bioassays, and specialized inhalation technology.

RESEARCH & DEVELOPMENT:

Conducts research and testing in the following areas:

Analytical research.

Metabolism studies.

Pre-clinical research.

Toxicity tests (general toxicology studies, inhalation, reproduction, and experimental toxicology studies), diagnostics.

Clinical pathology.

Neurotoxicology.

Wound healing.

Biomaterials.

Long-term continuous infusion.

Immunotoxicology.

Genetic toxicity of new drugs and chemicals, occupational health and safety.

Hormone immunomodulators.

Thrombolytic agents.

Monoclonal antibodies.

PRODUCTS ON MARKET:

Clinical, analytical, and preclinical research on a contract basis for pharmaceutical, chemical, pesticide and biotechnology companies.

AGREEMENTS BEING SOUGHT:

Distribution

Marketing

Research Contract

Joint Venture

Technology Transfer

Financing

To introduce the services Bio-Research has to offer to biotech companies to aid in their product development.

Large contract research laboratory offering service and testing to biomedical device companies to help them get their product to market.

BIOCHEM PHARMA Inc.

2550 Daniel Johnson Blvd.

Suite 600

Laval, Québec H7T 2L1

Canada

Telephone: (514)681-1744**FAX:** (514)681-4207**Founded:** 1986**Employees:** 300**R&D:** 55 PhDs**Contact:** Jim McDonald (VP, Public Affairs)**Sales:**

HISTORY:

Founded in 1986 when scientists from McGill University, Ayerst, and the National Research Council went public with the biochemical division of Institut Armand Frappier.

Acquired 50% interest in North American Vaccines (2/90).

Agreed to purchase two diagnostics subsidiaries of IFCI Holding International SA: IFCI CloneSystems SpA and Chemila SpA (8/91).

FACILITIES:

22,000 sq. ft. diagnostics and fine chemicals manufacturing, and administration facility in Montréal.

8,600 sq. ft. R&D facility and 4,000 sq. ft. vaccine research and manufacturing facility in Laval.

5,000 sq. ft. corporate headquarters in Laval.

Plan to build two new laboratories, one for vaccine production, the other as an R&D centre, completion date (1993).

STOCK-FINANCIAL HISTORY:

NASDAQ: BCHXF

Traded on Montréal and Toronto Stock Exchanges. BCH

SUBSIDIARIES/DIVISIONS:

IAF BioVac; wholly owned.

CloneSystems SpA; 70%.

Chemila SpA; 70%.

INVESTMENTS:

North American Vaccine Inc. (Laurel, MD) (AMEX: NVX) joint venture with American Vaccine, February 1990.

In May 1990, BioChem Pharma Inc. purchased the vaccine division of Institut Armand-Frappier, which is involved in the production of classical vaccines such as tetanus, flu viral, measles and rubella.

INVESTORS:

Pension Funds; 18.6%.

Industria Farmaceutica Cosmetica Italiana SpA; 9.1%.

Glaxo Canada, Inc; 10.5%.

Public; 47%.

AGREEMENTS:

Agen Biomedical; HIV synthetic peptides; non exclusive licensing agreement; (1989).

Behringwerke AG; HIV synthetic peptides; non exclusive licensing agreement; (1988).

Cambridge Biotech Corp; gp 120 envelope protein; sublicensing agreement on Cambridge's patent; (6/91)

Canadian Patents & Development Ltd.; conjugate vaccine technology; exclusive worldwide licensing agreement; (1987, 1988).

Coulter; HIV diagnostic kit; non exclusive distribution agreement; (1990).

Glaxo / Biochem Pharma Inc.; AIDS antiviral; joint venture company for commercialization of AIDS antiviral in Canada and US; (1990).

Glaxo Canada Inc.; nucleoside analogues; research agreement; (1990).

Glaxo Canada Inc.; therapeutic compounds to treat cancer and viral diseases; 50/50 joint venture to develop; (1991).

Glaxo Inc. (US); AIDS antiviral; distribution agreement with BioChem/Glaxo Canada joint venture company.

Glaxo plc; AIDS antiviral; exclusive licensing agreement outside the US and Canada; (1990).

MIT; vaccine microcarrier technology; licensing and development agreement through IAF BioVac; (1990).

North American Vaccine; vaccines and related technology; joint venture, research and marketing rights (excluding Canada); (1990).

Organon Teknika; HIV diagnostic kit; non exclusive distribution agreement; (1989).

Organics; HIV synthetic peptides; non exclusive licensing agreement; (1987).

Rockefeller Foundation; rabies vaccine; funding to IAF BioVac for technology transfer to developing countries; (1990).

Technicon Instruments; HIV synthetic peptides; non exclusive licensing agreement; (1988).

RESEARCH & DEVELOPMENT:

Nucleoside analogues for use as antiviral or anticancer therapeutics, opiod peptide analogues, anthracyaline analogues, and other rational drug design projects.

Pediatric vaccines and infectious disease diagnostic kits.

Diagnostic tests.

Synthetic Vaccines.

Viral sub-unit vaccines.

Molecular probes.

Drugs.

Viral Insecticides.

Health care products for people and animals.

Food irradiation.

PRODUCTS ON MARKET:

Chemical specialties and diagnostics tests.

Health care products for people and animals.

HIV-1/HIV-2 synthetic peptides.

HTLV-1/HTLV-2 peptides.

AIDS diagnostic kit.

Viral vaccines; protein conjugate vaccines:

- Engerix-B: recombinant hepatitis B.

- Fluviral: influenza virus vaccine.

- Measles: Schwartz strain.

- Rubella-G.

BCG vaccine.

Brucella veterinary vaccines.

Tetanus and diphtheria toxoids.

Specialty fine chemicals.

DETECT-HIV™ diagnostic kit.

DETECT-HTLV™ diagnostic kit.

SELECT-HTLV™ diagnostic kit.

DETECT-Rubella™ diagnostic kit.

PRODUCTS IN DEVELOPMENT:

HTLV diagnostic kit (DETECT-HTLV™): in clinicals in the US.

AIDS HIV-1/HIV-2 and HTLV-I/II diagnostic kit (DETECT-PLUS™).

BCH-189 (3TC) AIDS antiviral: in clinicals .

Polio vaccine: in preclinicals.

Acellular pertussis L4 vaccine (NAVA): in clinicals .

Rabies vaccin: in clinicals.
Conjugate vaccine: in preclinicals.
Whooping cough, Meningitis A + C-.
Meningitis B, Group B Streptococci.

INTERNATIONAL AGREEMENTS BEING SOUGHT:

Distribution.....X..	Joint Venture.....X..
Marketing.....X..	Technology Transfer...X..
Research Contract.....	Financing.....

Therapeutics: R&D alliances.
Vaccines: Develop and commercialize alliances.
Diagnostics: Manufacturing and marketing alliances.

BIOMATRIX MEDICAL CANADA Inc.

275 Labrosse
Pointe-Claire, Québec H9R 1A3
Canada

Telephone: (514)697-8851**FAX:** (514)697-3670 / (514)697-8737**Founded:** 1991**Employees:****R&D:****Sales:**

Contact: Endre A. Balazs (President, CEO)
John Fielder (Advisor of the Board)

FACILITIES:

A facility of 28,000 sq. ft. presently being completed.

INVESTORS:

Biomatrix Inc.; (U.S.A.)

BioCapital, Investment Fund in Biotechnology: \$575,000 (06/91).

BUSINESS STRATEGY:

To manufacture and commercialize health care products derived from hyaluronic acid.

AGREEMENTS:

Biomatrix Inc. (U.S.A.)

RESEARCH & DEVELOPMENT:

Development of new products all based on cross-linking of hyaluronic acid for arthritis.

AGREEMENTS BEING SOUGHT:

Distribution.....

Marketing.....

Research Contract.....

Joint Venture.....

Technology Transfer.....

Financing.....

BIOSCAN CONTINENTAL Inc. (BCI)

350 Industriel Blvd.
Suite 201
St-Eustache, Québec J7R 5V3
Canada

Telephone: (514)974-0151

FAX: (514)491-3069

Founded: 1981

Employees: 3

R&D:

Contact: Upendra K. Banik (VP & CEO)

Sales: \$0 - 1 M

HISTORY:

Bioscan is primarily a pharmaceutical/biomedical research and development (R&D) laboratory. Bioscan has unique expertise in bringing forward new ideas and technologies for launching biomedical products to the marketable stage.

FACILITIES:

2nd laboratory located at:
655 Rivière Sud, St-Eustache,
Québec, J7R 4K3, Canada.

SUBSIDIARIES/DIVISIONS:

135952 Canada Inc., (holding company).

INVESTORS:

135952 Canada Inc., (holding company).
U. K. Banik.

BUSINESS STRATEGY:

Searching for Canadian and foreign companies to form a strategic alliance for marketing (distributing) existing diagnostic and over-the-counter (OTC) products and for developing new diagnostics and OTC products.

AGREEMENTS:

Government of Canada & Québec: antigens; R&D grants, (1987-89).

NCR, Canada: antigens, hormones; R&D grant, (1988-89).

RESEARCH & DEVELOPMENT:

Diagnostic reagents (hormones and antigens).
OTC health products.

PRODUCTS ON MARKET:

Panacil® (gastrointestinal composition) for promoting bowel movement and relieving acidity and heartburn.

Restorin® (gastrointestinal gas and resulting colic).

Oradent® (dental powder) for gum problems and halitosis (bad breath).

CEA.

Bioscan's more than 30 diagnostic hormones and other agents are gaining to national and international markets.

Hormones including human and animal gonadotropins, TSH and subunits.

BIOAMP™ solid amphiphilic adsorbent to remove fat globules, mucins, cellular debris, and colloidal particles from biological fluids.

PRODUCTS IN DEVELOPMENT:

BIOAMP: new solid amphiphilic adsorbents for removing fat globules, mucins, cellular debris and colloidal particles from biological fluids, thus facilitating further purification of proteins.

Human chorionic gonadotropin (hCG).

Active principles of Restorin.

CEA and hormones.

AGREEMENTS BEING SOUGHT:

DistributionX..

Marketing

Research Contract

Joint VentureX..

Technology Transfer . . .X..

Financing

To conduct clinical studies of Restorin as it is.

To prepare the active fraction(s) of Restorin using in vitro cell culture. Should this project become successful, Restorin along with Panacil would be excellent preventative and curative products for GI ailments which cost the health care system millions of dollars annually.

BIOSIGNAL Inc.
316 Carré St-Louis
Montréal, Québec H2X 1A5
Canada

Telephone: (514)844-0118
FAX: (514)843-7372

Founded: 1991
Employees: 5
R&D: 2 PhDs
Sales:

Contact: Guy Lambert (President)

HISTORY:

Founded by Dr's Michael Dennis and Guy Lambert.
Incorporated in Québec, June 1991.
In operation since January 1992.

FACILITIES:

BioSignal Inc. occupies 75 sq. m. of laboratory space, in addition to cell culture facilities at the Biotechnology Research Institute (BRI), Montréal.

BUSINESS STRATEGY:

BIOSIGNAL's major commercial focus is to assemble the most comprehensive collection of cell surface receptors and accessory proteins, and provide these as drug discovery tools to the pharmaceutical and related industries.

BIOSIGNAL's ready-to-use reagents for drug screening procedures permit characterization of receptor subtype specificity as well as biological activity of ligands under study.

BIOSIGNAL believes that its drug discovery tools constitute a promising alternative to the use of laboratory animals in pharmaceutical research.

RESEARCH & DEVELOPMENT:

Through licensing genes from several academic institutions and its own R&D activities, BIOSIGNAL is initially focussing its efforts on the G protein-coupled class of receptors, a large family of neurotransmitter and hormone receptors which includes major drug targets in numerous therapeutic areas.

BIOSIGNAL is also pursuing activities in the development of novel robust and high-throughput systems for screening and selection of potential new drugs acting on G protein-coupled receptors.

PRODUCTS ON MARKET:

BIOSIGNAL is introducing in 1992 several series of recombinant receptor subtypes in the form of "kits" for use as drug discovery tools.

PRODUCTS IN DEVELOPMENT:

BIOSIGNAL's products under development include cloned receptors, G protein subunits, reconstituted signal transduction systems and non-radioactive drug screening technologies.

AGREEMENTS BEING SOUGHT:

DistributionX . . .
MarketingX . . .
Research Contract . . .X . . .

Joint VentureX . . .
Technology Transfer . . .X . . .
FinancingX . . .

Through corporate partnerships and with additional equity investment, Biosignal will undertake its own drug discovery program by taking advantage of its proprietary screening and selection systems.

BIOVET Inc.
 1550 Metcalfe
 Suite 1100
 Montréal, Québec H3A 1X6
 Canada

Telephone: (514)847-5751
FAX: (514)285-4597

Founded: 1991
Employees:
R&D:
Sales:

Contact: Camil Moore (Vice President)

HISTORY:

BIOVET Inc. is a company set up in November 1991 to develop products in the veterinary field.

INVESTORS:

MOPORC Inc.

Corporation de développement économique et touristique de Bromont, Waterloo, Lac Brome.
 BioCapital, Investment Fund in Biotechnology.

RESEARCH & DEVELOPMENT:

A corporation involved in the development of diagnostic kits for the detection of pathogens and viruses in the hog industry.

This company sponsors major R&D projects to the Faculty of the Veterinary Medicine School of the University of Montréal, for the development of three specific kits.

AGREEMENTS BEING SOUGHT:

Distribution.....
 Marketing.....
 Research Contract.....

Joint Venture.....
 Technology Transfer.....
 Financing.....

BURROUGHS WELLCOME Inc.

16751 Trans-Canada Highway
Kirkland, Québec H9H 4J4
Canada

Telephone: (514)694-8220

FAX: (514)694-8201

Founded: 1906

Employees: 449

R&D:

Contact: Kristina Adomonis
(Director, Business Development)

Sales:

FACILITIES:

Administration and manufacturing Fine Chemicals.

PRODUCTS ON MARKET:

Wellferon.

Digibind.

AGREEMENTS BEING SOUGHT:

Distribution.....X....

Marketing.....X....

Research Contract.....

Joint Venture.....X....

Technology Transfer...X....

Financing.....

CANADIAN MEDICAL RESEARCH ASSOCIATES Inc.

550 Sherbrooke West
Suite 1205
Montréal, Québec H3A 1B9
Canada

Telephone: (514)842-3759
FAX: (514)842-7871

Founded: 1986
Employees: 3
R&D: 180

Contact: Oleg Romar (Chairman of the Board)

Sales:

HISTORY:

R&D contract laboratory.

Conglomerate encompassing a variety of business ventures including development of monoclonal antibodies in therapeutic and diagnostic application; marketing of activated carbon-based products.

INVESTMENTS:

Major participation in Phoenix International Life Sciences Inc.
Participation in ACTICARB Inc.

INVESTORS:

Private company with over 540 shareholders.
Approximately 70% of the shareholders are physicians.

BUSINESS STRATEGY:

Acquisition and joint ventures.
Acquisition of new technology, R&D, licensing in and out.

AGREEMENTS:

License agreement for the commercialization of monoclonal antibody diagnostic kits.
License agreement for the commercialization of an anti-cancer drug delivery system.

RESEARCH & DEVELOPMENT:

Clinical research and development contract laboratory.
Monoclonal antibody filters.
HLA system.
Activated carbon-based products.
Bioactive compound delivery system.

PRODUCTS ON MARKET:

Manufacturing of medical products based on activated carbon technology.

PRODUCTS IN DEVELOPMENT:

Bioactive compound delivery system.

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract

Joint VentureX..
Technology Transfer . . .X..
Financing

CGF PHARMATECH Inc.

3516 Griffith
St-Laurent, Québec H4T 1A7
Canada

Telephone: (514)343-0344
FAX: (514)343-0340

Founded: 1990

Employees:
R&D:

Contact: Jean-Paul Chausseau (President)

Sales:

HISTORY:

CGF Pharmatech Inc. was founded with an aim to market and distribute in Canada an integrated line of third party and proprietary pharmaceutical, biological and diagnostic products, specifically in the areas of Organ transplantation, immunotherapy, and related areas.

FACILITIES:

3000 cubic feet of refrigerated space (2-8C).

100 cubic feet of deep-freeze space (below -20C).

All equipment with electronic temperature controls, monitoring and alarm apparatus.

Deep-freeze space below -70C, planned for 1992.

BUSINESS STRATEGY:

The company is building its integrated line of products by using a double strategy:

- Market and distribute third party products in Canada.
- Conduct R&D proprietary products of its own.

RESEARCH & DEVELOPMENT:

A research program in immuno-suppression will be initiated in 1992 (treatment of GVH disease).

PRODUCTS ON MARKET:

Full line of vaccines used in Health units in the province of Québec.

Influenza vaccine marketed in private clinics.

Immuno-suppressive globulins.

Interleukins immuno-assays (to be launched mid-1990).

The company also contracts for the preparation of INDs (Investigational New Drugs) and NDSs (New Drug Submission) for the regulatory authorities.

AGREEMENTS BEING SOUGHT:

Distribution **X**

Marketing **X**

Research Contract

Joint Venture

Technology Transfer

Financing

Regulatory work and monitoring of clinical trials in preparation for the launching of products.

HAEMACURE BIOTECH Inc.

245 Hymus Blvd.
Pointe-Claire, Québec H9R 1G6
Canada

Telephone: (514)630-8839
FAX: (514)630-8845

Founded: 1989
Employees: 10
R&D:
Sales: \$500,000

Contact: Marc Paquin (President)

HISTORY:

Haemacure Biotech Inc. (HBI) is the Research & Development division of Health Assurance Corporation (HAC), founded in December 1989.

Haemacure Transfusion Inc. (HTI) was founded in January 1991 to manufacture and market under license all products developed by HBI, and to distribute synergistic products in the field of blood and tissue collection, biological cryopreservation and coagulation factors used in transfusion.

HBI expects to start sterile production for human clinical trials, of its plasma-based fibrin sealant, upon completion of its development pilot plant facility in April 1992.

FACILITIES:

Located at the Institut National de la Recherche Scientifique - Santé (University of Québec) in Pointe-Claire.

The company is currently negotiating for the acquisition of a 40,000 sq. ft. building located next to the INRS to be converted as a biopharmaceutical manufacturing facility.

SUBSIDIARIES/DIVISIONS:

HBI and HTI are two wholly owned subsidiaries of HAC which acts as the corporate holding company.

STOCK-FINANCIAL HISTORY:

HAC has initiated negotiations with investment banking firms to package an IPO of \$ 18M (1992).

The funds will be used for the acquisition and construction of a production facility, the building of a marketing team for Canada, and the expansion and acceleration of its research and development.

INVESTORS:

The company received financial support estimated at \$ 2.2 M from Canadian and Québec governments.

The company raised additional private equity from private investors and venture capital.

BUSINESS STRATEGY:

The organization's main focus is in the development of biological (blood / plasma-based) and synthetic bioadhesives for wound healing market and coagulation factors for the hematology / oncology market.

AGREEMENTS:

Canadian Irradiation Centre (CIC): the company has secured, under a collaborative agreement, a development laboratory facility located on the campus of Armand Frappier Institute (IAF) in Laval, Québec.

Intitut de recherche nationale scientifique - santé: collaborative agreement with INRS-Santé giving access to a state-of-the-art facility with significant scientific and administrative support.

Université de Montréal (Hopital Notre-Dame): collaborative R&D agreement for the integration of growth factors in a bio adhesive; being completed Q1-1992.

NABI (US): distribution agreement for the collection of pediatrics blood.

New York Blood Bank: licensing agreement on viral deactivation.

Teama SA: distribution agreements with a division of Air Liquid (France) for computerized cryopreservation freezers.

Unnamed Co: distribution agreement for human applications of Hemaseel™; to be completed in Q2-1992

RESEARCH & DEVELOPMENT:

The company specializes in the fractionation and purification of blood coagulation factors.

Developing and manufacturing a biological glue, Fibrin Sealant products, for human and animal applications, along with other plasma derivatives. Fibrin Sealant is polymer-based bone adhesive with sealing, hemostytic and gluing properties, which does not interfere but enhances or replaces sutures in wound healing.

Plasma derived coagulation factors for hematology and oncology transfusions.

PRODUCTS ON MARKET:

The company anticipates that veterinary fibrin sealant will be a first on the world market and will be released by fall/winter 1992. It estimates market release for the human fibrin sealant by Q1-1993, in Canada.

PRODUCTS IN DEVELOPMENT:

Fibrin Sealant incorporating: growth factors, collagen and cytokines.

High purity Factor IX.

Protein C&S.

Anti-Thrombin III.

Human Thrombin.

AGREEMENTS BEING SOUGHT:

DistributionX..

MarketingX..

Research Contract

Joint VentureX..

Technology TransferX..

FinancingX..

Company seeking partnership with large pharmaceutical / biopharmaceutical organization for:

- Distribution: for Hemaseel™ veterinary and dental applications.
- Marketing: product distribution of blood related technologies.
- Joint Venture: biopharmaceuticals.
- Technology Transfer: Bioadhesives (biologicals or polymer-based).
- Financing: Equity investment.

IBEX TECHNOLOGIES Inc.

5645 Chemin St-François
St-Laurent, Québec H4S 1W6
Canada

Telephone: (514)956-8430
FAX: (514)956-7485

Founded: 1989
Employees: 11
R&D:

Contact: Robert Heft (President)

HISTORY:

Her parent company, Continental Pharma Cryosan Inc., had for several years been funding a research project at the MIT. As the MIT technology matured, IBEX Technologies Inc. was spun off and mandated to commercialize a line of products for cardiac surgery and hemodialysis.

FACILITIES:

5000 sq. ft laboratory and production space.
Lease laboratory space at the Biotechnology Research Institute of Montréal.

INVESTORS:

Ibex Technologies Inc. has received approximately \$6 million in grants and loans from various government agencies.

BUSINESS STRATEGY:

Production of glucosaminoglycan modifying enzymes and their uses in hematology diagnostic, blood detoxification filters, research reagents and glucosaminoglycan manipulation.

AGREEMENTS:

Baxter Diagnostics Inc.
Medtronic Inc.

RESEARCH & DEVELOPMENT:

Protein immobilization of heparinase and other proteins to biocompatible material constitutes the basic technology of IBEX Technologies Inc.

Glycoaminoglycan engineering.

Fermentation.

Purification.

Immobilization.

PRODUCTS ON MARKET:

Heparinase based hematology diagnostics.

PRODUCTS IN DEVELOPMENT:

Heparin filters to remove heparin from patient's blood in conjunction with extracorporeal procedures.

Extracorporeal blood detoxification.

Heparin monitoring and control.

Heparinase.

Chonotroitinase.

Coagulation assays.

AGREEMENTS BEING SOUGHT:

Distribution.....
Marketing.....**X**..
Research Contract.....

Joint Venture.....**X**..
Technology Transfer.....
Financing.....

Ibex Technologies Inc. is flexible in structuring a full spectrum of alliances with other companies active in hematology diagnostics, cardiac surgery, hemodialysis and other extracorporeal procedures.

Ibex Technologies Inc. has further interest in collaborating in the area of glycosaminoglycan and glycoprotein engineering using a line of enzymes from Flavobacterium Heparinum.

IMMUNOCORP SCIENCES Inc.

5800 Royalmount Ave.
Montréal, Québec H4P 1K5
Canada

Telephone: (514)733-1900

FAX: (514)733-1212

Founded: 1982

Employees: 22

R&D: 3 PhDs

Contact: Pierre Du Ruisseau (Vice-President)

Sales:

HISTORY:

Founded in the 1970s as BIO-RIA, purchased by Medicorp Sciences in 1988 and renamed Immunocorp.

Canada's largest manufacturer and distributor of immunodiagnostic products.

FACILITIES:

17,000 sq. ft. headquarters and ultramodern laboratories supporting an outlook of strong Canadian sales in the short term, and penetration of export markets in the medium term.

Fully automated manufacturing process approved by the U.S. FDA.

SUBSIDIARIES/DIVISIONS:

Affiliate of Medicorp Inc.

INVESTORS:

Medicorp Sciences Inc.

SGF Québec.

BUSINESS STRATEGY:

Laboratory and hospital immunodiagnostics.

Research biochemicals.

Microbiology and biochemistry reagents.

AGREEMENTS:

Becton Dickinson Microbiology Systems; microbiology tests and reagents; distribution agreement for Canada; (10/89).

Binax; non-isotopic immunoassay kits; distribution agreement for Canada; (5/88).

Biosource International; cytokines, growth factors, antibodies, and assays; distribution agreement for Canada; (6/91).

Byk-Sangtec (Germany); tumor marker assays; distribution agreement for Canada; (6/90).

Clonatec; MAbs; distribution agreement for Canada; (11/89).

Eiken; CEA RIA; distribution agreement for Canada; (6/85).

E-Z-EM, Inc; D-14 CEA Histosystem™ immunohistochemistry kits and reagents for detecting colorectal tumors; exclusive distribution agreement for Canada; (5/90).

Euro-Diagnostics BV; MAbs; distribution agreement for Canada; (3/90).

Geltech; electrophoresis gels; distribution agreement for Canada; (2/91).

ICN Biomedicals; full line of immunoassay products; distribution agreement for Canada; (10/85).

Meridian Diagnostics; microbiology tests; distribution agreement for Canada; (1/87).

New Horizons; gonorrhea test; distribution agreement for Canada; (1986).

Quidel; non-isotopic immunoassay kits; distribution agreement for Canada; (1/89).

Wako; clinical chemistry reagents; distribution agreement for Canada; (10/89).

RESEARCH & DEVELOPMENT:

Immunodiagnosics, microbiology tests, and immunohistochemical products.

Immunocorp Sciences Inc. has the capability of doing isotopic labelling in tube and/or in 96 wells plate solid phase coating of antigens or antibodies.

PRODUCTS ON MARKET:

Full line of RIA, IRMA, and microbiology kits.

Latex agglutination immunodiagnosics for hormones, drugs and microbiology.

It also distributes a growing line of genetic engineering reagents to the molecular biologists and research reagents to the microbiologist / immunologist.

Immunocorp Sciences Inc. sells its solid phase radioimmunoassay kits through distributors in Europe, and produces solid phase antibody coated tubes for other firms on an OEM basis.

PRODUCTS IN DEVELOPMENT:

Line extension of above.

Immunocorp Sciences Inc., with the introduction of a line of biospecific monoclonal antibodies, is developing a series of enzyme immunoassays for hormone determinations.

AGREEMENTS BEING SOUGHT:

DistributionX..

MarketingX..

Research Contract . . .X..

Joint VentureX..

Technology Transfer . . .X..

FinancingX..

Strategic marketing / R&D alliances to develop commercial products in clinical chemistry (mainly non-isotopic automated immunoassays), microbiology and molecular biology, strategic business alliances to provide access to Immunocorp Sciences's expertise in OEM antigen or antibody solid phase tube or 96 well plated coating.

ITR LABORATORIES Inc.

19061 Clark Graham Blvd.
Baie d'Urfé, Québec H9X 3T1
Canada

Telephone: (514)457-7400
FAX: (514)457-7303

Founded: 1989
Employees: 50
R&D:

Contact: J. Eidnes (Manager Accounting)

Sales:

HISTORY:

Company founded in 1989 by foreign investor.
Present facility on 35,000 sq. ft. of land conveniently located close to Montréal's international airport.

FACILITIES:

10 animal rooms, laboratory and office space.
35,000 sq. ft. with surgical and physiology suites as well as clinical pathology and histopathology units.
Expansion planned in 1992 which will increase the facilities to a total of 30 animal rooms.

INVESTORS:

Yamanouchi International Inc.

BUSINESS STRATEGY:

Preclinical testing according to regulatory (world-wide) guidelines in support of registration
Government liaison.
Regulatory management, study design, pharmacology.

AGREEMENTS:

At present, not actively pursuing R&D, but will be considered in future expansion plans.

AGREEMENTS BEING SOUGHT:

Distribution.....
Marketing.....X....
Research Contract.....

Joint Venture.....
Technology Transfer.....
Financing.....

KAMI MARK Inc.
791 Lajoie
Dorval, Québec H9P 1G7
Canada

Telephone: (514)633-9064
FAX: (514)633-9064

Founded: 1984
Employees:
R&D: 3

Contact: Robert Roy (President)

Sales:

HISTORY:

Research in biotechnology started after acquisition of process and technology in 1989.

FACILITIES:

Laboratories: 1000 sq. ft.
Pilot scale plant: 1000 sq. ft.

BUSINESS STRATEGY:

Contract R&D for other companies.
Investment in our own R&D program.

PRODUCTS ON MARKET:

Biopeptide extracts.

PRODUCTS IN DEVELOPMENT:

Test kits.
Therapeutic bioextracts.

AGREEMENTS BEING SOUGHT:

Distribution.....
Marketing.....
Research Contract...X...

Joint Venture.....
Technology Transfer...X...
Financing.....

LIPOPHARM Inc.
5929 Trans-Canada Highway
Suite 30
St-Laurent, Québec H4T 1A1
Canada

Telephone: (514)747-8942
FAX: (514)747-8944

Founded: 1988
Employees: 5
R&D: 3
Sales:

Contact: Serge Pitre (VP, General Manager)

HISTORY:

Founded in 1988 to develop and commercialize a novel drug delivery system based on the work of prominent Canadian researcher, Dr Michael Mezei.

FACILITIES:

2200 sq. ft. research laboratory for conducting formulation development and analytical testing of new formulas.

INVESTORS:

BioCapital, Investment Fund in Biotechnology.

BUSINESS STRATEGY:

The mission of the company is to become the leader in developing and delivering specialty skin care products.

AGREEMENTS:

American Lecithin Company: a subsidiary of Nattermann Phospholipid GmbH of Cologne, Germany. Lipopharm Inc. will be a major user of their lipids and is negotiating to become their sole distributor in Canada.

BioEurope: a major R&D company in biocatalysts and enzymatic synthesis. BioEurope owns many patents and has R&D contracts with foreign partners in Europe, Japan, U.S.A. and Australia.

Cooper Cies: distribute one of Lipopharm's products in the U.S.A. and Europe.

Sepracor: a company which specializes in the development of drug isomers whose encapsulation in artificial cell (liposome) could provide for some very unique and highly effective products.

Spirig: a well established dermatology company whose head office is in Switzerland and whose products are sold in many European countries.

RESEARCH & DEVELOPMENT:

Lipopharm Inc. has secured the rights to further develop and market a new drug delivery system that has the capability of targeting drugs to specific areas of the body in a number of therapeutic applications. The new drug delivery system is based on second generation liposome encapsulating active ingredients that will travel to a specified site in their liposome vesicles prior to being released.

Within the group of topical medications, Lipopharm Inc. has identified certain drugs in which the efficacy can be dramatically improved and others in which serious side effects are either minimized or altogether eliminated through liposome encapsulation.

PRODUCTS ON MARKET:

Lipopharm Inc. is currently developing the following liposome encapsulated products such as anti-acne, anti-infective, anti-psoriatic, anti-aging and wound healing medications, and solar (U.V.) protectants based on melanin synthesis.

Through patentable processes involving the mass production of liposomes and through the use of leading-edge biotechnology, Lipopharm Inc. will commercialize a new generation of therapeutic prescription products that will be targeted principally for dermatology and gynaecology.

AGREEMENTS BEING SOUGHT:

Distribution.....X...
Marketing.....
Research Contract.....

Joint Venture.....X...
Technology Transfer...X...
Financing.....X...

MEDICORP SCIENCES Inc.

5800 Royalmount Ave.
Montréal, Québec H4P 1K5
Canada

Telephone: (514)733-3000

FAX: (514)733-1212

Founded: 1985

Employees: 11

R&D:

Contact: Pierre Du Ruisseau (VP, R&D)

Sales:

SUBSIDIARIES/DIVISIONS:

Affiliate of Immunocorp Sciences Inc.; manufacturer and distributor of immunodiagnostics.

INVESTORS:

Médocorp Sciences Inc.

BUSINESS STRATEGY:

Use the latest methods in immunology, immunochemistry and biochemistry to develop and commercially exploit improved sophisticated systems for cancer diagnostics and therapeutics, transplantation antigens, and bispecific hybridomas.

Medicorp Sciences Inc. is positioned to manufacture and distribute medical products in Latin America through its wholly owned subsidiary in Argentina, Medicorparg Ltda.

AGREEMENTS:

AMS Biotechnology (Europe) Ltd.: MAbs; distribution agreement, AMS to market to research community in UK, Italy, Switzerland, Spain, and Portugal; (11/89).

Binax; ELISA assays for Strep A; Medicorp has distribution rights in Canada; (10/87).

Cambridge Univ. (Dr Abraham Karpas); patent for Passive Hyperimmune Therapy (PHT), a process developed by Dr Karpas; Medicorp is the exclusive worldwide licensee of patent; (11/89).

Hemacare; Medicorp patented PHT (passive hyperimmune therapy) for AIDS; sublicensing agreement, HemaCare to commercialize exclusively in California; (12/89).

McGill University; CEA diagnostic using biospecific MAbs; research agreement; (7/88).

Medical Research Council of England; MAbs; Medicorp to have worldwide exclusive rights developed at Univ. of Cambridge; (6/88).

Quidel; Dipstick total IgE and regional allergy screens; Medicorp has distribution rights in Canada; (10/88).

Quidel; ULTRATEST and STREP-PAK test for pregnancy; distribution agreement, Medicorp to market to physicians and pharmacies, Immunocorp Sciences Inc. to market to hospital and clinical laboratories; (11/89).

Serva Fein Biochemica GmbH; QUADROMA™ biospecific MAb technology; distribution of Medicorp antibodies in Europe; (6/90).

Tebu SA (France); QUADROMA™ biospecific MAb technology; distribution of Medicorp antibodies in France; (5/90).

RESEARCH & DEVELOPMENT:

Diagnostic for cancer, including CEA.

Diagnostics and therapeutics for HIV.

MAbs.

Transplantation antigens.

Laboratory and physician's office diagnostics.

PRODUCTS ON MARKET:

Medicorp distributes primarily to physicians' offices rapid ELISA tests for the detection of infectious diseases and pregnancy.

Equate strep A tests.

Quidel allergy, pregnancy and strep tests.

Colo Trak fecal occult blood test.

MAbs for neuroscience.

QUADROMA™ bispecific hybridomas.

PRODUCTS IN DEVELOPMENT:

Passive Hyperimmune Therapy (PHT) for AIDS and ARC; in Phase II California IND clinical trials in collaboration with HemaCare (6/90).

Medicorp is also developing, using bispecific monoclonal antibodies, a CEA assay specific to colorectal cancer.

Additionally, Medicorp is developing a series of monoclonal antibodies against transplantation antigens.

AGREEMENTS BEING SOUGHT:

DistributionX..

MarketingX..

Research Contract . . .X..

Joint VentureX..

Technology Transfer . . .X..

FinancingX..

Strategic marketing / R&D alliances to develop commercial products for doctor's office market, new tumor markers or new antibodies to transplantation antigens and licensing agreements for the PHT treatment.

MERCK FROSST CANADA Inc.

16711 Trans Canada Highway
Kirkland, Québec H9H 3L1
Canada

Telephone: (514)695-7920

FAX: (514)630-2670

Founded: 1899

Employees: 1150

R&D:

Contact: Sandu Goldstein (Director,
Research Administration & Planning.)

Sales:

FACILITIES:

Merck Frosst Canada Inc. is a fully-integrated research and manufacturing facility. The Merck Frosst Centre for Therapeutic Research is a world-leading biomedical research centre dedicated to improving human health.

SUBSIDIARIES/DIVISIONS:

Human Pharmaceuticals:

MSD Agvet.

Frosst Consumer Health.

Radiopharmaceuticals:

Merck Vaccine Division.

Stable Isotopes.

RESEARCH & DEVELOPMENT:

Currently, the research centre is working toward discovering leukotriene receptor antagonists and leukotriene biosynthesis inhibitors that will be safe and effective treatments for bronchial asthma. While carrying on this major effort in leukotriene research, several smaller pilot projects have been initiated in an effort to identify areas in which to establish major drug discovery programs as the research centre expands.

Among these are an ion channel research program and a phosphotyrosine protein phosphatase program.

Among the diseases for which these research areas are relevant are cystic fibrosis and diabetes.

PRODUCTS ON MARKET:

Stable isotopes. Supplies prepared isotope-labelled compounds and stable isotopes.

Radiopharmaceuticals.

Animal Pharmaceuticals.

Human Pharmaceuticals.

AGREEMENTS BEING SOUGHT:

Distribution.....

Marketing.....

Research Contract.....

Joint Venture.....

Technology Transfer.....

Financing.....

OMEGA LABORATORIES Ltd.

11177 Hamon
Montréal, Québec H3M 3E4
Canada

Telephone: (514)335-0310

FAX: (514)339-1407

Founded: 1958

Employees: 50

R&D: 6

Contact: E. R. Vrancken (Director, R&D)

Sales:

RESEARCH & DEVELOPMENT:

MAB based in vitro diagnostics for allergies.

PRODUCTS ON MARKET:

Allergenic extracts for diagnostics and immunotherapy.

PRODUCTS IN DEVELOPMENT:

In Vitro allergy diagnostics.

In Vitro diagnostics for various infectious diseases.

AGREEMENTS BEING SOUGHT:

DistributionX..

MarketingX..

Research Contract

Joint VentureX...

Technology Transfer . . .X...

Financing

PFIZER CANADA Inc.
17300 Trans-Canada Highway
Kirkland, Québec H9J 2M5
Canada

Telephone: (514)695-0500

FAX: (514)426-7084

Contact: Gordon J. Fehr (President)

Founded:

Employees:
R&D:

Sales:

PRODUCTS ON MARKET:

Manufactures and distributes antibiotics, enzymes, bacterial gums, organic acids and other products of Pfizer, USA.

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract

Joint Venture
Technology Transfer
Financing

PHOENIX INTERNATIONAL LIFE SCIENCES Inc.

2330 Cohen
St-Laurent, Québec H4R 9Z7
Canada

Telephone: (514)333-0033

FAX: (514)333-8861

Founded: 1989

Employees: 105

R&D:

Contact: John W. Hooper (President)

Sales: \$ 15 M

HISTORY:

Grew from a new company in 1989 to become one of the six largest North American contract research laboratories with combined clinical research and bioanalytical capabilities.

FACILITIES:

39,000 sq.ft. of R&D facility, including 90 beds for clinic, 40 chromatographic analytical laboratory and extensive computer systems.

SUBSIDIARIES/DIVISIONS:

Phoenix International Life Sciences Scientific Software Inc.

BUSINESS STRATEGY:

Provides a contract research service to the pharmaceutical and allied industries to assist them in the registration of their products.

Has extensive experience in designing, conducting and reporting pharmacokinetic, bioequivalence and bioavailability studies in almost every therapeutic category.

Phoenix has a large pool of healthy volunteers allowing rapid study start-up, special population panels of geriatrics, sterile females, etc.

Phoenix's analytical scientists are amongst the best in the industry in developing, validating and performing highly sensitive assays of drugs in biological fluids. Phoenix also conducts phase I-IV clinical trials, metabolism (ADME) and animal pharmacokinetics.

AGREEMENTS BEING SOUGHT:

Distribution

Marketing

Research Contract

Joint Venture

Technology Transfer

Financing

POLYCHOL Inc.
 1550 Metcalfe
 Suite 1100
 Montréal, QC H3A 1X6
 Canada

Telephone: (514)847-5751
FAX: (514)285-4597

Founded: 1991
Employees:
R&D:
Sales:

Contact: James McDonald (President)

HISTORY:

A company founded in 1991 to develop polymeric resins to lower the cholesterol in blood.

INVESTORS:

BioCapital, Investment Fund in Biotechnology: \$ 370 000, (1991)
 Biochem Pharma Inc.
 Public (SPEQ).

RESEARCH & DEVELOPMENT:

A major R&D contract has been granted to the Department of Pharmacology of the Faculty of Medicine of the University of Montréal to conduct pre-clinical testing of the polymeric resins to reduce blood cholesterol.

AGREEMENTS BEING SOUGHT:

Distribution.....
 Marketing.....
 Research Contract.....

Joint Venture.....
 Technology Transfer.....
 Financing.....

QUANTUM BIOTECHNOLOGIES Inc.

6100 Royalmount Ave.
Montréal, Québec H4P 2R2
Canada

Telephone: (514)496-6380

FAX: (514)496-6232

Founded: 1991

Employees: 8

R&D: 2 PhDs

Contact: Steve Slilaty (President)

Sales:

HISTORY:

Quantum Biotechnologies Inc. is a spin-off from research carried out in genetic engineering at the Biotechnology Research Institute in Montréal. The company has been set up by the principal scientist Dr. Steve Slilaty who was involved in the research.

FACILITIES:

Occupies approximately 130 sq. m of leased space at the Biotechnology Research Institute, Montréal.

INVESTORS:

Société de développement industriel du Québec (SDI).

BioCapital, Investment Fund in Biotechnology.

BUSINESS STRATEGY:

Design and manufacturing of second generation molecular biology products for research.

High-level bacterial and human cell expression systems available for joint ventures and other agreements.

Find licensees for commercialization.

RESEARCH & DEVELOPMENT:

High-level expression systems.

Gene isolation / cloning.

Enzyme technology.

Protein engineering.

Site-directed mutagenesis.

cDNA synthesis.

Protease mechanisms.

PRODUCTS IN DEVELOPMENT:

Site-directed mutagenesis kit.

A yeast lytic enzyme.

New color-selection cloning vectors.

cDNA synthesis/cloning kit.

High-level *E. Coli* and human cell expression systems.

Plasmid purification kit.

AGREEMENTS BEING SOUGHT:

Distribution

Marketing

Research Contract

Joint Venture

Technology Transfer

Financing

QUÉLAB LABORATORIES Inc.

2331 Dandurand
Montréal, Québec H2G 3C5
Canada

Telephone: (514)277-2558**FAX:** (514)277-4714**Founded:** 1974**Employees:** 52**R&D:** 3**Contact:** Roger Boulais (CEO)**Sales:****HISTORY:**

Company specialized in the production of dehydrated culture media, ready-to-use culture media and diagnostic products.

FACILITIES:

2,400 sq. m.

SUBSIDIARIES/DIVISIONS:

E.F.C. Control Inc.

INVESTORS:

Société de développement industriel du Québec (SDI).

BUSINESS STRATEGY:

Manufacturer of excellence and innovation in microbiology and diagnostic market.

AGREEMENTS:

Société d'exploitation Algene Biotechnologies Inc.

Société d'investissement R&D Algene Inc.

RESEARCH & DEVELOPMENT:

Tissue culture media.

Serum free media.

Diagnostic kits.

PRODUCTS ON MARKET:

The line of microbiology products, sold under the QUE-BACT brand name, is used in clinical, agri-food and pharmaceutical laboratories, as well as in fundamental microbiology.

PRODUCTS IN DEVELOPMENT:

Tissue culture media.

Serum free media.

Diagnostic kits.

AGREEMENTS BEING SOUGHT:

Distribution

Marketing

Research Contract . . . X . .

Joint Venture X . .

Technology Transfer . . . X . .

Financing

Technology sought:

- Technology related to the production of diagnostic kits.

- Tissue culture media technology.

- Monoclonal antibodies related to clinical diagnosis.

Technology offered:

- Joint venture in producing dehydrated and ready-to-use culture media, and other microbiology products.

RICHELIEU BIOTECHNOLOGIES Inc.

5726 Laurier
St-Hyacinthe, Québec J2S 3V8
Canada

Telephone: (514)774-3505

FAX: (514)773-7433

Contact: Richard Parsons (President)

Founded: 1986

Employees:

R&D:

Sales: \$ 1 M

BUSINESS STRATEGY:

Commercial production of peptides and reagents for peptide synthesis.

RESEARCH & DEVELOPMENT:

Richelieu's biologically active peptides are prepared using the company's own amino acid derivatives and coupling reagents in its own laboratories handling more than 20 peptides at a time.

PRODUCTS ON MARKET:

Richelieu manufactures and distributes peptides in milligram to kilogram quantities and reagents for peptides synthesis, especially B.O.P. (Castro's R.).

The peptides have both human and veterinary applications.

PRODUCTS IN DEVELOPMENT:

New products commercialized are novel coupling reagents: HBTU and TBTU.

The markets for these products are the same as Richelieu's existing products.

AGREEMENTS BEING SOUGHT:

Distribution

Marketing

Research Contract

Joint Venture

Technology Transfer

Financing

Richelieu Biotechnologies Inc. (RBI) would like to have access to the license issued by the Salk Institute in reference to the "GRF" peptide. This could be accomplished through a joint-venture or some other method.

ROUGIER BIO-TECH Ltd.

8480 St-Laurent Blvd.
Montréal, Québec H2P 2M6
Canada

Telephone: (514)381-5631
FAX: (514)383-4493

Founded: 1985
Employees: 15
R&D: 3 PhDs
Sales:

Contact: Hanna Sikorska (Director, R&D)

HISTORY:

Established in 1985 as a biotech division of Rougier, Desbergers Ltd., a private Canadian pharmaceutical company.

FACILITIES:

Research laboratories (2,000 sq. ft.) equipped for protein purification and tissue culturing including radioisotope handling area.

SUBSIDIARIES/DIVISIONS:

Rougier Inc.

INVESTORS:

Rougier Inc: 100%.

BUSINESS STRATEGY:

Develop novel MAbs and antibody-based products for licensing or joint venture agreements.

AGREEMENTS:

CHUS: MI imaging kit; R&D agreement; (1987-1990).

IRAP, NR: MI imaging kit; R&D agreement; (1987-1991).

IRAP, NRC: anticancer vaccine; R&D funding; (1991-1992).

Rhomed: Tc-99m labelling; technology development agreement; (4/90).

Guelph University: Pseudomonas serotyping, technology licensing agreement.

RESEARCH & DEVELOPMENT:

MAB-based therapeutics and diagnostics for myocardial infarctus, cancer, and marine toxins.

Cancer treatment.

Pseudomonas serotyping.

PRODUCTS ON MARKET:

Carcinoembryonic antigen (CEA), anti-CEA MAb.

Anticardiac myosin light-chain MAb, anticardiac myosin heavy-chain MAb.

Anti-okadaic acid MAB.

Internal image of okadaic acid (OA) anti-idiotypic MAB.

Mouse IgG ELISA.

Protein A ELISA.

PRODUCTS IN DEVELOPMENT:

HVLC ELISA.

Pseudomonas aeruginosa serotyping kit: pilot production, clinical trials.

MI imaging: (in pre-IND stages).

ELISA for detection of marine toxin: in pilot production.

AGREEMENTS BEING SOUGHT:

Distribution.....X..

Marketing.....X..

Research Contract.....

Joint Venture.....X..

Technology Transfer.....

Financing.....

SANDOZ CANADA Inc.

385 Bouchard Blvd
Dorval, Québec H9R 4P5
Canada

Telephone: (514)631-6775

FAX: (514)631-3373

Contact: Sylvie Bouchard (Medical Director)

Founded: 1947

Employees: 550

R&D: 3 MDs, 15 PhD

Sales: \$ 126 M (1991)

HISTORY:

Develops, manufactures and supplies pharmaceutical and other products of Sandoz AG, Switzerland.

FACILITIES:

No in-house R&D facilities.

Basic and clinical research conducted in universities and hospitals.

BUSINESS STRATEGY:

Formal involvement in biotechnology R&D since late 1980s.

RESEARCH & DEVELOPMENT:

Growth factors, interleukins, monoclonal antibodies.

Immunomodulation, cancer treatment or adjuvant therapies.

PRODUCTS ON MARKET:

Leucomax (Granulocyte - Macrophage Colony Stimulating Factor - GM-CSF): Hematopoiesis support.

PRODUCTS IN DEVELOPMENT:

CD7 Monoclonal antibody: immunomodulation.

AGREEMENTS BEING SOUGHT:

Distribution.....
Marketing.....X...
Research Contract.....

Joint Venture.....X...
Technology Transfer.....
Financing.....

SCHERING CANADA Inc.
 3535 Trans-Canada Road
 Pointe-Claire, Québec H9R 1B4
 Canada

Telephone: (514)426-7300

FAX: (514)695-7334

Founded:

Employees:

R&D: 14

Contact: Claude Petitclerc (Medical Research)

Sales:

HISTORY:

Manufactures and distributes pharmaceutical and veterinary products of Schering-Plough Corp., USA.

PRODUCTS ON MARKET:

Interferon-alpha-2b (INTRON a).

PRODUCTS IN DEVELOPMENT:

Granulocytes-Macrophage Colony Stimulating factor (Leucomax).

AGREEMENTS BEING SOUGHT:

Distribution.....

Marketing.....

Research Contract.....

Joint Venture.....

Technology Transfer....X..

Financing.....

SYNERMED Inc.
1688, 50th Ave.
Lachine, Québec H8T 2V5
Canada

Telephone: (514)633-1112
FAX: (514)633-8039

Founded: 1989
Employees:
R&D:
Sales:

Contact: Jerry Denney (President)
Guido Bosmans (VP, Intl Affairs)

HISTORY:

Synermed Inc. is a Canadian company incorporated in 1989. The company conducted research and development during its first year of operation in two areas: biochemistry reagents for use in diagnostic tests on human blood and tests for the evaluation of cancer therapy.

FACILITIES:

All research & development and manufacturing of the clinical chemistry products are conducted at the 10,500 sq. ft. premises in Lachine.

BUSINESS STRATEGY:

To develop and commercialize diagnostic reagents for use in hospitals and laboratories throughout the world.

RESEARCH & DEVELOPMENT:

Cancer therapy evaluation testing.
Biochemistry reagents for automation.

PRODUCTS ON MARKET:

Clinical chemistry reagents for laboratory automation utilizing liquid stable, infrared detection technologies.

AGREEMENTS BEING SOUGHT:

DistributionX . . .
MarketingX . . .
Research Contract

Joint VentureX . . .
Technology Transfer . . .X . . .
FinancingX . . .

QUEBEC BIOTECHNOLOGY COMPANIES
NUTRITION

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
N	AGROPUR COOPERATIVE ALIMENTAIRE	510 Principale P. O. Box 6000	Granby, Québec J2G 7G2	(514)375-1991	(514)375-2099	Jacques Cartier	President
						Yvan Grégoire	Director, R&D
						Pierre La Haye	Dir, Technical Services
						Robert Poirier	General Director,
N	ALIMENTS DELISLE Liée	100 de Lauzon	Boucherville, Québec J4B 1E6	(514)655-7331	(514)655-2201	Robert Aubin	President
						Robert Bluteau	Dir, Technical Services
N	FROMAGES SAPUTO Liée	1195 Johnson	St-Hyacinthe, Québec J2S 7Y6	(514)773-1004	(514)773-2042	Jacques R. Rolland	Director, R&D
N	LACTEL GROUP	180 Bégin Blvd.	Ste-Claire, Québec G0R 2V0	(418)883-3301	(418)883-2346	André Houle	Director, R&D
						André Roy	Director, Marketing
N	LALLEMAND Inc.	1620 Préfontaine	Montréal, Québec H1W 2N8	(514)522-2133	(514)522-2884	Clifford Caron	Vice President
						Jean Chagnon	President
						Nina Chagnon	Sr Scientist
						Richard Degré	Director, R&D
						Guy Marleau	VP, Production
N	LYO-SAN Inc.	500 Aeroparc Blvd. P.O. Box 598	Lachute, Québec J8H 4G4	(514)562-8525	(514)562-1433	Serge Brault	Exec. Vice President
N	ROSELL INSTITUTE Inc.	8480 St-Laurent Blvd.	Montréal, Québec H2P 2M6	(514)381-5631	(514)383-4493	Jean-Louis Bilodeau	Manufacturing Director
						Edouard Brochu	President
						Jean-Paul Julien	Coordonator, R&D
						Francine Mondou	Director, R&D
N	VINS ANDRES DU QUEBEC Liée	3755 Picard	St-Hyacinthe, Québec J2S 1H3	(514)773-7468	(514)773-0789	Nicholas G. Sikorski	VP, General Manager

AGROPUR COOPERATIVE ALIMENTAIRE

510 Principale
P. O. Box 6000
Granby, Québec J2G 7G2
Canada

Telephone: (514)375-1991

FAX: (514)375-2099

Founded: 1938

Employees: 3,100

R&D:

Contact: Yvan Grégoire (Director, R&D)

Sales: \$ 1 B

HISTORY:

Agropur is the largest dairy cooperative in Canada and processes about 1.2 billion litres of milk annually with sales exceeding \$1 billion.

The cooperative founded in 1938 is made up of some 4400 farmers with more than 3100 employees in 24 plants.

FACILITIES:

24 plants: fluid milk, ice cream, butter, cheese, fine cheeses, juices.

Distribution centres in all major areas in Canada.

SUBSIDIARIES/DIVISIONS:

Natrel Inc., Longueuil, Québec.

RESEARCH & DEVELOPMENT:

Manufacture cheese and other milk products.

Lactic acid fermentations and proteases for cheese-making.

Lactosera proteins hydrolysis.

Lactose enzymatic hydrolysis.

Wastewater purification treatment.

Supply lactic bacteria cultures.

PRODUCTS ON MARKET:

Lactic ferments.

Dairy Products.

AGREEMENTS BEING SOUGHT:

Distribution.....

Marketing.....

Research Contract.....

Joint Venture.....

Technology Transfer....X.

Financing.....

ALIMENTS DÉLISLE Ltée

100 De Lauzon
Boucherville, Québec J4B 1E6
Canada

Telephone: (514)655-7331
FAX: (514)655-2201

Founded: 1931
Employees: 400
R&D:

Contact: Robert Bluteau (Dir., Technical Services)

Sales: \$ 75 M

HISTORY:

Founded in 1931 by Jude Délisle with the opening of the first yogourt manufacturing plant in Montréal.

Production of natural yogourt only until 1964 with the introduction of stirred yogourt with fruit.

Construction of a large scale production plant in 1968 at the actual location, Boucherville, Québec.

FACILITIES:

Manufacturing plant: 8000 sq. m., Boucherville, Québec.

RESEARCH & DEVELOPMENT:

Production techniques.

Fermentation methods.

PRODUCTS ON MARKET:

Yogourt:	Stirred:	Natural and with fruits:	"Délisle", "Délisle Light".
	Firm:	Natural and with fruits:	"Délisle", "Délisle Light".
	Stirred:	Low fat, no sugar:	"Silhouette".

Cottage cheese and sour cream "Délisle", "Silhouette".

PRODUCTS IN DEVELOPMENT:

Yogourt based food products.

AGREEMENTS BEING SOUGHT:

Distribution.....
Marketing.....
Research Contract.....

Joint Venture.....X.
Technology Transfer.....X.
Financing.....

FROMAGES SAPUTO Ltée

1195 Johnson
St-Hyacinthe, Québec J2S 7Y6
Canada

Telephone: (514)773-1004
FAX: (514)773-2042

Founded: 1954
Employees: 700
R&D:
Sales:

Contact: Jacques R. Rolland (Director, R&D)

HISTORY:

Started as a small cheese company making mozzarella and other Italian cheeses.
The company has grown to become the major mozzarella manufacturer in Canada.

FACILITIES:

The company has 7 cheese plants in Canada, 2 in the U.S.A.
One major whey processing plant at St-Hyacinthe.

INVESTORS:

The Saputo family; exclusive ownership.

RESEARCH & DEVELOPMENT:

Protein functionality in foods.
Cheese starters.
Lactose crystallization.
Modified whey protein concentrates.
Dairy blends.

PRODUCTS ON MARKET:

Many types of cheese; full distribution.
Cheese starters.
Whey protein concentrates.
Lactose.
Italian and Canadian cheeses.
Dairy blends.
Distribution of several food and pizzeria ingredients.

PRODUCTS IN DEVELOPMENT:

Many dairy blends for specific applications.
Starter media.

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract

Joint VentureX.
Technology Transfer
Financing

LACTEL GROUP
180 Bégin Blvd.
Ste-Claire, Québec G0R 2V0
Canada

Telephone: (418)883-3301

FAX: (418)883-2346

Founded: 1990

Employees: 795

R&D: 9

Contact: André Houle (Director, R&D)

Sales: \$ 350 M

HISTORY:

Partnership of six agro-food cooperative enterprises.
4,500 milk producers members of 5 regional milk cooperatives.
Established clientele in 30 countries.

FACILITIES:

Head Office:

Groupe Lactel
1205 Ampère road, Suite 101
Boucherville, Québec
Canada J4B 7M6

Tel: (514)449-6113

Fax: (514)449-6117

AGREEMENTS:

UNION LAITIÈRE NORMANDE; collaboration for animal milk replacers.

WYETH; collaboration for co-production of UHT products and infant formula.

RESEARCH & DEVELOPMENT:

Lactel Group works in close co-operation with a number of university researchers and European businesses. The research centre includes an experimental farm, an analysis and formulation laboratory and a pilot-plant for producing cheese and UHT products.

Fluidized bed-dryer.

UHT treatment.

Tetrapak packaging.

Ultrafiltration (milk, whey).

Multiplate anaerobic digester: wastewater treatment.

Mix Plant for milk replacer.

PRODUCTS ON MARKET:

The company processes 17% of Québec's milk production and 9% of Canada's milk production, (500 M litres annually).

Supplier to more than 200 wholesalers and distributors throughout Canada.

Close to 20 products offered nation-wide, in different sizes and brand names.

Butter.

Cheddar cheese (pasteurized, preheated).

Specialty cheeses (mozzarella, mamirolle, brick...).

Processed cheese spread.

Milk powder (skim and whole milk).

Milk powder mixes for the food industry.

Infant formula.

Evaporated milk.

UHT milk drinks.

Milk replacers for animal feed.

AGREEMENTS BEING SOUGHT:

Distribution.....

Marketing.....

Research Contract.....

Joint Venture.....X....

Technology Transfer...X....

Financing.....

Strategic research and development alliances with respect to:

Development of new cheeses and optimization of output.

Whey and permeat utilizations.

Dairy ingredients.

LALLEMAND Inc.
1620 Préfontaine
Montréal, Québec H1W 2N8
Canada

Telephone: (514)522-2133
FAX: (514)522-2884

Founded: 1923
Employees: 180
R&D: 14

Contact: Richard Degré (Director, R&D)

HISTORY:

Lallemand Inc. has been producing and marketing yeast along with ancillary bakery products to the domestic baking trade since 1923.

FACILITIES:

Yeast Plants:

Lallemand, Montréal.
American Yeast, Baltimore.

Bacteria Plant:

Aurillac, France.

SUBSIDIARIES/DIVISIONS:

Macco Organiques, Valleyfield, Québec.

RESEARCH & DEVELOPMENT:

Carrying out research on drying of active yeast, control of yeast fermentation, production of wine yeasts and the mechanisms of resistance of yeast to freezing and high concentrations of ethanol. Nutrition and growth of yeasts and bacteria on both a research and commercial scale (10 L to 150,000 L).

Development, production and marketing of novel strains.

DNA fingerprinting methodologies, including image enhancement and strain classification by computer.

Yeast drying technology; development of modified yeast strains through mutation and recombinant DNA techniques.

Mechanism and applications of "KILLER" yeasts for vinification.

PRODUCTS ON MARKET:

Produces yeasts for bakery products.

Fresh Baker's Yeast: solid in blocks, bulk bag and liquid form to Canadian and American market.

Dry Wine Yeast: sold in vacuum pack to major wine regions of the world. At present more than 40 different strains are sold.

Bacterial Cultures: more than 100 strains of bacteria are produced and sold by its French subsidiary EQUIPHARM.

Nutritional Yeasts: both autolyzed yeasts and yeast extracts are sold worldwide for nutritional, flavour and fermentation uses.

Probiotics: active yeast added to a culture media are being sold as a feed supplement for ruminant and monogastric animal health needs.

PRODUCTS IN DEVELOPMENT:

Yeast for use in frozen, unbaked dough systems.

Active yeasts for animal health applications.

Yeasts with colour promoters for aquaculture.

Immobilized yeasts in alginate for Champagne production.

Yeast extracts for nutritional / flavour applications.

AGREEMENTS BEING SOUGHT:

Distribution.....	Joint Venture.....
Marketing.....	Technology Transfer.....
Research Contract.....	Financing.....

Develop novel strains of yeast for new applications (i.e. health uses).

Develop novel yeast by-products for the food / beverage industries.

LYO-SAN Inc.
 500 Aeroparc Blvd.
 P.O. Box 598
 Lachute, Québec J8H 4G4
 Canada

Telephone: (514)562-8525
FAX: (514)562-1433

Founded: 1983
Employees: 15
R&D: 1

Contact: Serge Brault (Exec. Vice President)

Sales:

HISTORY:

LYO-SAN Inc. is a manufacturer of freeze-dried foods specialized in the preparation, fermentation and freeze-drying of different types of yogurt cultures, lactic acid bacteria and other types of bacteria.

FACILITIES:

Plant size: 45,000 sq.ft. (4,180 sq. m.) equipped with mixers, grinders, kettles and freeze-driers.

BUSINESS STRATEGY:

Ensure actual markets and increased activity in Asia.

RESEARCH & DEVELOPMENT:

Project on freeze drying of bifidobacteria.

PRODUCTS ON MARKET:

Freeze-dried yogurt cultures and lactic bacteria.
 Freeze-dried bifidobacteria.
 Freeze-dried food in general.

PRODUCTS IN DEVELOPMENT:

Bifidobacteria fermented milk starter.

AGREEMENTS BEING SOUGHT:

DistributionX..
 Marketing
 Research Contract . . .X..

Joint Venture
 Technology Transfer . . .X..
 FinancingX...

ROSELL INSTITUTE Inc.

8480 St-Laurent Blvd.
Montréal, Québec H2P 2M6
Canada

Telephone: (514)381-5631
FAX: (514)383-4493

Founded: 1934
Employees: 60

Contact: Francine Mondou (Director, R&D)

R&D:
Sales: \$ 4 M

HISTORY:

Since its foundation, Rosell Institute Inc. has specialized in the production of lactic ferments. The company developed an effective technique for producing and concentrating cultures by freeze-drying. The technology permits to export products all around the world.

FACILITIES:

Fermenters, centrifuges, filtration systems, freeze-dryers, laboratories.

BUSINESS STRATEGY:

Produce bacteria, yeast and fungi for the milk and food industries, agriculture, human and animal nutrition, prophylaxis and therapy.

AGREEMENTS:

FRDC (Food Research and Development Centre, Agriculture Canada).
Fromagerie Domafro.
Groupe Lactel.

RESEARCH & DEVELOPMENT:

Carrying out research on new methods of concentration, stabilization of bacteria, nitrogen fixing bacteria, the effects of lactic acid bacteria.

PRODUCTS ON MARKET:

Freeze-dried bacteria for the :
Dairy industry (yogourt, kefir, acidophilus milk, cheese flavouring, mesophilic, thermophilic and propionic cultures).
Food Industry (cultures for dry and semi-dry sausages, fermentation of sauerkraut).
Agriculture (culture for silage, leguminous plants).
Probiotics (human and animal).
Dietetics and hygiene.

PRODUCTS IN DEVELOPMENT:

Bifidobacterial cultures.
Direct-Vat cultures (yogourt, cheese).

AGREEMENTS BEING SOUGHT:

DistributionX..
MarketingX..
Research Contract . . .X..

Joint Venture
Technology Transfer . . .X..
Financing

VINS ANDRÈS DU QUÉBEC Ltée

3755 Picard
St-Hyacinthe, Québec J2S 1H3
Canada

Telephone: (514)773-7468

FAX: (514)773-0789

Founded: 1974

Employees: 36

R&D:

Sales: \$ 12 M

Contact: Nicholas G. Sikorski (VP, General Manager)

FACILITIES:

The winery has a capacity of 1.8 million gal. of fermentation with 105 stainless steel tanks. There are two high speed bottling lines and two bag-in-a-box lines. Vins Andrès du Québec Ltée has a distilling operation.

SUBSIDIARIES/DIVISIONS:

Vins Andrès du Québec Ltée is a division of Andrès Canada with head-office in Winona, Ontario. Andrès Canada has six wineries in Canada:

Port-Moody, BC

Morris, Manitoba

St-Hyacinthe, Québec

Calgary, Alberta

Winona, Ontario

Truro, Nova-Scotia

Subsidiaries:

Peller Wines, California

Superior Wines Ltd.

S.A.R.L., France

Pelwin Agencies Ltd.

Watleys Ltd., Winona.

STOCK-FINANCIAL HISTORY:

Stocks are traded on Toronto & Montréal Stock exchanges

BUSINESS STRATEGY:

To be the most profitable winery in Canada.

To increase sales by taking advantage in the table wine segment.

RESEARCH & DEVELOPMENT:

De-alcoholized wine through reverse osmosis.

Vins Andrès du Québec Ltée can test for 77,000 different components in wine and uses this knowledge to create standard and norms for wines.

PRODUCTS ON MARKET:

Fermenting of grape juice: wines, de-natured wine, cooking sauce, distilling.

Brand names: Baby Duck

Hochtaler

Cuvée du Marché

Cuisi-Vin (cooking wine)

L'Auberge

PRODUCTS IN DEVELOPMENT:

New import line for the restaurant business.

AGREEMENTS BEING SOUGHT:

Distribution

Marketing

Research Contract . . . X . .

Joint Venture X . . .

Technology Transfer

Financing

QUEBEC BIOTECHNOLOGY COMPANIES
PULP & PAPER, FORESTRY

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
P	BIOASKA Inc.	1030 Rémi-Lachance	L'Assomption, Québec J0K 1G0	(514)589-9620	(514)589-9621	Yvon Brousseau	President
						Michel Caron	VP, R & D
P	CASCADES Inc.	471 Marie-Victorin	Kingsey Falls, Québec J0A 1B0	(819)363-2747	(819)363-2921	Claude Audet	Coordinator, Environment
						Martin P. Pelletier	Director, R&D
P	CENTRE DE RECHERCHE EN SYLVICHIMIE	11 Main P. O. Box 38	Gatineau, Québec J8P 6J1	(819)643-9099	(819)643-1295	Yvon Gauthier	President
P	DOMTAR RESEARCH CENTRE	22025 Trans-Canada Road West	Senneville, Québec H3R 1L6	(514)457-6810	(514)457-4527	P. Desjardins	President
						Robert Eamer	Vice President, R & D
P	JEAN-MARIE BELANGER Inc.	1436 Ducharme Blvd.	LaTuque, Québec G9X 3N8	(819)523-9559	(819)523-3403	J. M. Bélanger	President
						Christian Bélanger	Vice President
P	PAMPEV Inc.	212 Rang St-Lazare	St-Apollinaire, Québec G0S 2E0	(418)881-3114	(418)881-2438	Normand Bélanger	Vice President
P	PAPRICAN	570 St-Jean Blvd.	Pointe-Claire, Québec H9R 3J9	(514)630-4135	(514)630-4134	Lubo Jurasek	Head, Bio. Chemistry
						Joseph Merka	Grants & Contracts
						Jim Rogers	Sr Vice President
						P. E. Wrist	President
P	TEMECO ENTERPRISES Inc.	P. O. Box 3000	Temiscaming, Québec J0Z 3R0	(819)627-1070	(819)627-1042	Robert Benson	President
						Gerry Grewe	Vice President
P	TEMFIBRE Inc.	P. O. Box 3000	Témiscaming, Québec J0Z 3R0	(819)627-9505	(819)627-1042	Robert A. Benson	VP, General Manager
						Peter Dilling	Manager, Manufacturing
						F. A. Dottori	President, CEO

BIOASKA Inc.
1030 Rémi-Lachance
L'Assomption, Québec J0K 1G0
Canada

Telephone: (514)589-9620

FAX: (514)589-9621

Founded: 1991

Employees:

R&D:

Contact: Yvon Brousseau (President)

Sales:

HISTORY:

BIOASKA Inc. is a start-up company involved in reafforestation activities.

FACILITIES:

BIOASKA Inc. has the engineering expertise and access to industrial equipment to produce up to 10 million applications of the biofertilizer (one application/seedling) per year for the field trials and market testing, over the next 3 years.

In a near future BIOASKA Inc. will decide on the business opportunity to invest in an industrial production facility to reach its sales projections. The investment will be \$ 6.5 M.

INVESTORS:

Private investment.

BUSINESS STRATEGY:

BIOASKA's corporate strategy is to produce in industrial bioreactors various microorganisms and/or their added-value substances to be used for environmental and agri-food purposes.

BIOASKA's mandate is to be a private manufacturer offering production at an industrial level with conventional and/or non-conventional bioreactors.

Production could be carry out on house product or on product under licensing.

AGREEMENTS:

BIOASKA Inc. is negotiating with various groups (government and private sectors) to demonstrate to foresters that it is advantageous and cost efficient to plant ectomycorrhizal seedlings.

RESEARCH & DEVELOPMENT:

Develop technology to produce a biofertilizer (vegetative liquid form of ectomycorrhizae). Mycorrhizal fungi are naturally associated with the roots of forest tree species. Their relationship is mutually beneficial and of considerable economic importance to forest owners and managers. Research to demonstrate the advantages of inoculation needs to be done on a large scale under realistic nursery and fields conditions.

PRODUCTS IN DEVELOPMENT:

BIOASKA Inc. is required to realize pan-Canadian field trials to further illustrate the efficiency of the biofertilizer under Canadian ecosystem and to demonstrate how the use of ectomycorrhizae (biofertilizer) can contribute to the reduction of herbicide and phytocide applications.

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract

Joint VentureX...
Technology Transfer
FinancingX...

BIOASKA Inc. is looking for an industrial partner interested in the development of biofertilizer, biopesticide and bio-food additives.

We are ready to negotiate with companies different types of business options (strategic alliances) toward a financial involvement. This financial involvement will provide different returns on investment (commercial rights, licences...). All options are open to reach mutuals benefits.

CASCADES Inc.
471 Marie-Victorin
Kingsey Falls, Québec J0A 1B0
Canada

Telephone: (819)363-2747
FAX: (819)363-2921

Founded: 1964
Employees:
R&D: 14
Sales: \$ 850 M

Contact: Martin P. Pelletier (Director, R&D)

HISTORY:

Cascades Inc. was founded in 1964 by Bernard Lemaire and his brothers.
R&D operations started in 1985 by Martin P. Pelletier in Kingsey Falls.

FACILITIES:

Over 40 companies in the group.

RESEARCH & DEVELOPMENT:

Re-use and/or reevaluation of biomass in several different products.
Fermentation technology applied to clean up mill effluents.

AGREEMENTS BEING SOUGHT:

Distribution.....
Marketing.....
Research Contract.....

Joint Venture.....
Technology Transfer.....
Financing.....

CENTRE DE RECHERCHE EN SYLVICHIMIE

11 Main
P. O. Box 38
Gatineau, Québec J8P 6J1
Canada

Telephone: (819)643-9099
FAX: (819)643-1295

Contact: Yvon Gauthier (President)

Founded: 1984
Employees: 12
R&D: 2 PhDs
Sales: \$ 0 - 1M

HISTORY:

Founded in 1984, the C.R.S. is dedicated to the development and promotion of new technologies for the economic transformation of wood waste into marketable products.

FACILITIES:

200 sq. m. of furnished office space.
300 sq. m. of laboratory space.
1200 sq. m. of storage area.
250 sq. m. of mechanical and electrical workshop.
Fermentation and distillation capacity for 27 million liters ethanol per year.
Storage capacity of 5 million liters.

RESEARCH & DEVELOPMENT:

Agriculture: biodecomposition and fermentation.
Forestry: products, cellulolysis and fermentation, lignification.
Single-cell proteins.
Waste treatment.
New products.
Systems development.
Chemical products and alternative energies.

PRODUCTS IN DEVELOPMENT:

Process development for the production of fuel alcohol and pulp fiber, without residues, using low grade hardwoods (enzymatic hydrolysis).
Development of a composting technique using lignocellulosic materials (bark, sawdust, clarifier sludge).

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract

Joint Venture
Technology Transfer
Financing

DOMTAR RESEARCH CENTRE

22025 Trans-Canada Road West
Senneville, Québec H3R 1L6
Canada

Telephone: (514)457-6810
FAX: (514)457-4527

Founded: 1903
Employees: 14,000
R&D: 70
Sales: \$ 30 M

Contact: Robert Eamer (Vice President, R & D)

BUSINESS STRATEGY:

Pulp and paper.
Packaging.
Construction materials.
Research centre.

RESEARCH & DEVELOPMENT:

Evaluation of specialized microorganisms for bleaching, waste treatment and site remediation.
Research activities in pulp and paper, construction materials, gypsum, and new process development.

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract

Joint Venture
Technology Transfer
Financing

JEAN-MARIE BÉLANGER Inc.

1436 Ducharme Blvd.
LaTuque, Québec G9X 3N8
Canada

Telephone: (819)523-9559**FAX:** (819)523-3403**Founded:** 1966**Employees:****R&D:****Contact:** Jean-Marie Bélanger (President)**Sales:****HISTORY:**

Founded in 1966 to commercialize forestry equipment.

FACILITIES:

Land and field trials.

Workshop testing.

SUBSIDIARIES/DIVISIONS:

BIOTEK Inc.

INVESTORS:

C.A.E., LaTuque.

Fonds de Recherche GVT.

BUSINESS STRATEGY:

Develop natural fertilizers from forestry residues.

RESEARCH & DEVELOPMENT:

Exploitation of fragmented wood branches.

Exploitation of animal manure.

PRODUCTS ON MARKET:

BIOTEK 2000: natural fertilizers.

F 3-2-1: natural fertilizers

PRODUCTS IN DEVELOPMENT:

BIOTEK 2001.

BIOTEK 2002.

AGREEMENTS BEING SOUGHT:

Distribution.....
Marketing.....X....
Research Contract.....

Joint Venture.....
Technology Transfer.....
Financing.....X....

PAMPEV Inc.
 212 Rang St-Lazare
 St-Apollinaire, Québec G0S 2E0
 Canada

Telephone: (418)881-3114
FAX: (418)881-2438

Founded: 1979
Employees: 35
R&D:
Sales: \$ 1.4 M

Contact: Normand Bélanger (Vice President)

FACILITIES:

4 forest nurseries growing containerized seedlings, (1 in Alberta, 3 in Québec).

SUBSIDIARIES/DIVISIONS:

Bonnyville Forest Nurseries.
 PAMPEV Internationale.
 Pépinière Baie-des-Chaleurs.

BUSINESS STRATEGY:

Increase of the value-added products in production.

AGREEMENTS:

I.R.B.V (Institut de recherche en biologie végétale): research contract.

RESEARCH & DEVELOPMENT:

Ectomycorrhizal inoculants.

PRODUCTS ON MARKET:

Forestry explants in the culture media (seedlings and cuttings).

PRODUCTS IN DEVELOPMENT:

Edible mushrooms ectomycorrhizal inoculants.
 Ectomycorrhizal tree seedlings.

AGREEMENTS BEING SOUGHT:

Distribution
 Marketing
 Research Contract . . .X..

Joint Venture
 Technology Transfer . . .X.
 Financing

PAPRICAN
 570 St-Jean Blvd.
 Pointe-Claire, Québec H9R 3J9
 Canada

Telephone: (514)630-4135
FAX: (514)630-4134

Founded: 1925
Employees: 380
R&D:
Sales:

Contact: Lubo Jurasek (Head, Bio. Chemistry)

HISTORY:

Non-profit, cooperative research in the field of pulp and paper supported by industry and Federal Government, assisted by major Canadian universities (McGill, U.B.C., Université de Montréal).

FACILITIES:

Laboratories:

- (1) Pointe-Claire, Québec (18,000 sq.m.)
- (2) Vancouver, B.C. (9,000 sq. m.)

SUBSIDIARIES/DIVISIONS:

Pulp and Paper Centres:

McGill University,
 Montréal campus,
 U.B.C., Vancouver.

INVESTORS:

Costs borne largely by Canadian pulp and paper company members.
 Grants from the Federal Government and Allied Industry, contract research.

BUSINESS STRATEGY:

Carrying out basic and applied research and development program with wide range of scientific and engineering disciplines for pulp and paper industry.

AGREEMENTS:

Canadian Government.
 The Canadian Pulp and Paper Association.
 McGill University.
 University of British Columbia.
 Université de Montréal.

RESEARCH & DEVELOPMENT:

Biotechnology (20% of total research effort).
 Biological bleaching, pulping and treatment of waste materials.
 Anaerobic fermentation of industry effluents.
 Ligninolytic and carbohydrate hydrolysing enzymes.
 Biopolymer applications.

AGREEMENTS BEING SOUGHT:

Distribution
 Marketing
 Research Contract . . .X. . .

Joint Venture
 Technology Transfer . . .X. . .
 Financing

TEMECO ENTERPRISES Inc.

P. O. Box 3000
Temiscaming, Québec J0Z 3R0
Canada

Telephone: (819)627-1070
FAX: (819)627-1042

Founded: 1989

Employees: 20

R&D:

Contact: Robert Benson (President)
Gerry Grewe (Vice President)

Sales: \$ 9 M

HISTORY:

High purity ethyl alcohol plant started in 1990.

FACILITIES:

Process is based on fermentation of spent sulfite liquor from adjoining pulp mill.
Produce 18 M litres per year of 95% ethanol.

RESEARCH & DEVELOPMENT:

Fermentation of pentose/sugars.
Conversion of cellulose waste and sawdust to ethanol.

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract

Joint Venture
Technology Transfer
Financing

TEMFIBRE Inc.
P. O. Box 3000
Témiscaming, Québec J0Z 3R0
Canada

Telephone: (819)627-9505

FAX: (819)627-1042

Founded: 1977

Employees: 20

R&D:

Contact: Robert Benson (VP, General Manager)

Sales: \$ 5 M

FACILITIES:

Phenol-formaldehyde resin plant.

Lignosulfonate production plant.

RESEARCH & DEVELOPMENT:

Produce lignosulphonates and develop new lignosulphonate products.

Phenol-formaldehyde resin drying.

AGREEMENTS BEING SOUGHT:

Distribution.....

Marketing.....

Research Contract.....

Joint Venture.....

Technology Transfer.....

Financing.....

QUEBEC BIOTECHNOLOGY COMPANIES
SUPPLIERS

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
S	BIO-EXPERT Inc.	3075 Hamel Blvd. Suite 227	Québec, Québec G1P 4C6	(418)877-5711	(418)877-5713	Jean-François Bourassa	General Manager
						Alain Marchand	President
S	BIORAM Inc.	2633 Le Corbusier Blvd.	Laval, Québec H7S 2E8	(514)973-8228	(514)973-1966	Yvon Brousseau	VP, Bus. Development
						Michel English	VP, Finance & Operation
						Pierre Michaud	President
						Claude Podier	VP, Engineering
S	CANADIAN LIQUID AIR Ltd.	1155 Sherbrooke West	Montréal, Québec H3A 1H8	(514)499-2604	(514)499-8136	Yves Bourhis	Director, R&D
S	EALING SCIENTIFIC Ltd.	6010 Vanden Abeele	St-Laurent, Québec H4S 1R9	(514)335-0792	(514)335-3482	Elie Massuda	Director, R&D
S	GROUPE BIO-CONTROLE	2600 Dalton	Ste-Foy, Québec G1P 3S4	(418)653-3101	(418)653-3096	Pierre Racine	Director
S	MPB TECHNOLOGIES Inc.	1725 N. Service Rd. Trans-Canada Hwy.	Dorval, Québec H9P 1J1	(514)683-1490	(514)683-1727	Morrel Bachynski	President
S	PHARMACIA BIOTECH CANADA	500 Morgan Blvd.	Baie d'Urfé, Québec H9X 3V1	(514)457-6661	(514)457-4616	Jack Ball	Director, Canadian Sales
						Michel Geadah	President and Dir., R&D
S	ROBINSON ELECTRONIC SYSTEMS Inc.	5027 Mira Road	Montréal, Québec H3W 2B9	(514)482-2686	(514)482-2686	Anthony Robinson	President
S	SARSTEDT CANADA Inc.	5655 Bois-Franc	St-Laurent, Québec H4S 1B2	(514)337-6908	(514)337-3640	Alain Côté	President
S	SIMPORT PLASTICS Ltd.	176 du Parc	Beloeil, Québec J3G 4T1	(514)464-1723	(514)464-3394	André Lafond	President
S	STEPHENS ANALYTICAL Inc.	2750 Brabant-Marineau	Montréal, Québec H4S 1L1	(514)332-1230	(514)335-6566	Alan Lee	President
S	TECKSOL Inc.	2505 Dalton	Ste-Foy, Québec G1P 3S5	(418)651-2007	(418)651-8725	Simon Robitaille	President
S	XYMOTEC BIOSYSTEMS Inc.	8180 Devonshire Road Suite 8	Mont-Royal, Québec H4P 2K3	(514)738-1386	(514)738-8499	Charles Salama	General Manager

BIO-EXPERT Inc.
 3075 Hamel Blvd.
 Suite 227
 Québec, Québec G1P 4C6
 Canada

Telephone: (418)877-5711

FAX: (418)877-5713

Founded: 1988

Employees: 10

R&D:

Contact: Alain Marchand (President)

Sales: \$ 0.5 - 1.0 M

HISTORY:

Bio-Expert Inc. was founded to integrate multidisciplinary expertises in biochemical engineering, electronics and computer science by developing instrumentation for the biotechnology processing industry.

BUSINESS STRATEGY:

Over the last years, Bio-Expert developed the ID System for bioprocess control. For now, activities are concentrated in commercialization and production.

Bio-Expert is also involved in enhancing its products line by developing new instrumentation and equipment.

PRODUCTS ON MARKET:

ID SYSTEM: The Bio-Expert's ID System is a computer bioprocess control equipment that provides both powerful software and hardware devices. The ID System enables taking charge of the bioreactor equipment and provides real time Direct Digital Control. The ID System can handle all probes and sensors normally used in bioprocesses with Bio-Expert original conditioning and interface cards. Signals from analog modules are also supported by ID System. The system also includes power and relay units to supply a wide range of actuator types.

BIOREACTORS: Bio-Expert is manufacturing bioreactor vessels and supply all instrumentation for a complete integrated fermentation system.

SERVICES: Bio-Expert is offering bioengineering consultation services for design, scale-up, optimization and control of bioprocesses. Technical services are also offered for existing installation repair and improvement (vessels and piping, electronics, actuators).

PRODUCTS IN DEVELOPMENT:

Optical probes.

New bioreactor designs.

ID System upgrades: network, analytical peripheral interfaces.

AGREEMENTS BEING SOUGHT:

DistributionX..

MarketingX..

Research Contract

Joint VentureX..

Technology Transfer . . .X..

Financing

Interested in strategic R&D alliances with scientific centres or firms involved in electronic, software and photonic areas or any technology oriented toward instrumentation to improve bioprocessing control (sensor, control system, analytical instrument).

Bio-Expert is looking for agents, distributors or instrument manufacturers to penetrate the American, Asian and European markets.

Bio-Expert offers to manufacture on Original Equipment Manufacturer (OEM) basis for a strategic business alliance with manufacturers producing instrumentation for the biotechnology field on their respective markets.

BIORAM Inc.
 2633 Le Corbusier Blvd.
 Laval, Québec H7S 2E8
 Canada

Telephone: (514)973-8228
FAX: (514)973-1966

Founded: 1991
Employees:
R&D:
Sales:

Contact: Pierre Michaud (President)

HISTORY:

BIORAM Inc. was founded in 1991 with aim to market biosensors for industrial, medical, environmental, defense and agricultural markets.

FACILITIES:

BIORAM Inc. has the engineering expertise and access to industrial equipment to execute research, development and production of biosensors.

SUBSIDIARIES/DIVISIONS:

BIORAM Inc. is a subsidiary of Multisens Inc., a sensor and instrumentation manufacturer.

BUSINESS STRATEGY:

BIORAM Inc. has focussed its attention on the piezoelectric technology for the development of future biosensors.

RESEARCH & DEVELOPMENT:

Development of probe measuring cellular concentration in bioreactors.

AGREEMENTS BEING SOUGHT:

Distribution
 Marketing
 Research Contract

Joint Venture
 Technology Transfer
 Financing

BIORAM Inc. is looking for an industrial partner interested in being involved in the development of biosensors.

CANADIAN LIQUID AIR Ltd.

1155 Sherbrooke West
Montréal, Québec H3A 1H8
Canada

Telephone: (514)499-2604**FAX:** (514)499-8136**Founded:** 1911**Employees:** 1,300**R&D:****Contact:** Yves Bourhis (Director, R&D)**Sales:**

RESEARCH & DEVELOPMENT:

Assisted oil recovery, pulp and paper, wastewater treatment, non-ferrous metal.

PRODUCTS ON MARKET:

Suppliers of oxygen, nitrogen, carbon dioxide and other bulk industrial gases, and specialty gases.

AGREEMENTS BEING SOUGHT:

Distribution.....

Marketing.....

Research Contract.....

Joint Venture.....

Technology Transfer...X...

Financing.....

EALING SCIENTIFIC Ltd.

6010 Vanden Abeele
St-Laurent, Québec H4S 1R9
Canada

Telephone: (514)335-0792
FAX: (514)335-3482

Founded: 1959

Employees:
R&D:

Contact: Elie Massuda (Director, R&D)

Sales:

SUBSIDIARIES/DIVISIONS:

Wholly owned subsidiary of Harvard Apparatus, South Natick, MA 01760, U.S.A.

PRODUCTS ON MARKET:

Data acquisition and control systems.
Equipment for laboratory animals.
Pumping systems.
Pumps: infusion.
Pumps: perfusion.
Pumps: peristaltic.
Recorders: oscillographic.

AGREEMENTS BEING SOUGHT:

Distribution.....X....
Marketing.....
Research Contract.....

Joint Venture.....
Technology Transfer.....
Financing.....

GROUPE BIO-CONTROLE

2600 Dalton
Ste-Foy, Québec G1P 3S4
Canada

Telephone: (418)653-3101
FAX: (418)653-3096

Founded: 1947
Employees: 10
R&D: 3

Contact: Pierre Racine (Director)

Sales:

HISTORY:

Extermination Sévigny Inc., a pest control company, was founded in 1947. It has since evolved into a group of consultants in pest management (agriculture, industrial and urban). Now known under the name of Le Groupe Bio-Contrôle, they are committed in the development of sound pest management tools and techniques, and distribute biotechnology products such as massreared biocontrol agents (parasites and predators).

BUSINESS STRATEGY:

To offer quality products and services in order to answer customer needs.

RESEARCH & DEVELOPMENT:

Pheromones and trapping devices.
Biological control agents.

PRODUCTS ON MARKET:

Distribute MULTIPHER traps and many other monitoring devices (traps, pheromones) used in pest management strategies.
Distribute insects and other living organisms (bio-control) which are predators or parasites insect pests.

PRODUCTS IN DEVELOPMENT:

Biological control agents (parasitoids) for different purposes: early development stage.

AGREEMENTS BEING SOUGHT:

Distribution.....X...
Marketing.....
Research Contract..X...

Joint Venture.....X...
Technology Transfer....X..
Financing.....

MPB TECHNOLOGIES Inc.

1725 N. Service Rd.
Trans-Canada Hwy.
Dorval, Québec H9P 1J1
Canada

Telephone: (514)683-1490

FAX: (514)683-1727

Founded: 1976

Employees: 200

R&D: 150

Sales: \$ 35 M

Contact: Morrel Bachynski (President)

HISTORY:

MPB Technologies Inc. was founded in 1976 as a spin-off of RCA Canada. Research and development laboratory operations were initiated in January 1977. Starting from an initial staff of 8, the company has grown to a strength of 200 employees.

FACILITIES:

Robotics laboratory, EMI/EMC measurement facility, clean rooms, reliability test laboratory, ASIC design, optical fibre facility, laser production facility.
70,000 sq. ft., Pointe-Claire (Québec).
30,000 sq. ft., Dorval (Québec).
10,000 sq. ft., Ottawa (Ontario).

SUBSIDIARIES/DIVISIONS:

Communications Division.
Electronic Systems Division.
Electromagnetics Division.
Fusion Technology Division.
Laser & Electro-optics Division.
Space & Photonics Division.

BUSINESS STRATEGY:

Telerobotics to achieve within five years an internationally recognized stature in Québec and the successful penetration of Québec technology into foreign markets in the field of robotics.

AGREEMENTS:

Telerobotics development Systems Program: led by MPB Technologies Inc. with CAE Electronics, Hydro-Québec (IREQ), and McGill University.
Additional funding from Precarn and Fonds de développement technologique, Québec Government.

RESEARCH & DEVELOPMENT:**MICRO-ROBOT:**

A high precision instrument for the physical manipulation and testing of cell-like structures. It is fitted with an interferometric vision system, designed to probe the protein structure of the cell interior. A high speed computer supports robotic control, a finite element model of the cell, and an operator control station. The immediate application is to medicine (micro-surgery) and biotechnology.

RESEARCH ROBOT:

Designed to test novel ideas in motor and limb design, and associated model-based control methods. The robot will make use of direct drive motors to enable accurate model-based position and force control. The initial goal is a precision robot suitable for research applications.

PRODUCTS ON MARKET:

CO2 lasers and accessories.

Excimer lasers.

LIDAR.

Airborne imaging radiometer.

Microwave curing.

Fibre-optic sensors.

PRODUCTS IN DEVELOPMENT:

Laser-based moisture sensors.

Micro-robot systems & subsystems.

Macro-robot systems & subsystems.

Fibre-optic sensors.

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract . . .X. . .

Joint VentureX. . .
Technology Transfer . . .X. . .
Financing

PHARMACIA BIOTECH CANADA

500 Morgan Blvd.
Baie d'Urfé, Québec H9X 3V1
Canada

Telephone: (514)457-6661
FAX: (514)457-4616

Founded: 1965
Employees: 33, 1 PhD
R&D:

Contact: Jack Ball (Director, Canadian Sales)

Sales:

HISTORY:

Established in Stockholm, Sweden, in 1911.

Entered Biotechnology in 1950's.

Established Canadian subsidiary in 1965.

Separation of pharmaceuticals and biotechnology business groups in 1991 (now Kabi Pharmacia and Pharmacia Biotech).

PRODUCTS ON MARKET:

Supplies a wide range of equipment and reagents for molecular biology including liquid chromatography, peptide and DNA synthesis and recombinant DNA technology.

A.L.F. TM DNA Sequencer	GenBlock [®]	Gene Assembler [®]
Ampholine [®]	BioPilot [®]	Bioprocess TM
CsTFA TM	Cytodex [®]	DRigest [®]
ExcelGel TM	Ficoll [®]	Ficoll-Paque [®]
GammaBind TM	Hiload TM	HiTrap TM
Immobiline [®]	LKB [®]	MABTrap [®]
MonoP [®]	MonoQ [®]	MonoS [®]
MonoBeads [®]	Multiphor [®]	NAP TM
NICK [®]	PepRPC [®]	Percoll [®]
Pharmacia [®]	Pharmalyte [®]	PhastGel [®]
PhastSystem TM	Polybuffer [®]	ProRPC [®]
QuickPrep TM	T7QuickPrime TM	Sephacel [®]
Sephacryl [®]	Sephadex [®]	Sephagals TM
Sepharose [®]	SMART TM	Superdex TM
SuperFrac TM	Superose [®]	SuperPac [®]
Pure Performance TM	VacuGene TM	Ultrascan TM
Uvicord [®]	Pure Performance in Molecular and Cell Biology TM	

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract

Joint Venture
Technology Transfer
Financing

ROBINSON ELECTRONIC SYSTEMS Inc.

5027 Mira Road
Montréal, Québec H3W 2B9
Canada

Telephone: (514)482-2686
FAX: (514)482-2686

Founded:
Employees:
R&D:
Sales:

Contact: Anthony Robinson (President)

HISTORY:

The company provides service on liquid scintillation counters, gamma counters, and on other types of equipment that use radioactive materials.

FACILITIES:

Service is performed on-site (hospitals, universities).

BUSINESS STRATEGY:

The company is interested in expanding by servicing a broader range of laboratory equipment made in USA, England, France, Germany, etc.

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract

Joint Venture
Technology Transfer
Financing

SARSTEDT CANADA Inc.

5655 Bois-Franc
St-Laurent, Québec H4S 1B2
Canada

Telephone: (514)337-6908

FAX: (514)337-3640

Contact: Alain Côté (President)

Founded:

Employees:
R&D:

Sales:

HISTORY:

Founded in October 1979 by M. Walter Sarstedt.

PRODUCTS ON MARKET:

Supply plastic labware including test, centrifuge and micro-tubes.

Blood collection products clinical.

Tissue culture products.

Plastic and centrifuge tubes.

Spectro cuvettes.

Pipette tips.

Serological pipettes.

Transport tubes.

AGREEMENTS BEING SOUGHT:

Distribution

Marketing

Research Contract

Joint Venture

Technology Transfer

Financing

SIMPORT PLASTICS Ltd

176 du Parc Street
Beloeil, Québec J3G 4T1
Canada

Telephone: (514)464-1723**FAX:** (514)464-3394**Founded:** 1976**Employees:** 60**R&D:** 3**Contact:** André Lafond (President)**Sales:**

SUBSIDIARIES/DIVISIONS:

LabPlas Inc.

DispoPlas Inc.

PRODUCTS ON MARKET:

Test tubes

Specimen containers

Measuring cylinders

Sampling bags

Pipets

Inoculating loops

Bottles

Carboys

Jars

Mailing containers

Petri dishes

Funnels

Processing & Embedding Cassettes

Cryogenic vials

Closures of all kinds

Centrifuge tubes

PRODUCTS IN DEVELOPMENT:

Products for microtechniques

AGREEMENTS BEING SOUGHT:Distribution.....**x**....

Marketing.....

Research Contract.....

Joint Venture.....

Technology Transfer.....

Financing.....

STEPHENS ANALYTICAL Inc.

2750 Brabant-Marineau
Montréal, Québec H4S 1L1
Canada

Telephone: (514)332-1230

FAX: (514)335-6566

Founded:

Employees:

R&D:

Sales:

Contact: Alan Lee (President)

FACILITIES:

Stephens Analytical Inc.

333 Wyecroft Road

Suite 5

Oakville, ON L6K 2H2

Tel.: (416)844-2415

Fax: (416)842-5010

PRODUCTS ON MARKET:

Analyzers, moisture.

Instrument calibration and repair.

AGREEMENTS BEING SOUGHT:

Distribution.....

Marketing.....

Research Contract.....

Joint Venture.....

Technology Transfer.....

Financing.....

TECKSOL Inc.
2505 Dalton
Ste-Foy, Québec G1P 3S5
Canada

Telephone: (418)651-2007
FAX: (418)651-8725

Founded: 1973
Employees: 250
R&D: 5

Contact: Simon Robitaille (President)

Sales:

BUSINESS STRATEGY:

Commercial and industrial wastewater treatment.

RESEARCH & DEVELOPMENT:

Carrying out research on the applications of ozone for wastewater treatment and pulp and paper bleaching.

R&D in collaboration with Trailigaz, France.

PRODUCTS ON MARKET:

Distribution, sale and installation of Trailigaz ozone generator equipment from France.

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract

Joint Venture
Technology Transfer
Financing

XYMOTEC BIOSYSTEMS Inc.

8180 Devonshire Road
Suite 8
Mont-Royal, Québec H4P 2K3
Canada

Telephone: (514)738-1386
FAX: (514)738-8499

Founded: 1988
Employees: 6
R&D:
Sales: \$ 2.3 M

Contact: Charles Salama (General Manager)

SUBSIDIARIES/DIVISIONS:

2 Sheppard Ave. East
Suite 900
Willowdale, Ontario
Canada M2N 5Y7

Phone: (416)283-2977

PRODUCTS ON MARKET:

Importation and distribution of supplies, accessories & equipments for biotechnology and health fields.

Transfer membranes for life science research (NC™, BA-S™, Westran™, Nytran™, DEAE™, Trans-a Bind™)

Devices and apparatus for molecular biology, nucleic acid and protein research (Minifold-I™, Minifold-II™, Elutrap™, Elutip™, Elu-Kwik™, Zapcap™, Accutran™).

Cell harvesters for receptor binding and thymidine studies.

Multi-channel perfusion systems. (Superfusion-600™, Superfusion-20™, Multichannel).

Complete line of homogenizers and cell disrupters (Bead Beater™, Biomixer™, Bio-homogenizer™).

Ultraviolet products for life science research. (Transilluminators, UVC-515 Multilinker™, HR-100 Reaction Chamber™, UVAC-80™, UV Portable lamps and protective eye-wear.)

Cell Transfer systems (Quixell™, Pixell™).

AGREEMENTS BEING SOUGHT:

DistributionX . . .
MarketingX . . .
Research Contract

Joint Venture
Technology Transfer
Financing

QUEBEC BIOTECHNOLOGY COMPANIES
VENTURE CAPITAL

<u>Alias</u>	<u>Company</u>	<u>Address</u>	<u>City, Province, Zip</u>	<u>Telephone</u>	<u>Fax</u>	<u>Contacts</u>	<u>Title</u>
V	ALTAMIRA CAPITAL CORP.	475 Dumont Ave. Suite 300	Dorval, Québec H9S 5W2	(514)631-2682	(514)631-1257	Robert Mee	Vice President
V	BIOCAPITAL	1550 Metcalfe Suite 1100	Montréal, Québec H3A 1X6	(514)847-5750	(514)285-4597	Gérald André	VP, Scientific Affairs
						Normand Balthazard	President
						Bernard Coupal	Director General
V	NOVACAP INVESTMENTS Inc.	1981 McGill College Ave. Suite 515	Montréal, Québec H3A 2X1	(514)282-1383	(514)282-1344	Marc Beauchamp	President
V	PROMOTIONS TECHNOLOGIES R&D Inc.	2755 Dalton Suite 110	Ste-Foy, Québec G1P 3T1	(418)657-2666	(418)657-5600	Richard Painchaud	President
V	SOCIETE DE CAPITAL TECHNOLOGIQUE Inc.	550 Sherbrooke West Suite 1200	Montréal, Québec H3A 1B9	(514)842-7373	(514)842-7871	Claude McMaster	VP, Technology
						Oleg Romar	Chairman of the Board

ALTAMIRA CAPITAL CORP.

475 Dumont Ave.
Suite 300
Dorval, Québec H9S 5W2
Canada

Telephone: (514)631-2682
FAX: (514)631-1257

Founded: 1984
Employees:
R&D:

Contact: Robert Mee (Vice President)

CAPITALIZATION:
\$165 million CDN.

INVESTMENTS:
Biomira Inc.
Altagenetics Inc.

Investment interests in seed capital, venture capital, and development capital.

BUSINESS STRATEGY:
Review business plans for biotechnology opportunities, preferably Canada and Northeast U.S. region.
Fund start-up companies.

RESEARCH & DEVELOPMENT:
Cancer therapeutics.

BIOCAPITAL
 1550 Metcalfe
 Suite 1100
 Montréal, Québec H3A 1X6
 Canada

Telephone: (514)847-5750
FAX: (514)285-4597

Founded: 1990
Employees: 7
R&D:

Contact: Normand Balthazard (President)
 Bernard Coupal (Director General)

Sales:

HISTORY:

Biocapital is a limited partnership formed in May 1990, to invest in biotechnology and medical equipment and instrument, mostly in the province of Québec.

INVESTMENTS:

Through R&D partnership, finance \$ 10 million of R&D in collaboration with business and universities.

As of November 1991, eight investments in start-up and development phases of companies with average investment of \$500,000.

INVESTORS:

Fonds de solidarité des travailleurs du Québec (FTQ); (Montréal, Québec).
 Gestion et investissement en biotechnologie BIOCAPITAL, Inc.; (Montréal, Québec).
 Peter B. Moody, London, U.K.
 Société d'investissement de la Province de Namur (SIBS) S.A.; Belgique.

AGREEMENTS:

BioSurvey Inc., Belgium.

BUSINESS STRATEGY:

BioCapital is a biotechnology investment fund, encompassing the pharmaceutical, environmental and early development biomedical engineering and equipment fields.
 BioCapital invests primarily in the start-up of new companies or in fledgling companies wanting to expand their range of products.

BioCapital invests primarily in Québec, but may also jointly finance projects outside the province with possible spinoff potential for Québec.

NOVACAP INVESTMENTS Inc.

1981 McGill College Ave.
Suite 515
Montréal, Québec H3A 2X1
Canada

Telephone: (514)282-1383**FAX:** (514)282-1344**Founded:** 1981**Employees:** 5**R&D:****Contact:** Marc Beauchamp (President)**Sales:****HISTORY:**

Novacap started operations in 1981.

Recognized as one of the leaders in Québec's venture capital because of investment successes in telecommunication and waste management.

The company is looking actively in the biotechnology, health care, fine chemicals and nutrition sectors.

CAPITALIZATION:

\$ 45 M

PRIVATE PLACEMENTS:

In the form of equity ranging from \$ 1-9 M.

INVESTMENTS:

Northland Environmental Inc.: toxic waste treatment.

Imapro Corp.: computer graphics for the prepress market.

Pressenk Instruments Inc.: electronic controls for household appliances.

Maax Inc.: sanitary appliances.

Cable Axion Digitel Inc.: cable vision.

Mac Closures Inc.: plastic caps.

RCR International Inc.: hardware products.

Cascade Technologies Inc.: heating, ventilation and air conditioning products.

INVESTORS:

National Bank of Canada.

The SGF Group.

The Caisse de Dépôt et Placement du Québec.

CN Investments.

Laurentian Financial.

Air Canada, Pratt & Whitney and CBC Pension Funds.

BUSINESS STRATEGY:

To invest in proprietary product companies managed by a good management team.

RESEARCH & DEVELOPMENT:

We encourage companies in the portfolio to develop innovative products for their respective markets.

AGREEMENTS BEING SOUGHT:

Equity investments.

PROMOTIONS TECHNOLOGIES R&D Inc.

2755 Dalton
Suite 110
Ste-Foy, Québec G1P 3T1
Canada

Telephone: (418)657-2666
FAX: (418)657-5600

Founded: 1992
Employees: 2
R&D:
Sales:

Contact: Richard Painchaud (President)

CAPITALIZATION:
\$ 5 M

BUSINESS STRATEGY:
Financing major R&D projects using tax shelters.

AGREEMENTS:
Ressources Ste-Geneviève Ltd.

AGREEMENTS BEING SOUGHT:

Distribution.....
Marketing.....
Research Contract.....

Joint Venture.....
Technology Transfer.....
Financing.....X..

SOCIETE DE CAPITAL TECHNOLOGIQUE Inc.

550 Sherbrooke West
Suite 1200
Montréal, Québec H3A 1B9
Canada

Telephone: (514)842-7373
FAX: (514)842-7871

Founded: 1990
Employees: 5
R&D:

Contact: Oleg Romar (Chairman of the Board)

Sales:

HISTORY:

S.C.T. was founded in 1990 by Montréal businessmen with experience in finance, innovation management and strategic planning.

BUSINESS STRATEGY:

Provide financing for R&D projects with high potential for commercialization in a short to medium term.

Assist clients in technology transfert.

Consult and assist clients in the evaluation and preparation of R&D projects.

RESEARCH & DEVELOPMENT:

R&D projects which can result in the development in less than two years of new products with promising market potential.

AGREEMENTS BEING SOUGHT:

Distribution
Marketing
Research Contract

Joint VentureX . . .
Technology Transfer . . .X . . .
Financing

Consulting assignments.
R&D Financing.

QUEEN TP 248.195 .C2 Q4 1992
Canada. Industry, Science and
Québec biotechnology companies

INDUSTRY CANADA/INDUSTRIE CANADA



118402

